annual report image hiv virusgsk annual report gsk sciencele global healthcare company strategic report new ceo discuss measure performance performance manage risk new longterm priority page page create innovation performance longterm value business page page industry trend business contribute trust priority page page new longterm priority financial review innovation performance trust page page cover image cautionary statement year develop hiv inside cover document medicine research treatment cautionary statement prevention hiv continue remain forwardlooke statement forefront help people live hiv drive innovation working community world ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial performance aer aer group turnover cer new product salesb cer aer aer total operating profit cer adjust operating profit cer aer aer total earning share cer adjust earning share cer net cash flow free cash flow dividend declare dividend operating activity share strategic report remuneration report investor information glance chairmans annual statement quarterly trend chairmans statement annual report remuneration year record ceo statement remuneration policy summary product development pipeline create longterm value product competition financial statement industry trend intellectual property longterm prioritie director statement principal risk uncertainty measure success responsibility share capital control manage risk independent auditor report dividend pharmaceutical financial statement financial calendar vaccine note financial statement annual general meeting consumer healthcare financial statement tax information shareholder trust glaxosmithkline plc prepare shareholder service contact group financial review gaap law regulation group company governance glossary term chairman governance statement board footnote corporate executive team aer growth rate represent growth actual exchange rate use number adjust nonifrs measure leadership effectiveness report performance business describe include adjust result free cash flow nomination committee report cer growth rate measure management planning reporting purpose accountability directly comparable similarly describe measure company adjust result exclude audit risk committee report number item present management believe adjust result allow key trend factor drive performance easily clearly identify shareholder nonifrs measure relation stakeholder consider addition substitute superior information present accordance ifrs science committee report reconciliation total result adjust result set corporate responsibility define new product follow pharmaceutical relvarbreo ellipta incruse ellipta anoro committee report ellipta arnuity ellipta eperzantanzeum nucala tivicay triumeq vaccine menveo bexsero shingrix gsk annual report gsk glance purpose global business help people feel well live long goal world innovative good performing trust healthcare company strategy immune system tcell attack cancer cell bring differentiate highquality need healthcare product people possible global business scientific technical knowhow talented people value expectation value expectation heart form important culture value expectation patient focus courage herpe zoster virus shingle transparency accountability respect development integrity teamwork novamin key technology sensodyne repair protect gsk annual report strategic report governance remuneration financial statement investor information global business pharmaceutical leading position group turnover respiratory hiv focus new longterm priority read vaccine innovation page broad portfolio group turnover leading position meningitis performance opportunity shingle page read trust page consumer healthcare category leadership group turnover respiratory pain relief oral health read gsk annual report chairman statement board believe renew focus innovation enable gsk capitalise opportunity industry drive longterm value investors philip hampton chairman please report year cash generation remain key focus financial report good performance sale earning board please board mindful need growth important new product increase free cash flow year provide clear financial report approval continue cash return approve dividend share review aspect financial reporting shareholder line expectation expect framework change ensure remain line late regulatory follow emma walmsleys appointment note letter shareholder requirement good practice ceo april board year ago cash dividend industry commercial structure conduct review company excess free cash flow generation reporting requirement lead strategy management context case board complexity reporting operate environment industry establish policy achieving like great effort simplify dynamic global healthcare july time cash dividend cover range clarify possible emma present new strategy investment growth investor set longterm priority opportunity fund board change year main heading innovation cash retention business continue bring new skill performance trust priority capability board year culture improve performance welcome laurie glimcher central ensure longterm delivery pharmaceutical business seek independent nonexecutive director strategy develop culture growth pharmaceutical scientific medical expert year reward high performance board believe renew focus agm professor sir roy anderson seek build value innovation enable gsk capitalise join board stepdown company board please opportunity industry thank roy excellent contribution employee support mark drive longterm value investor special area scientific increase employee engagement early progress strategy score past knowledge broadly encourage board closely instance commercial practice patrick vallance step engage management delivery disappointing leading board end march leave gsk chief scientific regulatory intervention board capital allocation adviser government patrick focus improve framework company new capital fine leader board colleague culture control environment allocation framework help shape sir andrew witty moncef slaoui strategic priority improve pipeline executive team step long career new pharmaceutical product main follow announcement emma company thank priority company potential new ceo board involve letter mark improvement performance executive appointment hal new science committee good invest key product barron new chief scientific officer progress year crucial vaccine business expect president joined board enter important phase pipeline drive growth come year new president global pharmaceutical vaccine activity addition invest pharmaceutical luke miel new year barron consumer joint venture partner chief digital technology officer work closely committee novartis decide exercise option karenann terrell board take sell interest dividend keen interest balance like thank gsk employee represent allocation capital external recruit development partner hard work board mindful value internal succession planning shareholder customer shareholder attach dividend continue support look framework material acquisition forward successful low priority meet strict return criterion philip hampton chairman gsk annual report strategic report governance remuneration financial statement investor information ceo statement ambition drive highperformance culture put science heart gsk remain true value purpose help people feel well live long emma walmsley chief executive officer longterm priority delighted introduce gsk consumer healthcare sale drive annual report ceo power brand continue innovation outpace market growth sale start role new gsk innovation represent increasingly clear performance healthcare industry remain attractive approximately turnover sector enter period significant total earning share trust change bring challenge accounting charge billion opportunity addition despite improve relate tax reform adjust delivery recent year clear earning share aer cer area company need business strengthen group adjust operate margin improve pharmaceutical july set longterm reflect effective management cost prioritie company successful integration new focus innovation performance business vaccine consumer vaccine trust believe priority enable healthcare focus area improve renew emphasis cost consumer allow respond effectively cash discipline please operating environment focus healthcare free cash flow year deliver improve performance billion improvement well return shareholder million previous year short long term meet expectation pay dividend broad societal contribution pence share performance expect deliver group sale billion pipeline progress actual rate constant exchange end receive rate cer growth approval key new product business time group shingrix new vaccine represent sale reach billion new standard prevention year shingles juluca series new pharmaceutical vaccine product drug regimen hiv reduce sale billion continue number drug patient strong performance hiv live long medicine tivicay triumeq ellipta chronic disease trelegy ellipta portfolio biologic medicine nucala day inhaler respiratory meningitis vaccine combine medicine device treat chronic obstructive pulmonary performance new product disease copd great demonstration achieve commercial organisation focus successfully launch clear focus new product bring significant benefit patient continue maximise current portfolio footnote use number adjust nonifrs measure report performance describe gsk annual report ceo statement continue clear need strengthen hal senior leader pharmaceutical business pipeline appoint executive team year ultimately drive sustainable luke miel join new president longterm growth company pharmaceutical responsible driving performance commercial set organisation work closely refocus organisation hal ensure alignment area world karenann terrell join new leader respiratory hiv role chief digital technology potential area oncology immuno officer karenann join time inflammation pipeline potential overlap healthcare area innovative early technology apparent year continue receive potentially transformative role datum number key asset ensure gsk forefront inform progress exciting new opportunity new external appointment number change delight appoint hal senior leadership year barron chief scientific officer promote great internal talent president join bring fresh expertise outside calico alphabetfunde company company spend year roche genentech gain exceptional performance value base culture reputation lead highly productive ambition drive highperformance team like thank patrick culture put science heart vallance outgoing president gsk remain true value contribution year purpose help people feel ensure smooth transition well live long long history hal wish new role tackle world big health government chief scientific adviser challenge commitment improve uniquely qualified global health responsible business continue leadership corporate executive team mma walmsley imon dingemans karenann terrell chief executive officer chief financial officer chief digital technology officer hal barron ick hiron claire thomas hief scientific officer senior vice president global ethic senior vice president president compliance human resource roger connor brian mcnamara hil thomson president global manufacturing ceo gsk consumer healthcare president global affairs supply uke miel dan troy luc debruyne president global pharmaceuticals senior vice president president global vaccines avid redfern general counsel chief strategy officer page gsk annual report strategic report governance remuneration financial statement investor information great people commitment foundational gsk culture technology revolutionise healthcare year conduct new global employee survey align priority please meaningful improvement new frontier innovation genomic employee engagement score create major opportunity patient important driver performance outlook ability apply new technology maximise huge give momentum see activity create datum gsk apply new product recent launch major opportunity gsk currently artificial intelligence machine operating performance improvement industry learning allow identify drive benefit tax medicine enter trial fail pattern reform increasingly confident reach patient impossible identify traditional ability deliver outlook incomplete understanding method model right mid high single digit growth adjust link biological patient population find eps cagr cer target drug human disease clinical trial reduce generic competition pursue drug target human eliminate need study advair guidance genetic evidence support case predict outcome year reflect aside advair indication estimate double virtual patient allow expect face significant generic probability develop safe effectively manage diversity erosion mid effective medicine improve clinical trial align research development population demographic analyse finally want thank gsk productivity recent year clinical trial year employee partner customer approximately gsk new work especially gsk connect bring target support human support year ceo life patient data genomic genetic evidence gsk look forward work wearable device social medium company deliver emerge source ensure multimillion pound investment longterm priority improve leverage opportunity biobank support generation performance gsk present new genetic sequence datum half million volunteer information generate groundbreake health resource provide vital insight hope inform support development transformative medicine emma walmsley chief executive officer footnote use number adjust nonifrs image wellcome image measure report performance describe gsk annual report create longterm value sciencele global healthcare company business common aim improve health describe resource rely business activity span lifecycle product create longterm value shareholder society resource talented people distrib ute return invest scientific ein scientific pharmaceutical technical knowhow effective capital allocation vaccines purpose ati external collaboration erciali consumer healthcare supply chain fit ure longterm priority value expectation innovation patient focus courage transparency accountability performance respect development trust integrity teamwork gsk annual report strategic report governance remuneration financial statement investor information industry trend longterm priority measure success manage risk value create shareholder aim deliver sustained industryleade growth competitive cost margin cash flow distribute capital shareholder create value form dividend invest scientific research total earning share adjust earning share invest billion research development bring new medicine vaccine consumer healthcare product patient payer consumer strategic business development include external partnership dividend declare dividend share joint venture support inhouse scientific research patient consumer generate revenue profit aim bring differentiate highquality need healthcare product people possible generate revenue execute new product launch brilliantly sale exist portfolio business integrate strategy enable drive competitive cost margin cash flow company pack medicine vaccine sell consumer healthcare sell product reinv distribute return employee society capital allocation framework reinvest business provide want run company responsibly ethically return shareholder form dividend modern employer strong employee engagement positive contribution community operate create employment work supplier pay tax employee cash tax pay footnote use number adjust nonifrs measure report performance describe gsk annual report industry trend create longterm value operate fastchange environment potential growth outline key opportunity challenge influence new longterm priority global healthcare market grow healthcare industry enter strategic response global pharmaceutical sale period significant change bring strategy design respond billion month roll basis opportunity challenge life change environment bring september expectancy increase demographic differentiate highquality need september north america change support market healthcare product people remain large pharmaceutical growth contribute pressure possible global market share global sale healthcare sector particularly businesse scientific technical global vaccine sale total approximately price access knowhow talented people billion challenge new industry new longterm prioritie sale consumer healthcare market advance science technology innovation performance trust gsk operate total approximately transform way scientist help deliver strategy billion research disease likely improve patient diagnose treat future positive demographic demographic change increase life expectancy advance science expand global population drive technology disruption demand healthcare product grow prosperity change diet well understand human biology lifestyle fuel demand genomic change way healthcare product especially scientist research disease chronic condition ability develop novel treatment respiratory disease patient advance digital technology datum analytic enable pricing access researcher explore interpret everlarger volume biological datum increase demand healthcare partly fast technology lead demographic change continue central way people pressure government gain information compare payer budget impact buy healthcare product develop develop market include europe public privately fund organisation look way address affordability medicine im datum internal datum gsk annual report strategic report governance remuneration financial statement investor information longterm priority measure success manage risk societal expectation company expect behave great integrity fairness transparency positive contribution society company sustainable create longterm value stakeholder include shareholder genericisation competition employee customer communitie patent protection apply pharmaceutical medicine patent expire challenge uphold competition authority patient payer gain access generic alternative lower price generic competition result low sale patent product regulatory political environment healthcare highly regulated industry reflect public expectation product comply stringent level quality safety efficacy globally change national politic impact operating environment particularly government make healthcare priority summary impact brexit gsk longterm prioritie innovation performance trust gsk annual report longterm priority create longterm value industry trend innovation strong patient payer focus pipeline competitive claim label brilliant execution launch gsk annual report strategic report governance remuneration financial statement investor information measure success manage risk innovation read innovation innovation pharmaceutical page innovation vaccine page innovation consumer healthcare page ggsskk aannnnuuaall rreeppoorrtt longterm priority create longterm value industry trend performance sustain industryleade growth competitive cost margin cash flow ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn measure success manage risk performance read performance performance pharmaceutical page performance vaccine page performance consumer healthcare page ggsskk aannnnuuaall rreeppoorrtt longterm priority create longterm value industry trend trust maximise social impact ensure reliable supply highquality product people possible highly engage employee ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn measure success manage risk trust read trust business address global health sustainable access science highquality product page page modern employer ethical conduct environmental sustainability page page gsk annual report measure success create longterm value industry trend longterm priority identify operate key performance indicator kpi track progress new group turnover longterm prioritie aer cer innovation innovation sale pipeline value progress performance turnover profit cash flow market growth aer cer share talent key role trust supply service level employee engagement corporate reputation provide performance datum operate kpis report externally commercial sensitivity plan publish datum perform operating kpis group turnover year increase aer cer billion growth deliver business pay performance remuneration policy reward performance pharmaceutical sale aer cer reflect continued strong growth new respiratory hiv product executive include measure link kpi partly offset decline old respiratory product vaccine sale page aer cer reflect strong performance meningitis influenza vaccine consumer healthcare sale grow aer cer reflect strong performance power brand pain oral health category partly offset impact continue competitive pressure allergy category broad market slowdown operate profit margin earning share total total adjustedc adjustedc growth growth total adjust aer cer total adjust aer cer perform perform total operating profit billion high aer basis increase total earning share reflect reduce impact high cer charge arise revaluation liability contingent consideration option associate group hiv adjust operate profit billion high aer consumer healthcare business benefit swiss tax reform basis high cer adjust operate margin improve performance relevant business partly offset percentage point high percentage point charge arise tax reform high cer basis reflect improved operating leverage drive sale growth favourable mix continue tight adjusted earning share aer cer control ongoing cost business line guidance provide july link remuneration gsk annual report strategic report governance remuneration financial statement investor information manage risk new productinnovation sale free cash flow growth definition definition identify series new pharmaceutical vaccine calculation free cash flow describe product expect deliver billion revenue reconciliation provide annum cer basis list product include perform definition provide increase free cash flow million invest perform priority review voucher approximately million sale new pharmaceutical vaccine product billion inventory primarily support new launch increase aer cer represent approximately pharmaceutical vaccine turnover year exchange rate equivalent value sale billion link remuneration link remuneration dividend declare employee engagement favourable response global employee survey dividend description measure employee engagement twice annually invite gsk employee participate global employee survey engagement kpi base favourable response question pride company feel value employee opportunity meaningful challenging work recommend gsk great place work employee participate perform new survey engagement score set baseline future improvement score represent declare dividend shareholder increase question directly comparable share give total return billion year footnote revise include contingent consideration payment djuste result exclude significant legal charge revise definition prior year figure revise use number adjust nonifrs measure report performance business describe include adjust result free cash flow cer growth rate nonifrs measure consider addition substitute superior information present accordance ifrs include special dividend gsk annual report manage risk create longterm value industry trend longterm priority measure success principal risk regularly review cet list principal risk manage group include assessment change risk year macro event mitigate gsk activity gsk exposure macro post risk description assessment mitigate activity environment mitigation patient safety macro environment remain unchanged patient safety regulation good pharmacovigilance practice failure appropriately collect review follow report adverse event potential remain consistent source act relevant finding gsk exposure level remain unchanged risk timely manner maintain appropriate level continue strong oversight develop capability detect safety issue make key safety process standard simple effective product quality macro risk level remain unchanged continue industrylevel regulatory scrutiny datum integrity drug failure comply current good manufacturing practice inadequate control governance shortage expectation timely communication quality supply chain cover supplier issue authority standard manufacture distribution gsk exposure level remain unchanged risk product maintain appropriate level effective response external inspection continuous improvement datum integrity programme quality management system financial control report macro risk level remain unchanged material increase financial reporting requirement failure comply current tax law incur significant loss treasury activity gsk exposure level reduce strong risk failure report accurate financial information management governance approach compliance accounting standard embed system change control standardisation applicable legislation process simplification antibribery corruption abac macro risk level increase stringent abac law rise enforcement regulator failure gsk employee complementary worker party comply gsk exposure level remain unchanged enhance abac principle standard use datum well inform business decision strengthen applicable legislation management abac risk party network introduce improve abac standard clarify stance expect behaviour government investigation china business operation ongoing commercial practice macro risk level increase great competitive pressure increase regulatory enforcement expansion failure engage commercial activity consistent letter spirit digital marketing law regulation evolve law industry group requirement gsk exposure level remain unchanged continue relate marketing communication develop robust control mature commercial practice medicine associate therapeutic order apply appropriate oversight assurance area appropriate interaction healthcare market increase digital capability gsk professional hcp patient legitimate transparent transfer value enhance internal control mitigate risk gsk annual report strategic report governance remuneration financial statement investor information arrow key increase risk change risk decrease risk gsk exposure macro post risk description assessment mitigate activity environment mitigation research practice macro risk level remain unchanged despite evolve regulation continue industrylevel regulatory scrutiny failure adequately conduct ethical sound preclinical clinical research addition failure datum integrity engage scientific activity consistent gsk exposure level remain unchanged risk letter spirit law industry maintain appropriate level group requirement failure secure strengthen governance structure include enterprise adequate patent protection gsk product wide management risk enable well information share increase focus system datum analytic party oversight tpo macro environment remain unchanged industry continue vigilant thirdparty risk global source failure maintain adequate governance oversight thirdparty relationship failure supply consumer investor expectation mature party meet contractual regulatory gsk exposure level reduce follow rollout confidentiality obligation tpo programme risk assess party directly engage enable identify manage risk consistently proportionately improvement plan place require insight programme inform source process mitigate risk environment health safety macro risk level increase great emphasis sustainability ehss environment antimicrobial resistance increase emerge market regulation potential impact chemical failure manage environment health safety legislation great use party develop sustainability risk line objective policy relevant law regulation pipeline asset gsk exposure level remain unchanged continued execution enterprise strategy strengthen ehss control information protection macro risk level continue increase threat pharmaceutical business industry generally risk gsk business activity information disclose authorised sophisticated target evidence wannacry information system fail available notpetya global incident new regulation corrupt typically cybersecurity introduce include general data protection regulation threat accident malicious insider despite gsk exposure level remain unchanged action contributory cause development programme safeguard include risk failure collect secure use personal information accordance datum cyberattack protect critical information privacy law system ability balance demand regulation digital transformation involve increase data collection analysis supply chain crisis macro risk level remain unchanged ongoing stringent management regulation continue focus contract manufacturer outside useu increase datum integrity expectation failure deliver continuous supply compliant finished product inability respond effectively gsk exposure level reduce improve risk crisis incident timely manner recover management supplier portfolio progress complete sustain critical operation include key supply remediation programme improvement supply chain crisis continuity management framework information page viability statement gsk annual report oncology immune system tcell attack cancer cell gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical pharmaceutical business broad portfolio innovative establish medicine focus develop new medicine respiratory hiv oncology immunoinflammation discovery research explore area pharmaceutical sale aer significant cer reflect continue strong pharmaceutical approval trelegy ellipta growth nucala ellipta portfolio provide medicine respiratory tivicay triumeq day single inhaler treat copd dave oncology scientist hiv juluca drug regimen oncedaily join force partner rapidly single pill hiv help reduce evolve science immunooncology medicine patient need area work increase ability bodys immune system help detect pharmaceutical turnover attack cancer cell respiratory hiv immunoinflammation establish pharmaceutical total fran cancer survivor gsk employee innovation pharmaceutical page performance pharmaceutical page report trust priority footnote business use number adjust nonifrs measure report performance page describe gsk annual report pharmaceutical innovation priority strengthen pharmaceutical business focus few asset improve commercial interface brilliant execution launch pharmaceutical business continue create integrated grow global leader competitive pharmaceutical business respiratory hiv significantly strengthen exist bestinclass medicine approve trelegy partnership commercial ellipta oncedaily triple therapy significant chronic obstructive pulmonary disease leadership appointment include copd single inhaler juluca hal barron chief scientific officer twodrug regimen oncedaily single president luke miel pill hiv important president global pharmaceutical progress pipeline asset highly respect leader track record bring new medicine deliver bestinclass innovation market respiratory need focus medicine leader respiratory great potential stop medicine nearly year remain project follow review forefront scientific research drug development process area offer innovative medicine aim focus priority asset area treat patient symptom reduce world leader respiratory risk disease worsen hiv potential area oncology immunoinflammation trelegy ellipta ensure sufficient funding year gain resource priority area european regulatory approval trelegy medicine gsk ellipta new oncedaily triple therapy support patient strengthen copd single inhaler launch exist business long term add portfolio oncedaily inhale terminate preclinical respiratory medicine broad clinical programme include industry end collaboration janssen achieve positive headline result biologic sirukumab start trelegy ellipta phase iii impact process identify new owner study patient study find rare disease gene therapy medicine oncedaily triple therapy achieve significant reduction moderatesevere exacerbation copd patient compare oncedaily dual medicine ellipta portfolio submit additional regulatory filing support impact datum aim expand patient population trelegy ellipta copd investigate efficacy safety trelegy ellipta phase iii study captain treatment patient asthma gsk annual report strategic report governance remuneration financial statement investor information respiratory asset juluca continue lead respiratory biologic november receive fda strategy action believe nucala mepolizumab offer approval juluca oncedaily single highly competitive profile receive pill regimen hiv juluca combine scientific innovation fda approval additional indication dolutegravir rilpivirine edurant heart gsk mepolizumab target janssen medicine complete treatment uncontrolle eosinophilic regiman treat hiv adult high priority granulomatosis polyangiitis egpa virologically suppress build wave submit regulatory file resistance sword study mepolizumab treatment copd patient phase iii trial growth company show juluca achieve noninferior viral priority respiratory asset suppression compare traditional target copd phase drug regimen purchase trial danirixin firstinclas oral use priority review voucher cxcr antagonist nemiralisib accelerate approval highly selective firstinclass follow june submission phosphatidylinositol kinase delta european medicine agency ema pik inhibitor regulatory approval expect hiv response longstanding commitment hiv asset hiv investigate new paradigm clinical trial programme hal barron treatment prevention cure chief scientific officer dolutegravir number core agent consist phase iii clinical trial president globally success tivicay complete sword study support approval juluca triumeq offer important benefit study report wide range patient need booster show superior efficacy different clinical dolutegravir lamivudine study generally tolerate investigate versus traditional drug high barrier resistance regimen treatmentnaive hiv patient interaction commonly gemini study medication tango trial patient achieve viral suppression tenofovir alafenamide today advance antiretroviral fumarate tafbase regimen therapy art people live hiv near normal life expectancy compare longacte cabotegravir general population spend rilpivirine investigate decade hiv treatment innovative administration week virally research drug regimen suppress adult hiv infection initiate response physician atlas flair addition patient demand reduce longterm atlas study start investigate art exposure administration month phase iii study begin evaluate cabotegravir longacte monotherapy prevention hiv trial conduct publicprivate funding collaboration gsk annual report pharmaceutical continue oncology immunoinflammation oncology focus deliver immunoinflammatory disease transformational therapy lengthen relatively common chronic debilitate live patient cancer condition remains significant progress emerge significant unmet medical need portfolio generation therapy discover breakthrough immune area immunooncology cell therapy mediate disease focus epigenetic transformational medicine potentially alter course inflammatory monoclonal antibody disease induce sustainable remission bcma potential target number tumour type include relapse receive approval refractory multiple myeloma promise new subcutaneous formulation early result suggest highly competitive benlysta treatment systemic lupus profile compare exist approve erythematosus enable home read pharmaceutical treatment multiple myeloma hospital administration medicine pipeline page grant european prime fda receive approval japan breakthrough status potentially result use benlysta time fast review regulatory authority phase immunoinflammation file priority asset monoclonal exercise option gain antibody block effect anti exclusive global licence adaptimmune granulocytemacrophage colony stimulate investigational spear factor gmcsf rheumatoid arthritis tcell receptor target nyeso osteoarthritis receptor grant european prime fda interact protein rip kinase inhibitor breakthrough status oncology psoriasis ulcerative colitis therapy investigational rheumatoid arthritis inducible tcell costimulator icos agonist future pipeline optionality antibody enter human clinical trial outside core therapy area asset phase iii trial number promise programme include latestage priority asset oral daprodustat phase iii trial anaemia associated chronic renal disease antisap therapy amyloidosis currently phase strengthen ensure strong partnership commercial commercial function priority interface help ensure deliver differentiate medicine competitive profile robust evidence plan compete effectively todays dynamic market single strategy commercial ensure alignment focus business simplifying process eliminate complexity parallel strengthen commercial medical resource drive performance gsk annual report strategic report governance remuneration financial statement investor information accelerate priority asset new technology frontier strategy action improve pace medicine digital technology impact development enhance speedto business goal clinical decision make change harness development datarich governance adapt way informationbase medicine accelerate design conduct clinical trial drug discovery development drive business forward support acceleration establish new board committee global scientific collaboration remain key innovation expert science committee ensure year join force emerge scientific medical external company harness artificial knowledge integrate strategic intelligence exscientia specialist planning addition new development machinelearning insilico medicine advisory committee provide board leader ail drug discovery strategic guidance aspect cofounde privatepublic current future development activity accelerate therapy opportunity consideration emerge trend medicine atom consortium base alternative approach aims cut preclinical cancer information drug discovery year early research infrastructure supercomputer analyse data discovery performance unit fail programme aim dpus project accountability find pattern vital clue aid budget encourage competitive successful future development dimension propose area discovery support biobank ground research capital allocation break initiative generate anonymise genetic sequence datum volunteer participant deliver insight people great risk disease addition continue work open target programme support open access search engine search evaluate integrate biologic genetic disease datum drug discovery development regulatory drug discovery preclinical clinical trial review manufacturing compound approve number volunteer drug phase phase phase iii year year year source pharmaceutical research manufacturers america yrevocsiderp elfi yrotaluger dettimbus noitacilppa gurd wen dettimbus ecnallievrus gnitekramtsop digital technology transform aspect develop new medicine interact customer karenann terrell chief digital technology officer gsk annual report pharmaceutical continue performance pharmaceutical sale aer cer reflect continued strong growth new respiratory hiv product performance summary immunoinflammation sale million aer cer pharmaceutical turnover year million aer cer sale establish pharmaceutical total sale million million decline aer aer cer primarily drive cer reflect percentage new respiratory hiv product point impact recent divestment europe sale million noncore asset aer cer reflect continued transition respiratory pharmaceutical operate margin portfolio generic competition kivexa percentage point disposal romanian aer percentage point distribution business international sale cer primarily reflect increase million aer investment include priority cer review voucher low operating margin reflect increase respiratory sale aer investment new product support cer million new respiratory continued impact low price product record combine sale particularly respiratory partly offset million offset favourable product mix primarily decline seretideadvair drive growth hiv sale hiv sale increase aer cer continue cost reduction benefit million year growth group pharmaceutical drive continue increase restructure programme market share triumeq tivicay partly offset impact generic competition epzicomkivexa particularly affect european market deliver world ambitious commercial effort asthma medicine relvarbreo class capability focus drive continuous growth ellipta focus target customer priority brand large group help medicine market notably new respiratory portfolio team continue generate evidence billion brand help clinical trial support right million patient year patient medicine differentiation brand strategic use data analytic enable optimise role engagement training salesforce help sure knowledge disease strategy competitive environment lead truly competitive customer engagement day launch gsk annual report strategic report governance remuneration financial statement investor information outlook create simple competitive supply chain strategy action year expect simplify manufacture low singledigit cagr sale supply chain achieve competitive strong sale new exchange rate despite high level sustainable performance deliver product divestment period strong result fundamental safety originally expect strong performance quality service improve achieve great thing new medicine financial performance focus focus discipline cost management expect few priority remove waste make enable business achieve thing simple current plan address operate margin low percentage productivity improvement procurement range exchange rate saving work supplier base automatically substitutable prioritise few strategic supplier generic version advair launch relationship track reduce supplier approximately leverage scale standardise driving performance specification use few bespoke profitable sustainable growth material improve cost good continue invest manufacturing refocus pharmaceutical luke miel network advanced manufacturing business strong president global pharmaceutical technology potential competitive order deliver improve improve product quality reduce sustainable return leadership material waste lead time new luke miel simplify capacity work continuous commercial management structure processing advanced reshape operation deploy reduce cost good aggressively reallocate resource long term area well able deliver profitable sustainable growth return digital transformation focus new medicine goal apply digital technology major market deliver truly competitive customer engagement drive well performance change make drive sharp prioritisation simple portfolio investment area underpin fast decision make effective appointment karenann terrell capital allocation strong focus chief digital technology officer execution join september help drive digital transformation programme begin streamline business pharmaceutical product portfolio exit divest noncore pharmaceutical business brand track reach new technology improve goal few brand performance increase focus include announce end improve customer experience manufacture sale type diabete include customercentric integrate therapy eperzantanzeum campaign personalised content expect end addition help healthcare professional deliver announce strategic review well patient outcome drive cephalosporin antibiotic business preference brand option sell restructure emerge market business improve growth profitability sustainability continue ensure access patient need medicine simplify geography reduce organisational layer simplify cost structure include move export model market support fast align execution footnote use number adjust nonifrs measure report performance describe gsk annual report shingle herpe zoster virus shingles gsk annual report strategic report governance remuneration financial statement investor information virginie laboratory technician vaccine new vaccine shingrix represent significant advance vaccine technology clinically demonstrate strong sustained immune response efficacy shingle painful complication alain shingle sufferer gsk employee vaccine vaccine business broad portfolio innovative pipeline vaccine help protect people life deliver million vaccine dose day people living country vaccine sale aer year receive fda cer primarily drive meningitis approval shingrix new vaccine vaccine bexsero grow represent new standard innovation region menveo europe prevention shingle vaccine high sale influenza product page vaccine turnover primarily europe meningitis influenza performance shingle vaccine establish vaccine page total report trust priority footnote business use number adjust nonifrs measure report performance page describe gsk annual report vaccine innovation advanced science technology platform capability enable discover develop vaccine help protect people country disease vaccine strategy bring follow approval food differentiate highquality need drug administration fda october vaccine people possible competitive position global scale shingrix strengthen positioned advantage change recommendation center demographic vaccine longterm disease control prevention asset volatility patent cliff cdcs advisory committee provide opportunity invest immunization practice acip naming lifecycle management improve preferred shingle vaccine adult competitive profile exist vaccine aged recommendation well meet patient need include revaccinate previously receive competitor vaccine focus find new candidate mean million people vaccine help protect people eligible shingrix vaccine age disease pipeline candidate vaccine currently january receive positive development believe core opinion european medicine competitive advantage expertise agencys emas committee medicinal technology platform facilitate product human use shingrix development effective vaccine result regulatory filing shingrix australia japan innovation action addition december announce new datum confirm receive regulatory approval safety efficacy shingrix immuno canada shingrix compromise autologous haematopoietic efficacy believe stem cell transplant patient provide step change prevention commercial manufacturing shingle anticipate drive team work closely onethird vaccine growth ensure shingrix launch execute people flawlessly take stage approach infect varicella zoster global launch order manage virus cause shingle strong anticipated demand develop shingles lifetime reliable supply breakthrough shingle painful potentially vaccine science condition shingrix develop specifically overcome agerelate decline immunity shingles vaccine combine nonlive antigen trigger target immune response specifically design adjuvant system asb response strong sustain adjuvant rtss vaccine prevention malaria children gsk annual report strategic report governance remuneration financial statement investor information deliver bestinclass innovation develop malaria vaccine candidate receive positive strategy action aim develop asset opinion european medicine good class investment unique agency ema global vaccine technology platform include adjuvant organisation deliver competitive advantage new technology frontier target new emerge remain support unique medical need new technology include technology platform adjuvant system structural vaccinology meningitis synthetic vaccine platform talented people focus maintain gsk help observation meningococcal meningitis market experimentation method vaccine develop vaccine leadership license candidate development create vaccine design meet exist vaccine aim broaden age antigen delivery range meningococcal vaccine system adjuvant help emerge need demonstrate impact increase immune system response infant meningococcal carriage vaccine adolescent february grant breakthrough designation gsk innovate adjuvant bexsero child aged year system year unique work new formulation approach lead development include fully liquid presentation adjuvant system family tetravalent vaccine menacwy menveo use combination adjuvant expect enter phase clinical achieve well immune response trial result phase iii fundamental generation study booster menveo vaccines portfolio emmanuel hanon expect commit selfamplifye mrna sam senior vice president develop single vaccine tackle technology use human body head vaccine common serogroup factory produce vaccine sam require traditional vaccine reflect active lifecycle management production method potentially vaccine strategically enable produce vaccine plan asset commercial journey quickly simply early final clinical trial onwards continue stage datum variety animal expand target population protection model sam perform way aim extend patient benefit increase use vaccine external partnership leader help prevent meningococcal disease collaboration central innovation external scientific line approach support collaboration extensive study examine candidate vaccine develop meningococcal vaccine reduce partnership collaboration enable spread meningococcal bacteria vaccine scientist global teenager herd immunity centre belgium italy involve vaccinate teenager learn expert stay close south australia high incidence emerge technology example meningococcal disease involve phase trial priority asset hiv vaccine group ngo pharmaceutical company lead build gsk exist respiratory national institutes health leadership position pharmaceutical business number candidate vaccine target respiratory disease include candidate vaccine chronic obstructive pulmonary disease copd begin phase proof concept study europe growth driver respiratory portfolio respiratory syncytial virus rsv candidate different approach tailor age group research collaboration focus read vaccine tuberculosis candidate pipeline vaccine currently phase trial gsk annual report vaccine continue performance demand worldleade meningitis portfolio contribute aer cer increase vaccine sale performance summary follow launches argentina belgium bexsero available vaccine sale grow aer cer country vaccine broad age million primarily drive indication provide competitive advantage meningitis vaccine bexsero grow europe offer region menveo fast series completion dose europe high sale influenza administer month product primarily europe menveo sale grow aer cer vaccine operate margin primarily drive impact favourable percentage point aer yearonyear cdc stockpile movement percentage point high cer partly offset supply constraint basis primarily drive improved international product mix benefit settlement lose thirdparty supply volume influenza continue restructure integration fluarixflulaval sale aer benefit partly offset cer million reflect strong increase sga sell general sale execution primarily administration resource support high demand europe business growth new launch shingle increase supply chain cost shingrix record initial sale low royalty income distributor million meningitis fda approval favourable meningitis sale grow aer cer acip recommendation million bexsero sale growth aer cer drive new national immunisation programme private market sale regional tender europe grow demand strong private market sale international global demand million dose meningitis vaccine bexsero bexsero distribute launch bexsero develop reverse image meningococcal vaccinology decode serogroup bacteria genome sequence meningitis commonly know select effective protein meningitis candidate use vaccine bexsero national immunisation programme andorra ireland italy bexsero current market share represent approximately adolescent market gsk annual report strategic report governance remuneration financial statement investor information establish vaccine drive performance profitable strategy action establish vaccine growth drive sustainable growth hepatitis vaccine mainly competitor supply shortage year decide discontinue focus high demand boostrix rotarix number commercially available maintain launch cervarix china vaccine established vaccine cervical cancer vaccine approve portfolio low volume leadership position launch country contribute medical need meet vaccine meningitis vaccine growth favourable yearon year cdc stockpile movement infanrix create simple competitive executing pediarix growth supply chain partly offset increase competitive global vaccine network include shingrix launch pressure infanrix pediarix vaccine manufacture site country flawlessly europe low synflorix sale international presence enable drive low pricing develop manufacture vaccine great country capacity efficiency flexibility aim critical production step inhouse possible outlook continue focus remove year expect complexity supply chain mid high singledigit cagr sale reduce number different exchange rate strong launch pack increase shingrix key priority believe manufacturing flexibility simplify vaccine big standardised product offering luc debruyne growth driver support commercial strategy president global vaccine period target operate profit margin process analytical robustness exchange rate process improvement analytical robustness enable produce bexsero vaccine efficiently new pyrogen test approve country improve assay robustness eliminate failure demonstrate feasibility increase yield reduce failure rate antigen manufacturing process synflorix process robustness programme complete continued deliver good result enable manufacture product major loss transaction saving excellent execution acceleration integration implementation plan manufacture global support function commercial network procurement help vaccine business deliver million novartis integration saving target footnote use number adjust nonifrs measure report performance describe gsk annual report oral health novamin key technology sensodyne repair protect gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare consumer healthcare business develop market consumerpreferre expertrecommende brand oral health pain relief respiratory nutrition gastrointestinal skin health consumer healthcare sale consumer healthcare turnover aer cer strong performance wellness power brand wellness oral health oral health partly offset competitive nutrition pressure allergy category skin health darren principal scientist sale new gsk innovation product total oral health introduction year novamin technology sensodyne repair rolling basis represent approximately protect seek form protective layer sale period notable footnote sensitive area tooth help relieve pain sensitive tooth launch line use number adjust nonifrs extension sensodyne include measure report performance describe generation sensodyne rapid relief sensodyne deep clean voltaren mess parodontax launch flonase sensimist continue global rollout flonase otc overthecounter van sensitive tooth sufferer innovation consumer healthcare page performance consumer healthcare page report trust priority business page gsk annual report consumer healthcare innovation priority execute brilliant product launch build strong differentiate pipeline consumerle sciencebase innovation claim continue demonstrate introduce sensodyne deep ability innovate consumer clean toothpaste number market healthcare market harnessing gsk provide deep clean sensitive scientific technical expertise alongside tooth small particle silica deliver deep consumer insight proportion longlaste freshness novel sale innovation launch coolant technology year approximately key innovation launch include key launch voltaren mess cap make product easy deliver bestinclass innovation messy apply address key consumer barrier topical new sensodyne rapid relief late painreliever unique innovative premium extension billion packaging assess extensively sensodyne brand launch new consumer sensory testing successfully market laboratory rollout continue develop ukbased oral health innovation hub launch parodontax brand design provide fast relief tooth clinically prove help prevent bleed sensitivity support clinical gum gingivitis time study active ingredient stannous fluoride seal layer beneath surface tooth enamel know dentine aid special polymer clinical datum show result relief pain sensitivity little second consumer insightdriven innovation new eno cool antacid create instant cool sensation take scientist develop formulation create cool effect research consumer sensory lab show consumer believe feel cool internally help soothe heartburn eno cooling launch india consumerle innovation create follow research consumer sensory facility india gsk annual report strategic report governance remuneration financial statement investor information continue success emerge market opportunity strategy action switch programme flonase sensimist successfully change prescription emerge market continue key medicine overthecounter opportunity area growth consumer deliver differentiate product enhance offer healthcare increase product consumer allergy market emerge market investment continue global rollout flonase focus particular china combine consumer launch market indiabase innovation hub insight scientific include canada spain czech continue identify local consumer republic switch flonase retailer insight underpin product technical excellence prescriptiononly overthecounter development marketing ensure recognise grow consumer demand remain locally relevant competitive great personal control healthcare india example discover nearly half indigestion treatment build industryleade use home remedy insight capability develop launch new variant eno antacid popular continue invest understand ajwain herb contribute strong meeting consumer retail brand growth customer need expand international network consumer sensory external innovation richard slater shopper science laboratory head new lab open singapore continue look gsk gsk consumer healthcare stateoftheart facility additional innovation opportunity differentiate gsk retailer feedback see significant increase show scientific approach proportion pipeline come shopper insight customer collaboration outside company identify put ahead competitor possible partnership formally review proposal integrate global innovation hub enter partnership colocate commercial increase external focus expert continue ensure strong internal science capability innovation sciencebase ensure able develop consumerle breadth deliver strong competitive pipeline network keep step consumerle sciencebase innovation local regional trend weather app theraflusponsore weather app boost sale keep consumer inform local cold flu level boost sale gsk brand team weather channel create theraflu cold flu tracker launch campaign theraflu expressmax caplet reflect social medium conversation app give likely cold flu level user area advise treat symptom theraflu million unique visitor expose theraflu message tracker brand sponsorship weather channel spark significant rise sale app user peak flu season gsk annual report consumer healthcare continue performance strong performance power brand wellness oral health help drive growth performance summary category basis sale wellness grow aer cer million consumer healthcare sale grew reflect strong performance aer cer million voltaren cold flu seasonal strong performance power brand product partly offset weak wellness oral health performance allergy product partly offset competitive pressure oral health sale grow aer cer allergy category impact flonase million sensodyne sale otc low sale tail brand continue drive performance nutrition nutrition skin health sale grow aer decline cer category addition report growth million adversely impact impact disposal nigeria sale nigeria beverage business beverage business implementation gst implementation good service continue competitive pressure tax gst india july net effect horlick india skin health sale grew partly offset benefit aer flat cer million comparison impact consumer healthcare operate margin demonetisation india percentage point aer divestment gst demonetisation percentage point higher combine reduce overall consumer cer basis reflect tight control cost healthcare cer growth approximately integration synergy principally sga percentage point partly offset increase investment sale new gsk innovation product power brand introduction year rolling basis represent approximately outlook sale period notable launch line year expect extension sensodyne include low mid singledigit cagr sale generation sensodyne rapid relief exchange rate expect sensodyne deep clean operate margin voltaren mess parodontax exchange rate launch flonase sensimist continue global rollout flonase otc footnote use number adjust nonifrs measure report performance describe gsk annual report strategic report governance remuneration financial statement investor information drive performance profitable industry partnership strategy action sustainable growth collaboration core aspect take significant step innovation sign partnership consumer strengthen performance google bring digital advertising healthcare market long term increase focus datum platform inhouse enable well perform brand priority well target relevant content consumer evolve invest market drive efficiency marketing digital capability campaign form partnership power brand alimama marketing forming groundbreaking strategy focus resource medium arm chinese technology group seven power brand regional core alibaba partnership help identify partnership continue brand continue deliver power potential consumer gain deep meet change brand include sensodyne voltaren understand online shopping panadol theraflu significantly behaviour reach consumer need outperform market high single right advertising appropriate time digit growth sensodyne continue drive continue prioritise building performance report growth relationship healthcare professional aer cer strong marketbeating hcp recommendation delivery region follow rollout key introduce new consumer generation sensodyne rapid brand seventy cent consumer relief launch pronamel strong trial sensodyne example bright drive dentist recommendation pain relief sale aer deploy new customer cer drive significantly voltaren relationship management platform see growth region benefit market hcp field force brian mcnamara ceo gsk consumer healthcare momentum hour variant system upgrade enable strong instore marketing activation engage relevant science expansion expert detail strong base dialogue hcp performance international market concentrate good performer create simple competitive announce divestment small supply chain nutrition brand include maxinutrition continue improve consumer health supply chain digital transformation quality safety service cost simplify network announced invest strongly digital plan exit site transformation programme intend streamlined number contract boost sale datadriven manufacturer cmo use market new ecommerce sale channel reduce complexity supply chain digitally power innovation supply chain successfully unlock efficiency saving example support strong growth optimise generate deploy highermargin power brand digital content extract value improvement productivity medium mix procurement system ensure robust reliable supply drive digital transformation appoint consumer healthcare chief digital officer establish digital advisory board external digital marketing datum ecommerce expert revise core training programme build digital ecommerce capability sale marketing general management team ggsskk aannnnuuaall rreeppoorrtt trust maximise social impact ensure reliable supply highquality product people possible highly engage employee ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statement investor information earn detail progress address trust global health need science create sustainable access highquality product responsible business modern employer practice create longterm value later year launch set stakeholder longterm commitment describe investor patient consumer action take demonstrate employee community rightly expect continue commitment deliver company consider social societal value seek financial impact seek establish clear ambitious target drive create value long term investing impact progress area balance set longterm priority address global health need innovation performance trust science business deliver financial return create sustainable access broad contribution society highquality product responsible business focus impact modern employer practice long history tackle continue seek transparent world big health challenge trust engagement scientific big impact use medical community address scientific technical knowhow environmental impact maintain address global health need like hiv ethical standard conduct malaria support sustainable business access highquality product responsible business section report progress modern employer practice support area detail available talented people well responsible business supplement available wwwgskcomresponsibility business contribute trust priority pharmaceutical vaccine consumer healthcare hiv drug dolutegravir vaccine business develop early consumer healthcare available brazil line malaria vaccine candidate business launch fiveyear treatment people live hiv receive positive scientific opinion partnership smile train provide receive treatment european medicine agency funding support expertise help national health programme recommendation pilot implementation child live cleft lip palate available line treatment world health organization lead productive life botswana gsk annual report trust continue address science technology tackle global health big global health challenge deliver lead scientific medical engagement science aim use science work open lab tre canto spain collaboratively transparently support seven new project run partner scientific community external scientist develop new medicine vaccine open year consumer healthcare product tre cantos facility support great need phase clinical trial new candidate drug phase study expect global health impact begin begin late stage preclinical study molecule big contribution potential shorten treatment improve health globally focus funding bill melinda disease impact people gate foundation world specific scientific receive fda approval technological expertise respiratory juluca important hiv oncology immunoinflammation milestone hiv care provide vaccine important role new treatment option play tackle big significant difference people live global health challenge include malaria hiv receive lifelong treatment case study tuberculosis chronic condition neglect tropical disease ntd hiv drug dolutegravir available commercial market brazil botswana create global health unit add essential medicine list drive integrate approach russia business innovate deliver commitment eliminate medicine vaccine tackle control ntds gsk donate nearly big global health challenge billion albendazole tablet malaria ntds reach million people lymphatic filariasis intestinal worm april togo african country eliminate public health problem seven country later year help pharmaceutical business follow successful phase iii trial beat malaria late stage development tafenoquine support plan singledose treatment pvivax malaria pilot malaria vaccine implementation common south asia horn programme subsaharan africa africa latin america approve proud work new treatment path ministry vivax malaria years health kenya ghana malawi stakeholder ensure vaccine business develop successful implementation pilot malaria vaccine candidate programme parallel gsk receive positive scientific opinion prepare implementation ema recommendation phase programme start pilot implementation manufacturing activity gsk donate million dose rtss vaccine support pilot programme subsaharan africa gsk annual report strategic report governance remuneration financial statement investor information prepare future health threat share anonymise patientlevel commit prepare datum interventional phase iiv clinical strategy action global health threat emergency trial month publication late maintain reserve capacity respond list trial create future influenza pandemic wwwclinicalstudydatarequestcom global health unit collaborate development platform use external researcher universal influenza vaccine candidate start initiative drive innovation research proposal request gsk fight antibiotic resistance delivery medicine datum approve decline effectiveness antibiotic vaccine tackle extensive use misuse sale marketing practice major public health crisis introduce policy stop global health challenge pay hcp speak prescriber important work malaria pharmaceutical industry government prescription medicine vaccine believe policy find creative way incentivise improve transparency trust reward new research development feedback scientific expert antibiotic support way reduce important scientific dialogue resistance gsk reduce early rank number intent policy transparent large pharmaceutical scientific dialogue engagement company access medicine expert interest foundation antimicrobial resistance work develop new medicine amr benchmark assess improve care patient pharmaceutical generics biotech phil thomson address feedback company response amr president global affairs consult hcp decide pharmaceutical pipeline gepotidacin change policy allow fair new class antibiotic market value payment expected progress phase iii clinical gsk expert researcher hcp research vaccine play critical speak science role avoid need antibiotic product disease clinical practice prevent bacterial viral limited number gsk sponsor infection medicalle meeting promote responsible antibiotic use believe change well train healthcare interest patient help effective professional hcp area transparent scientific dialogue allow appropriate antibiotic use prescribing hcp share new science guideline primary focus remain internal medical expert speak lead scientific product pay hcps medical engagement talk product outside approve medicalle scientific workshop believe important trust symposium transparent engagement continue strengthen scientific medical community online resource inhouse medical transparency clinical trial datum capability provide bespoke product gsk company information hcp publishe clinical study report exist channel increase overall positive negative end interaction customer report publicly digital interaction grow available clinical study register gsk eliminate use individual addition result summarie sale target pharmaceutical trial reflect longstanding vaccine sale representative commitment clinical trial transparency change implement year rank number expand alltrial transparency index market globally today sale representative incentivise base sell competency broad business performance gsk annual report trust continue sustainable expand access highquality medicine access vaccine consumer healthcare product people benefit use highquality product commit widen access world intellectual property highquality product organization wipo international embed equitable pricing federation pharmaceutical manufacturer strategy innovative business model association ifpma launch ensure product adhere new partnership call patinforme high quality safety standard facilitate access medicine patent information gsk play instrumental pricing role development partnership catalyse equitable pricing strategy medicine commitment information vaccine base country patent portfolio freely available disease area product type patient understand payer patient ability pay capped concern affordability develop price patent medicine market price new medicine develop country vaccine reflect goal work western europe long good interest patient manufacture cost cover shareholder balance reward vaccine dose innovation access affordability develop low middleincome negotiate payer gain country low vaccine price favourable placement formulary list offer organisation gavi product cover health insurer vaccine alliance support pharmacy benefit manager patient poor country generally low outofpocket cost company commit tenyear price medicine prefer treatment freeze support country transition formulary gsk patient gavi financing assistance programme provide prescribe medicine vaccine patient reduce child mortality launch fiveyear partnership save child aim save live million child poor country approach end year reach million child country lifesave intervention partnership create distribute potentially lifesave medicine chlorhexidine gel benefit newborn phase gsk save child partnership continue address child mortality launch image ilan godfrey save child gsk annual report strategic report governance remuneration financial statement investor information europe engage government track risk quality safety payer balance access standard global risk register strategy action affordability work perform audits sustainable health system support trial conduct reliable supply daily ongoing innovation party enhance policy priority management human safety information partnership support access gsk product train relevant business staff safeguard people invest community product involve world product cash donation clinical research charitable giving total reliability supply million reliable supply daily priority reinveste business profit sale pharmaceutical significant improvement achieve consumer healthcare product pharmaceutical supply performance develop country ldc instrumental million total strengthen enable growth key therapy area local healthcare infrastructure roger connor partnerships amref health africa ensure launch new president global manufacturing care international save child product go plan improvement supply result essential capabilitybuilding help train frontline infrastructure investment health worker help exceed supply chain improve safety quality goal reach million people consistent focus meet new programme botswana patient business need cameroon namibia training performance management frontline health worker ldc supply performance vaccine continue improve grow cleft surgery cost little manufacture output leave untreated child underpin strong financial struggle eat breathe speak properly performance maintain focus leave isolated community safety deliver vaccine ongoing health issue early high quality standard consumer healthcare business continue invest capacity update launch fiveyear partnership old facility build new capacity smile train provide funding support support longterm growth ambition expertise help child live cleft lip palate lead consumer healthcare supply productive life chain implement new way work include core business commitment quality planning process improve service safety level increase steadily significantly benchmark charitable giving total follow strict quality management fmcg competitor million million system comply regulation consumer healthcare product good manufacturing practice launch supply time regulatory inspection hold continue strive high target manufacturing site majority product supply maintain result zero minor observation quality safety standard commit addressing issue raise inspection continuous improvement programme regulatory authority accept propose plan corrective action product inkind cash management time pulse gsk annual report trust continue modern attract retain good talent commit employer modern employer drive high level employee engagement staff engage talent development conversation strong focus hold open number key inclusive conversation appointment corporate executive encourage leader employee team identify significant gsk role share ownership delivery support development talent strategy focus create include change approximately safe inclusive workplace manager role gsk feel able inspire promote exist talent realise potential hiring externally bring fresh idea skill leadership role engagement launch new employee performance system individual objective senior leader gsk playing link priority pivotal role engage people innovation performance trust strategy initiative new gskwide bonus system reflect new let talk programme case study progress priority october senior overall business performance leader attend threeday conference encourage regular consistent deepen understanding performance development strategy priority develop conversation effective tool inspire team train people support promotion second deliver performance line leadership addition cultural change gsk leader share knowledge help improve colleague performance strong value purpose coach programme fundamental way operate central year graduate development highperformance postgraduate join future leader valuesbase culture alignment esprit development programme people longterm business gsk rank guardian priority approach graduate employer evolve gsk culture retain time graduate reinforce value introduce employer new expectation guide behaviour employee courage accountability development teamwork engage strategic success rely survey question align employee ability engage employee new priority result strategy gsk longterm priority discuss leader employee identify priority focus area plan conduct survey twice year people take gsk global employee survey well response new let talk programme rate employee engagement score encourage employee discuss key setting issue share view idea baseline year improvement strengthen gsk leader employee recommend gsk business host conversation great place work team range topic feedback previous survey proud insight collate share work employee senior leader help shape future organisation gsk annual report strategic report governance remuneration financial statement investor information diverse inclusive workplace early rank stonewall workplace equality index strategy action hampton alexander review lgbt inclusive ftse company find gsk employer gsk familyfriendly eighthhigh proportion woman commit remove barrier policy key success board line increase understanding ensure ftse average female factor drive employee disability representation executive committee opportunity disability confidence engagement member direct report network employee resource group continue focus improve employee member number come year overall country support global proportion woman management disability council drive change role gsk promote disability confidence woman half new graduate esprit participant health wellbee new apprentice science technology engineering role woman commit provide health traditionally underrepresented programme service help people lead healthy life publish datum gender pay programme claire thomas gap time follow service available country senior vice president new legislation gender pay gap human resource permanent ukbased gsk employee cover employee globally mean outperform national partnership prevention programme average continue offer employee family review pay equity global level member access preventive healthcare service immunisation cancer screen little extra accelerate difference cost expand programme programme provide coach asia pacific region prepare support highperforme female extend europe manager begin programme reportable injury illness rate promote compare woman hour work gsk period compare rate woman management comparable leading company diverse reverse mentoring sector remain low provide leader opportunity svpvp year learn junior employee director different background help leader manager flexible lifefriendly practice develop inclusive leadership skill total mentoring pair gsk familyfriendly policie employee gender number place key success factor drive employee male female total seven nationality represent engagement board board executive committee increase maternity leave mother management seventyeight nationality week introduce week total future leader graduate programme pay parental leave parent adoptive people complete parent partner bond management senior manager define company act strategic report director emerge leader programme singapore new baby raise commitment report regulation include person develop asia leadership pipeline familyfriendly policy responsible planning direct control activity company strategically significant global lgbt council continued market example pakistan company board include director engage people gsk lgbt revise maternity policy eligible undertaking include consolidated account issue support lgbt employee increase fully pay maternity employee resource group spectrum leave day employee seek improve worklife member country balance range flexibility model world market offer taxfree holiday programme enable employee sacrifice salary exchange day extra holiday programme usage rate eligible employee base benchmarke datum pharmaceutical safety group gsk annual report trust continue ethical aim run business ethically conduct environmentally sustainable way environmental sustainability ethical conduct work party expect supplier strive build valuesbased culture party comply standard train people standard ethic labour right health safety expect encourage reporting environment end concern act swiftly deploy rollout transparently issue occur party oversight programme party expect remainder living value complete early provide mandatory annual training risk assessment party value code conduct help conduct employee complementary worker improvement plan agree manage ethical dilemma programme begin base value practice work initial risk assessment live value training emphasise party undergo extensive zero tolerance bribery corruption independent assessment highlight commitment issue standardise programme enable product quality datum protection identify manage party risk explain key risk effectively embed employee complementary process use engage worker complete training supplier people additional training antibribery corruption help conduct party audits manage specific risk inherent health safety ethic environment role responsibility labour right audits quality process assess value embed conduct identify unsatisfactory area value maturity assessment engage party develop past year improvement plan track progress significant issue remain unresolved employee discipline reporting investigate concern suspend terminate work breakdown type policy violation speak campaign raise party awareness multiple channel offer people outside gsk human right voice concern ask question signatory global independent party compact commit confidentially anonymously preferred uphold universal declaration year receive report human right core labour review standard set international formal investigation initiate labour organization ilo expand information act employee fail adhere human right expectation live policy employee train completion marketing value train particularly labour code conduct promotional activity discipline policy violation right supply chain hold attendance local work include fail workshop senior manager build payroll iog lau tla ioti sns complete mandatory living understanding labour right risk ano tra ibn ure policy tra ins imn eti oib ery mrr identify team training requirement practice violation receive document warning continue monitor exist supplier receive verbal warning screen new supplier include dismiss standardised labour right clause agree leave voluntarily party contract update supplier portal human right policy information labour right support compliance gsk annual report strategic report governance remuneration financial statement investor information environmental sustainability platform gsk water supplier exchange encourage supplier continue seek way use water aim minimise environmental share good practice sustainability operation supply chain impact stage value chain recognise outstanding performance use product extend access product annual supplier environmental reduce water use people sustainability award water use increase drive growth vaccine business carbon use product overall carbon footprint significant impact scope end scope emission direct emission majority patient pharmaceutical consumer healthcare operation scope emission use propellantbase inhaler ventolin manufacturing site complete water supply chain use propellant greenhouse gas risk assessment line water product release use reduce impact stewardship standard site propellant complex continue develop plan address risk operational emission scope research feasible solution identify include reduce compare issue include change way work local community previous year result manufacture reduce stakeholder effort enhance water continue focus energy efficiency propellant maintain efficacy stewardship prioritise site area measure purchase renewable safety patient water stress energy baseline reduce annual carbon emission gsk new generation inhaler product waste energy use save cumulative ellipta device develop cut operational waste million tonne coe launch dry powder inhaler produce hazardous dpis release greenhouse waste nonhazardous waste scope emission fall gas emission certify progress million tonne coe assessment respiratory inhaler target slow waste portfolio carbon trust show produce remain baseline year result lifecycle carbon footprint increase novartis integration increase dpi time low focus reclaim waste sale propellantbase inhaler propellantbase inhal reuse recycling recovery engage supplier drive month treatment improvement example encourage site worldwide supplier monitor disclose achieve zero waste landfill performance ecodesk external tonne operational waste resource offer benchmarke end landfill information help develop recycle incinerate improvement plan recover energy carbon emission plus intensity ratio regulation tonne coea scope emission scope emission datum available scope emission intensity ratio scope emissionssales revenue tonne coem scope fte tonne coefte carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise edition datum include novartis site emission headcount recently available scope datum publish datum online late month treatment dose propellant inhaler carbon footprint coe pack compare dose oncedaily ellipta dpi carbon footprint coe pack ggsskk aannnnuuaall rreeppoorrtt group financial review continue group financial review section cfos statement approach brexit approach tax viability statement report framework noncontrolle interest viiv healthcare group turnover total result adjust result cash generation conversion financial position resource critical accounting policy treasury policy gsk annual report strategic report governance remuneration financial statement investor information group financial review continue progress deliver strategy financial goal set financial architecture simon dingemans chief financial officer result reflect continue focus magnitude charge relate execution include drive growth impact tax cut job exist product recent launch act enact exclude control cost tightly help build well adjust result operate leverage group gsk continue present total invest future growth adjust result table driver improve cash generation commentary provide increase capacity support reconciliation investment dividend pay shareholder sale growth financial architecture business deliver financial architecture growth ensure delivery strategic priority innovation performance pharmaceutical sales aer trust translate clear financial goal cer growth hiv product embe group ellipta portfolio nucala offset decline sale seretide goal target deliver advair establish pharmaceutical viability statement strong growth sale improve drag divestment viability statement set innovation business assessment prospect drive earning share fast sale vaccine generate significant group year well operate leverage growth meningitis flu portfolio present tight cost control continue financial benefit increase demand efficiency convert establish vaccine finish year earning cash overall vaccine sales aer reinveste business return cer shareholder critically goal need consumer healthcare deliver growth deliver right way consistent aer cer reflect strong value objective building performance power brand trust gsk pain oral health category partly architecture offset impact continue competitive goal help create stepchange pressure allergy category alignment operation broad market slowdown key fully integrate business include category addition report growth new endtoend emphasis cost cash impact divestment capital discipline nigerian beverage business implementation good report framework service tax india reporting framework describe detail follow operate leverage detailed review change total operating margin core result rename sale compare adjust result include increase margin reflect primarily ordinary course legal charge low accounting charge relate remeasurement liability contingent consideration option preferential dividend footnote use number adjust nonifrs measure report performance business describe include adjust result free cash flow cer growth rate nonifrs measure consider addition substitute superior information present accordance ifrs gsk annual report group financial review continue capital allocation framework key priority capital pharmaceutical pipeline invest business consumer healthcare option innovation vaccine capacity improve share dividend expect performance cash shareholder return focus rebuild free cash flow time generation target cover return dividend growth trust transaction strict discipline return adjust operating margin tax reform contingent consideration percentage point high enactment tax cut job end gsk liability percentage point high act december expect contingent consideration payment cer basis reflect improve positive impact future tax billion billion relate operating leverage drive sale growth earning gsk business estimate present value future favourable mix primarily reduction federal payment shionogi viiv healthcare business benefit corporation tax rate january payment shionogi calculate vaccine settlement lose party expect benefit group quarter base highteen supply volume favourable yearonyear effective tax rate adjust profit percentage revenue relevant comparison inventory adjustment percentage point product principally dolutegravir tight control ongoing cost intend apply flexibility cash discount fair value total future business contribute benefit reform provide payment reflect current expectation benefits restructure accordance capital allocation total future sale product integration partly offset framework detail provide note increase investment include contingent consideration liability enactment new law charge million priority result number additional charge free cash flow review voucher utilise hiv reduce total earning net cash inflow operating activity continue price pressure particularly million billion free cash flow group respiratory supply chain investment charge represent management billion compare billion work maintain tight control cost estimate impact tax reform sterling increase group include supply chain group base information currently reflect improved operating profit efficiency mixture site closure available information detailed performance positive currency benefit consolidate manufacturing supplier application act available reduce cash spending restructuring base simplify global distribution assumption underlie estimate capital expenditure partly offset logistic network change consequent adjustment increase work capital mainly stepping focus procurement charge take build inventory advance new new global organisation material impact result group product launch financial efficiency earning share net debt financial efficiency remain priority total eps net debt end amount successfully refinance mature debt increase reflect primarily low billion billion lower allow hold net accounting charge relate end reduction primarily finance cost relatively flat year remeasurement liability attributable improve free cash flow continue focus protect contingent consideration option billion disposal proceed credit profile funding flexibility preferential dividend billion translation benefit billion sterling value adjust eps aer nonsterling denominate debt cer reflect improve operating offset cash dividend pay leverage deliver earning growth shareholder year billion fast sale growth gsk annual report strategic report governance remuneration financial statement investor information capital allocation framework event substitutable generic approach brexit priority use capital version advair introduce remain present july market group expect evaluated impact brexit focus particular priority adjust eps growth cer business operation include invest business deliver cash base expect decline supply chain quality oversight return shareholder dividend advair sale priority maintain continuity potentially access strategic event midyear introduction gsk supply medicine vaccine acquisition strengthen substitutable generic competitor advair health product patient business subject meeting strict group expect fullyear consumer set return criterion establish advair sale million priority investing business uncertainty remain future cer adjust eps flat identify primary focus relationship cer strengthen pharmaceutical business result agree particular pipeline scenario reflect benefit riskbase approach mitigation confirm attractiveness accept tax reform expect effective organisation implementation consumer healthcare option tax rate adjust profit contingency plan underway exercise continue expand able guidance total january immediate capacity key product line result reliably forecast certain focus supply chain include vaccine business material element total result expand ability conduct reteste certification strengthen allocate capital future fair value movement medicine transfer marketing ensure allocate funding contingent consideration option authorisation register attractive return return shareholder entity update packaging available implement clearer maintain ordinary packaging leaflet amend framework create new board dividend line commitment manufacturing importation licence govern allocation capital shareholder time secure additional warehousing business close novartis transaction early currently anticipate cost expand use cash flow gsk recognise importance implement necessary base return metric individual dividend shareholder aim change million project assessment distribute regular dividend payment year able create fully integrate business determine primarily reference subsequent ongoing additional cost unit pharmaceutical vaccine free cash flow generate business approximately million year consumer healthcare able funding investment necessary include additional custom duty apply consistent cash return support group future growth transaction administration cost invest capital croic methodology charge represent estimate prioritise investment group board intends maintain dividend impact brexit base information compare return current level share currently available information integrate business subject material change external change business allocate capital environment performance expectation require brexit regularly benchmark time free cash flow strengthen available assumption underlie peer relevant intend build free cash flow cover estimate change business annual dividend target range consequent adjustment return dividend guidance growth additional cost expect expect continue progress incur continue adjust include sale growth contribution fuller review financial result plan expect financial impact new recent product launch hiv set page negotiation regulation develop respiratory vaccine deliver necessary complex expectation adjust eps change march ambitious growth dependent number factor potentially disruptive short term include particular uncertainty relate support effort secure status timing extent potential generic quo transition period minimise competition advair simon dingemans disruption long term continue believe brexit chief financial officer material impact business gsk annual report group financial review continue approach tax understand understand responsibility pay total tax rate reflect appropriate tax fully reassessment estimate uncertain responsibility pay support effort ensure company tax position follow settlement appropriate appropriately transparent number open issue tax authority tax affair manage tax important jurisdiction tax element economic contribution tax risk manage set policy bring country operate financially efficient procedure ensure consistency engage artificial tax compliance tax legislation audit deliver arrangement business risk committee board commercial substance seek sustainable tax rate responsible approve tax policy avoid tax use tax haven risk management approach transaction fully disclose tax authority zero tolerance seek maintain open positive approach tax evasion facilitation relationship government tax tax evasion authority worldwide welcome constructive debate taxation policy substantial business employment presence country see enactment significant globe pay significant reform tax law multiple jurisdiction tax include corporation expect continue focus business taxis tax tax reform future drive associate employee oecds base erosion profit time responsibility shift bep project european shareholder financially efficient commission initiative fiscal state deliver sustainable tax rate aid investigation output approach look align investment oecd bep project clarify strategy country important principle tax pay substantial economic activity profit supply chain government policy promote profitmake activity take place regime attractive business gsk support bep proposal investment activity particular implementation transparent intent available oecds recommendation country relevant tax payer example include country report include exchange patent box research datum tax authority development expenditure credit datum validate exist information group corporate tax charge hold taxpayer support ability million million ensure multinational group pay profit million appropriate tax million represent effective tax rate detailed tax implication brexit cash dependent outcome negotiation tax payment million year million addition currently unknown continue taxis pay profit pay duty work closely abpi bia levy transactional employment taxis analyse potential implication adjust tax rate industry order highlight key focus area subject material government brexit change product mix negotiation direct tax implication material change tax regulation law particular expect limited country operate gsk indirect implication follow impact tax reform significant include potential group effective adjust tax rate custom duty cost additional year expect transaction administrative cost region associate manage import export obligation movement group total tax rate good high approach brexit set adjusted tax rate affect impact swiss tax reform approach tax set detail explain note public policy position section footnote transactionrelated charge arise website detail use number adjust nonifrs group option liability corporate tax charge year set measure report performance business describe gsk annual report strategic report governance remuneration financial statement investor information viability statement accordance provision revision code follow hypothetical downside scenario evaluate gsk assess prospect company long scenario business performance risk include key period month require go concern performance risk include low sale new product provision director confirm reasonable possible impact generic alternative seretideadvair expectation gsk continue operate meet liability intensify competition hiv market great adverse fall year director assessment impact generic competition competitive launch reference gsk current position gsk product possible supply manufacturing prospect strategy board risk appetite gsk challenge principal risk manage detailed page strategic report scenario external macroeconomic risk scenario reflect incremental risk business drive outside factor board review internal control risk management intense competition increase pricing pressure policy approve governance structure code europe potential impact material conduct appraise approve major financing investment negative change macroeconomic healthcare licensing decision evaluate monitor performance environment prospect gsk focus largely improve scenario principal risk scenario include severe longterm financial performance delivery company assessment potential loss impact principal risk business strategy align innovation performance relate patient safety product quality supply chain continuity trust priority antibribery corruption consequent regulatory board review gsk strategy make significant capital action fine fundamentally threaten investment decision long term time horizon base operation risk manage mitigating activity multiyear assessment return capital performance describe page company business unit market opportunity scenario option exercise scenario evaluate pharmaceutical vaccine consumer healthcare sector additional funding requirement assume early potential approach align gsk model achieve balanced exercise outstanding option hold partner growth invest high quality innovative product patient hiv consumer healthcare business consumer healthcare provider internal external parameter increasingly unpredictable year review make certain assumption long time horizon gsk focus detailed bottomup plan normal level capital recycling likely occur consider year cycle plan review annually additional financing facility require respective level director approve business forecast show expect funding flexibility headroom financial impact director believe year assessment result stress testing certain combination period viability statement appropriate align hypothetical scenario increase funding demand company establish business planning process gsk require mitigate change group fund strategy balance long term nature investment pharmaceutical light liquidity available group base vaccine consumer healthcare sector assessment analysis director reasonable expectation period analysis near term business performance stress test describe company able realistically visible continue operation meet liability fall plan stress test series robust operational year period assessment principal risk downside scenario board review risk downside scenario consider gsk cash flow sustainability dividend fund strategy insurance provision recovery key financial ratio period metric subject sensitivity analysis involve flex number main assumption underlie forecast individually combination mitigate action realistically take avoid reduce impact occurrence underlie risk gsk annual report group financial review continue report framework presentation group result contingent consideration group financial review discuss operate financial gsk recognise significant liability contingent performance group cash flow financial position consideration million december fair value resource compare result year primarily discount basis million represent estimate result precede year present value future amount payable shionogi relate viiv healthcare discount payment shionogi use number adjust nonifrs measure report calculate base sale performance life performance business measure relevant product principally dolutegravir describe management planning reporting purpose discussion effect require ifrs accounting treatment gsk presentation investment analyst rate agency recognise fair value liability balance sheet directly comparable similarly describe remeasurement charge reflect immediately operate measure company nonifrs measure income charge adjust total result present consider addition substitute superior adjust result gsk cash payment future information present accordance ifrs discharge liability record profit total result loss account future earning total report result represent group overall performance result contain material unusual non free cash flow operational item obscure key trend factor adjust free cash flow long report determine group operational performance result free cash flow definition amend include report adjust result nonifrs measure contingent consideration payment period adjust result free cash flow nonifrs measure define announce april change financial report net cash inflow operating activity capital expenditure framework press release core result contingent consideration payment net interest dividend pay rename adjust result instead legal charge noncontrolle interest plus proceed sale property expense significant legal charge expense exclude plant equipment dividend receive joint venture order present adjust result legal charge associate management planning reporting expense include adjusted result significant legal charge purpose discussion presentation investment expense arise settlement litigation analyst rate agency free cash flow growth calculate government investigation normal course report basis reconciliation net cash inflow materially large regularly occur individual matter operation free cash flow present include certain major legacy legal matter new free cash flow conversion significant legal matter exclude order present adjust free cash flow conversion free cash flow percentage result disclose time total earning result enactment tax cut job act december gsk record charge initial application work capital conversion cycle reduce total earning billion set work capital conversion cycle calculate number magnitude gsk report charge day sale outstanding plus day inventory outstanding adjust item obscure key trend day purchase outstanding group operational performance year cer aer growth adjust result exclude follow item total result order illustrate underlying performance practice amortisation impairment intangible asset exclude computer discuss result term constant exchange rate cer growth software goodwill major restructuring cost include represent growth calculate exchange rate cost follow material acquisition significant legal charge net determine result overseas company sterle insurance recovery expense settlement litigation remain unchanged previous year cer government investigation transactionrelate accounting represent growth constant exchange rate aer adjustment significant acquisition item include represent growth actual exchange rate disposal associate product business operate income royalty income tax effect item impact enactment tax cut job act gsk believe adjust result representative performance group operation allow key trend factor drive performance easily clearly identify shareholder definition adjust result set align group result majority peer company report earning reconciliation total adjust result set include detailed breakdown key adjust item provide shareholder ensure visibility transparency assess group performance gsk annual report strategic report governance remuneration financial statement investor information noncontrolle interest viiv healthcare trading profit allocation contingent consideration payable posttax basis viiv healthcare subsidiary group shionogi december million december operating result turnover operate profit profit tax million expect pay year include group income statement portion exit right earning allocate noncontrolle interest own shareholder line respective equity pfizer request ipo viiv healthcare time shareholding pfizer shionogi gsk consent ipo offer shareholder include gsk entitle preferential dividend complete month pfizer require gsk acquire determined performance certain product shareholde original agreement gsk shareholder contribute relative performance unconditional right long subsequent distribution product change time proportion overall earning shareholder withhold consent exercise viiv healthcare allocate shareholder change pfizer option result accordance ifrs gsk particular increase sale tivicay triumeq recognise liability option balance sheet favourable impact proportion preferential dividend gsk notify pfizer irrevocably give allocate gsk gsk entitle approximately right accordingly recognise liability option adjust earning viiv healthcare group balance sheet initial value million remeasurement liabilitie preferential dividend consistent revise treatment end allocate pfizer shionogi include adjust gsk recognise liability future preferential dividend item operating income anticipate payable pfizer shionogi group balance sheet acquisitionrelate arrangement closing balance liability relate pfizer shareholde agreement reach acquire shionogis interest follow shionogiviiv healthcare joint venture viiv healthcare agree pay additional consideration shionogi contingent performance product develop pfizer option joint venture principally dolutegravir liability pfizer preferential dividend contingent consideration estimate recognise group balance sheet date acquisition subsequent original agreement shionogi request remeasurement reflect operate income gsk acquire shareholding viiv healthcare month adjust item income statement window commence gsk cash payment shionogi viiv healthcare unconditional right long subsequent distribution quarter reduce balance sheet liability contingent shareholder withhold consent exercise consideration result record income shionogi option result gsk recognise liability statement total cash payment shionogi option balance sheet gsk notify respect contingent consideration amount million shionogi irrevocably give right accordingly payment calculate base sale performance recognise liability option group balance relevant product previous quarter reflect sheet initial value million shionogi cash flow statement partly operate cash flow partly irrevocably agree waive option result gsk investing activity tax relief payment derecognise liability option group balance reflect group adjust item tax charge sheet directly equity value liability million payment relate original estimate derecognise fair value contingent consideration acquisition gsk option shionogis shareholding viiv shionogiviiv healthcare joint venture million healthcare original agreement exercisable report investing activity cash flow statement month window commence gsk payment relate increase liability irrevocably agree waive exercise window acquisition report operate cash flow month window remain option movement contingent consideration payable shionogi fair value value accounting purpose follow contingent consideration begin year addition remeasurement income statement cash payment operate cash flow cash payment invest activity movement contingent consideration end year addition represent recognition preferential dividend payable shionogi gsk annual report group financial review continue group turnover group turnover geographic region turnover aer growth cer growth revise growth growth cer europe international sale growth aer cer drive continue strong performance triumeq tivicay growth respiratory portfolio strong performance hepatitis meningitis vaccine europe sale grow aer flat cer growth triumeq tivicay meningitis vaccine offset decline establish pharmaceutical include impact disposal group turnover romanian distribution business respiratory sale aer flat cer decline seretide offset growth growth cer growth new respiratory product pharmaceutical international sale growth aer cer reflect vaccine strong growth triumeq tivicay respiratory portfolio consumer healthcare establish pharmaceutical flat include impact group turnover divestment growth emerge market aer cer impact divestment group turnover year increase aer cer sale new pharmaceutical vaccine product million growth deliver business pharmaceutical sale aer cer reflect growth growth cer continue strong growth new respiratory hiv product respiratory partly offset decline old respiratory product include seretideadvair establish pharmaceutical include anoro ellipta impact recent divestment arnuity ellipta incruse ellipta vaccine sale aer cer reflect strong nucala performance meningitis influenza vaccine high demand establish vaccine benefit relvarbreo ellipta favourable yearonyear cdc stockpile movement cvmu eperzantanzeum consumer healthcare sale grow aer cer reflect strong performance power brand pain oral health hiv category partly offset impact continue competitive tivicay pressure allergy category broad market slowdown triumeq key category addition report growth impact pharmaceutical nigerian beverage business divestment bexsero implementation good service tax gst india menveo july shingrix vaccines gsk identify series new pharmaceutical vaccine product expect deliver billion revenue annum cer basis product set include trelegy ellipta juluca initial sale million million respectively group previously announce plan withdraw tanzeum exchange rate equivalent value sale billion sale new pharmaceutical vaccine product million grow million sterling term aer cer represent approximately pharmaceutical vaccine turnover year gsk annual report strategic report governance remuneration financial statement investor information respiratory total respiratory portfolio sale aer cer pharmaceutical aer cer europe aer flat cer international aer cer growth new respiratory product offset decline seretideadvair turnover aer growth cer growth new respiratory product record combine sale million sale ellipta product aer cer drive continue strong growth ongoing rollout europe international sales nucala million group turnover sterling increase million include sale million aggregate growth ellipta product drive primarily contribution sales aer cer market share gain total relvarbreo ellipta sale grow aer cer million aer cer million anoro ellipta sale grow aer cer million reflect market share gain ellipta product breo anoro incruse arnuity continue grow market share year seretideadvair sale decline aer cer pharmaceutical turnover million sale decline aer cer volume decline negative impact price payer rebate growth growth cer adjustment relate prior period favourably impact sale respiratory year europe seretide sale aer cer million volume decline negative impact hiv price reflect continued competition generic immunoinflammation transition respiratory portfolio new product establish pharmaceutical international sale seretide decline aer cer million volume decline negative impact price reflect increase generic competition transition pharmaceutical turnover million aer new respiratory product cer respiratory sale grow aer cer million drive ellipta portfolio nucala hiv sale pricing pressure affect old product ventolin aer cer million drive increase sale decline aer cer million include market share triumeq tivicay sale establish negative impact payer rebate adjustment relate prior period pharmaceutical decline aer cer reflect flixotideflovent sale aer cer percentage point impact recent divestment divestment million aer cer reduce overall pharmaceutical cer growth percentage net impact adjustment payer rebate prior period point significantly impact contribution europe respiratory portfolio broadly neutral report emerge market respiratory sale sale growth aer cer drive hiv portfolio new respiratory product europe sale grow aer decline cer reflect continued transition respiratory portfolio generic competition kivexa disposal romanian distribution business reduce growth percentage point report international sale growth impact benefit accelerated sale inventory supply agreement novartis disposal thrombosis anaesthesia business aspen reduce report growth international percentage point emerge market percentage point aer cer sales japan grow aer cer gsk annual report group financial review continue hiv establish pharmaceutical hiv sale increase aer cer million sale establish pharmaceutical million year aer cer europe aer decline aer cer impact comparison cer international aer cer growth accelerate sale inventory supply agreement novartis region drive continue increase market share disposal thrombosis anaesthesia triumeq tivicay partly offset impact generic business aspen disposal romanian competition epzicomkivexa particularly affect european distribution business impact disposal market ongoing increase patient number triumeq growth establish pharmaceutical portfolio tivicay result sale million million approximately percentage point respectively year juluca approve avodart franchise decline aer cer million november record initial sale million primarily loss exclusivity europe epzicomkivexa sale decline aer cer impact favourable rar adjustment million reflect ongoing generic competition dermatology sale grow aer cer million immunoinflammation reflect improved supply emerge market growth japan sale grow aer cer year negative impact augmentin sale grow aer cer million divestment raxibacumab record strong sale offset growth benlysta aer cer million drive strong performance gsk annual report strategic report governance remuneration financial statement investor information establish vaccine sale dtpacontaine vaccine infanrix pediarix vaccines boostrix aer flat cer boostrix sale grow aer cer benefit high demand region infanrix pediarix sale aer cer turnover mainly drive increase competitive pressure aer growth cer growth europe new market entrant europe partly offset favourable yearonyear cdc stockpile movement hepatitis vaccine grow aer cer million group turnover benefit competitor supply shortage high demand partly offset unfavourable impact cdc stockpile movement supply constraint europe international rotarix aer cer million reflect high demand europe international synflorix sales aer cer million low pricing emerge market partly offset high demand international priorixpriorix tetravarilrix sale flat aer cer million mainly supply constraint international vaccine turnover cervarix sale increase aer cer million growth growth drive recent launch china cer meningitis influenza shingle establish vaccine vaccine turnover grow aer cer million primarily drive meningitis vaccine bexsero grow region menveo grow europe high sale influenza product primarily europe establish vaccine growth drive hepatitis vaccine mainly competitor supply shortage high demand boostrix rotarix launch cervarix china favourable yearonyear cdc stockpile movement infanrix pediarix menveo contribute growth partly offset increase competitive pressure infanrix pediarix europe low synflorix sale drive primarily low pricing develop country meningitis meningitis sale grow aer cer million bexsero sale growth aer cer drive new national immunisation programme private market sale regional tender europe grow demand share gain strong private market sale international menveo sale grow aer cer primarily drive impact favourable yearonyear cdc stockpile movement partly offset supply constraint international influenza fluarixflulaval sale aer cer million reflect strong sale execution primarily high demand europe shingle shingrix record initial sale channel million fda approval favourable acip recommendation gsk annual report group financial review continue wellness wellness sale grow aer cer million consumer healthcare reflect strong performance voltaren cold flu seasonal product partly offset weak performance allergy product turnover aer growth cer growth respiratory sale aer cer strong broadly base growth theraflu otrivin particularly europe international partly offset competitive pressure flonase otc private label product group turnover pain relief sale aer cer drive significantly voltaren growth region benefit momentum hour variant strong instore marketing activation expansion expert detail strong performance international market panadol grow strongly europe benefit new advertising campaign international low single digit oral health oral health sale grow aer cer million sensodyne continue drive performance reporting growth aer cer strong delivery region follow consumer healthcare turnover roll generation sensodyne rapid relief launch pronamel strong bright sale parodontax continue growth growth cer grow strongly reflect doubledigit performance europe international drive brand reset increase dentist wellness recommendation launch quarter oral health denture care grow midsingle digits doubledigit growth nutrition emerge market partly offset slow consumption growth skin health germany nutrition nutrition sale grow aer decline cer million adversely impact sale nigeria beverage business revise growth growth cer implementation gst july continue competitive pressure horlick india net impact divestment nigeria beverage business implementation europe gst offset favourable comparison impact international demonetisation prior year reduce nutrition cer growth approximately percentage point consumer healthcare turnover aer cer skin health million impact slow global growth key category skin health sale grow aer flat cer strong performance power brand wellness oral million low singledigit growth slight decline health partly offset competitive pressure allergy europe international flat fenistil sale grow strongly category impact flonase otc low sale tail good performance central eastern europe germany brand nutrition skin health category broad middle east follow digital activation new medium market slowdown key category addition report growth campaign physiogel lamisil continue impact impact disposal nigeria beverage business competitor activity whilst lip care sale grow midsingle digit implementation good service tax gst india july net effect partly offset benefit comparison impact demonetisation india divestment gst demonetisation combine reduce overall consumer healthcare cer growth approximately percentage point sale new gsk innovation product introduction year rolling basis represent approximately sale period notable launch year include parodontax flonase sensimist continue global roll flonase otc line extension sensodyne include generation sensodyne rapid relief sensodyne deep clean gsk annual report strategic report governance remuneration financial statement investor information total result cost sale cost sale percentage turnover turnover aer growth cer growth percentage point sterling term percentage point cer term compare primarily reflect phase cost manufacture restructuring programme include noncash write down result plant closure write asset relate progressive withdrawal tanzeum continued adverse pricing pressure pharmaceutical primarily respiratory additional supply chain investment partly offset favourable product mix business particularly pharmaceutical reflect impact high hiv sale vaccine reflect benefit settlement lose party supply volume favourable yearonyear comparison inventory adjustment continue contribution integration restructuring saving business total operating profit aer growth cer growth sell general administration sga cost turnover percentage point low sterling cer term primarily reflect low restructuring cost tight control ongoing operating cost particularly consumer healthcare continue cost reduction pharmaceutical include benefit pharmaceutical restructure programme integration benefit vaccine consumer healthcare partly offset increase investment promotional product support particularly new launch respiratory hiv vaccine research development expenditure million turnover high aer high cer include charge million utilisation priority review total result group set voucher increase investment progression number mid latestage programme addition growth high restructuring cost primarily result provision future clinical obligation result progressive turnover turnover cer withdrawal tanzeum decision terminate right turnover sirukumab high intangible asset impairment cost sale sell general royalty operating incomeexpense administration net operate expense million research million primarily reflect low accounting charge arise development remeasurement contingent consideration liability relate royalty income shionogiviiv healthcare joint venture acquisition operating income novartis vaccine business value attributable expense consumer healthcare joint venture option liability operate profit pfizer option pfizer shionogi preferential net finance cost dividend viiv healthcare remeasurement charge profit disposal million million reflect update trading interest associate forecast change exchange rate assumption share tax unwind discount apply future liability profit associate million include charge million arise joint venture positive impact tax reform valuation profit taxation consumer healthcare hiv business charge taxation partly offset gain million disposal profit taxation anaesthesia business aspen royalty income million year million profit attributable shareholder earning share earning ad gsk annual report group financial review continue total result continue operate profit profit taxation total operating profit million compare take account net finance cost profit disposal million increase primarily reflect reduce associate share profit associate profit impact accounting charge relate remeasurement taxation million compare million liability contingent consideration option preferential taxation dividend addition operating profit benefit improve operating margin drive sale growth business particularly vaccine favourable mix current year charge business vaccine favourable yearonyear rest world current year charge comparison inventory adjustment benefit oneoff settlement cost sale continue tight control charge respect prior period ongoing cost benefit restructure integration total current taxation contribute improved margin vaccine consumer total defer taxation healthcare pharmaceutical benefit offset taxation total profit overall increase pharmaceutical investment include tax charge million total profit represent effective impact priority review voucher continue price tax rate include charge pressure particularly respiratory supply chain investment million arise tax reform describe detail support new product partly offset million benefit swiss net finance cost tax reform arise revaluation defer tax liability acquire consumer healthcare brand reflect reduction finance income headline tax rate interest income noncontrolle interest fair value movement allocation earning noncontrolle interest amount million million include noncontrolle interest allocation consumer healthcare profit million finance expense million allocation viiv healthcare profit interest expense increase million million loss include unwind discount liability impact change proportion preferential dividend remeasurement fair value movement shareholder increase allocation viiv finance expense healthcare profit primarily reflect impact low remeasurement charge increase allocation consumer healthcare profit reflect improved operating profit profit disposal associate benefit swiss tax reform profit disposal associate million nil earning share arise disposal entire shareholding total earning share compare associates river vision development ltd jcr increase reflect reduce impact charge arise pharmaceutical ltd revaluation liabilities contingent consideration option associate increase sterling value share tax profit associate joint venture group hiv consumer healthcare business benefit share profit associate joint venture million swiss tax reform improve performance relevant million business partly offset charge arise tax reform dividend board declare interim dividend result total dividend year penny line dividend declare note financial statement dividend gsk annual report strategic report governance remuneration financial statement investor information adjust item divestment intangible intangible significant total asset asset major transaction legal tax adjust adjust result reconciliation result amortisation impairment restructure relate item reform result december turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operating profit net finance cost profit disposal associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million divestment intangible intangible significant adjust total asset asset major transaction legal result adjust result reconciliation result amortisation impairment restructure relate item revise december turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operating profit net finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report group financial review continue adjust item continue intangible asset amortisation impairment aggregate impact unwind discount future intangible asset amortisation million compare potential liability million million million intangible asset impairment million include million consumer healthcare joint venture million include impairment relate progressive option million contingent consideration relate withdrawal tanzeum number commercial shionogiviiv healthcare joint venture remain asset follow refocus pipeline charge million drive adjustment trade amortisation impairment charge noncash forecast impact update exchange rate assumption item forecast relevant business update multiple valuation consumer healthcare joint major restructure integration venture option major restructure integration charge million incur million noncash charge contingent consideration cash payment million primarily reflect write asset shionogi company reduce balance sheet liability result decision withdraw tanzeum terminate right record income statement total contingent sirukumab arise establishment group new consideration cash payment amount million business priority write asset relate million include cash payment viiv reduction site network cash charge million healthcare shionogi relation contingent consideration million include charge result decision liability include preferential dividend amount withdraw tanzeum terminate right sirukumab cash million million payment million million include explanation accounting noncontrolle interest settlement certain charge previously accrue viiv healthcare set reflect deferral payment cash payment approximately billion expect programme impact profit tax transactionrelated adjustment deliver incremental cost saving billion include include accounting credit respect swiss tax reform billion currency benefit million arise revaluation defer tax liability acquire consumer healthcare brand reflect reduction charge combined restructure integration programme headline swiss tax rate date billion cash charge billion cash payment billion date noncash charge divestment item billion divestment item include profit disposal anaesthesia business aspen million number extension exist combined programme agree asset disposal equity investment impairment certain board july total cash charge combine adjust item significant legal charge million programme expect approximately billion million include benefit settlement exist matter noncash charge billion programme provision ongoing litigation significant legal cash deliver approximately billion annual saving include payment million million currency benefit billion extend programme expect deliver total annual saving billion tax reform constant currency basis estimate billion enactment tax cut job act result currency benefit basis average exchange rate number additional charge reduce total earning transactionrelated adjustment million transactionrelated adjustment result net charge firstly increase valuation hiv consumer healthcare million million primarily reflect business lower tax rate result increase accounting charge remeasurement liability relate liability contingent consideration option unwind discount effect contingent consideration million relate acquisition shionogiviiv healthcare joint secondly additional tax charge million comprise venture contingent consideration relate acquisition reduction value defer tax asset hold novartis vaccine business value attributable future liability pension current tax credit consumer healthcare joint venture option hold novartis amount million charge million arise transactionrelated adjustment exclude impact reserve subsidiarie entity group cash liability arise implementation tax cut impact charge spread year job act set separately approximately expect payable year charge partly offset allocation noncontrolle chargecredit interest amount million adjustment consumer healthcare joint venture option relate viiv healthcare consumer healthcare joint contingent consideration shionogiviiv venture healthcare joint venture include shionogi preferential dividend charge represent management estimate impact tax reform group base information currently viiv healthcare option pfizer preferential dividend available guidance treasury implementation act available particularly regard contingent consideration novartis vaccine business repatriation tax provision assumption underlie estimate adjustment change result adjustment charge take material impact result group total transactionrelated charge gsk annual report strategic report governance remuneration financial statement investor information adjust result sell general administration turnover aer growth cer growth revise growth turnover turnover cer sell general administration sga cost turnover percentage point low sterling term percentage point low cer basis primarily reflect tight control ongoing cost particularly consumer healthcare continue cost reduction pharmaceutical include benefit pharmaceutical restructure programme integration benefit vaccine consumer healthcare partly offset increase investment promotional product support particularly new launch respiratory hiv vaccine adjust operating profit aer growth cer growth research development growth turnover turnover cer research development expenditure million turnover high aer high cer include charge million utilisation priority review voucher increase investment progression number mid latestage programme revise growth djuste result exclude significant legal charge revise definition cer prior year figure revise discovery use adjust result nonifrs measure development metric include total result cash flow generation facility central support function manage performance group nonifrs measure total pharmaceutical consider addition substitute vaccine superior information present accordance ifrs consumer healthcare definition adjust result set research development cost sale growth development expenditure drive growth progression number mid latestage programme turnover turnover cer hiv respiratory anaemia utilisation cost sale priority review voucher continue high growth discovery expenditure reflect investment early stage cost sale percentage turnover oncology portfolio percentage point sterling term percentage point cer term compare reflect royalty income favourable product mix business particularly royalty income million million pharmaceutical include impact high hiv sale reduction primarily patent expiry cialis favourable product mix benefit settlement lose catchup adjustment record party supply volume favourable yearonyear comparison inventory adjustment vaccine contribution integration restructuring saving business offset continued adverse pricing pressure pharmaceutical primarily respiratory additional supply chain investment gsk annual report group financial review continue adjust result continue adjusted operating profit consumer healthcare adjust operate profit million aer high consumer healthcare operate profit million aer cer high turnover increase cer high cer high turnover increase adjust operate margin percentage point operate margin percentage point high percentage point high cer high percentage point high cer basis reflect improved operating leverage drive sale basis reflect tight control cost integration synergy growth favourable mix business principally sga partly offset increase investment vaccine benefit settlement lose party supply power brand volume favourable yearonyear comparison inventory adjustment continue tight control net finance cost ongoing cost business benefit restructure integration partly offset charge finance income million utilisation priority review voucher interest income increase investment continue fair value movement price pressure particularly respiratory supply chain investment finance expense adjust operating profit business interest expense unwind discount liability revise growth remeasurement fair value movement margin margin finance expense cer pharmaceutical pharmaceuticals share tax profit associate joint venture pharmaceutical share profit associate joint venture million vaccine million consumer healthcare adjust profit taxation corporate revise growth unallocate cost turnover turnover cer adjust operate adjusted profit profit tax pharmaceutical pharmaceutical operating profit million aer high taxation cer high turnover increase cer tax adjust profit amount million represent operating margin percentage point higher effective adjusted tax rate sterling basis percentage point noncontrolle interest cer basis primarily reflect increase investment allocation adjust earning noncontrolle interest include impact utilisation priority review voucher amount million million include operating margin reflect increase noncontrolle interest allocation consumer healthcare profit investment new product support continue impact million million allocation viiv low price particularly respiratory broad transition healthcare profit increase million respiratory portfolio partly offset favourable million include impact change proportion product mix primarily drive growth hiv sale preferential dividend shareholder increase continue cost reduction benefit group pharmaceutical allocation reflect comparison reduction restructure programme allocation noncontrolle interest high net loss vaccine group entity noncontrolle interest vaccine operate profit million aer high cer high turnover increase cer adjust earning share operate margin percentage point higher adjust eps aer cer compare sterling basis percentage point high cer cer increase adjusted operate profit basis primarily drive improved product mix benefit settlement lose party supply volume favourable yearonyear comparison inventory adjustment continue restructure integration benefit partly offset increase sga resource support business growth new launch increase supply chain cost low royalty income gsk annual report strategic report governance remuneration financial statement investor information cash generation conversion summary consolidate cash flow statement set reconciliation net cash inflow operating activity free cash flow reconciliation net cash inflow operating activity close equivalent ifrs measure free cash flow show net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity revise decrease cash bank overdraft net cash inflow operating activity cash bank overdraft begin year purchase property plant equipment decrease cash bank overdraft purchase intangible asset exchange adjustment proceed sale property plant equipment cash bank overdraft end year interest pay cash bank overdraft end year interest receive comprise dividend associate joint venture cash cash equivalent contingent consideration pay report overdraft investing activity contribution noncontrolle interest distribution noncontrolle interest net cash inflow operating activity year free cash flow million million increase primarily reflect improved operating profit performance positive future cash flow currency benefit partly offset increase work capital reflect long term expect future cash generate build inventory advance new product launch operation sufficient fund operate debt servicing increase contingent consideration payment legal settlement cost normal level capital expenditure obligation total cash payment shionogi relation viiv healthcare exist licensing agreement expenditure arise restructure contingent consideration liability year million programme routine outflow include tax pension million recognise cash flow operate contribution dividend subject principal risk activity million recognise contingent consideration uncertainty discuss page time pay invest cash flow payment deductible time additional demand finance acquisition tax purpose include potentially acquire increase ownership interest viiv healthcare consumer healthcare business capital expenditure financial investment minority shareholder hold option access multiple cash payment tangible intangible fix asset amount source liquidity short longterm capital market million million disposal realise financial institution need addition cash flow million million cash payment acquire equity operation investment million million sale equity investment realise million million investment appraisal capital allocation strengthen framework capital allocation free cash flow include creation new board govern allocation free cash flow cash generate business capital business utilise consistent cash return meeting obligation interest tax dividend pay invest capital croic methodology prioritise investment noncontrolle interest capital expenditure property group effectively plant equipment intangible asset compare return business allocate capital consider impact ep credit profile relevant free cash inflow discount rate perform financial analysis decide internally allow determination extent investment free cash flow million year cover cost capital individual investment discount rate million increase primarily reflect improved operating profit adjust account specific country business performance positive currency benefit increase project risk return rebate partly offset increase work capital work capital reflect seasonal factor build inventory advance new product launch increase contingent consideration payment purchase priority review voucher increase work capital percentage turnover dividend noncontrolle interest include catch work capital conversion cycle day adjustment high legal settlement free cash flow impact cost acquire hiv clinical asset reduction day compare bms million predominantly beneficial impact exchange approximately seven day partly offset build inventory advance new product launch increase trade receivable high sale gsk annual report group financial review continue financial position resource property plant equipment business sciencebase technologyintensive highly asset regulate governmental authority allocate significant noncurrent asset financial resource renewal maintenance property plant equipment minimise risk interruption production property plant equipment ensure compliance regulatory standard number goodwill process use hazardous material intangible asset investment associate joint venture total cost property plant equipment december million net book value million investment land building represent million plant defer tax asset equipment million asset construction million derivative financial instrument invest million new property plant noncurrent asset equipment mainly relate large number project total noncurrent asset renewal improvement expansion facility worldwide site property mainly hold freehold new investment current asset finance liquid resource december inventory contractual commitment future capital expenditure current tax recoverable million operating lease commitment million trade receivable believe property plant facility adequate derivative financial instrument current need liquid investment observe stringent procedure use specialist skill cash cash equivalent manage environmental risk activity environmental issue asset hold sale date operation modify discontinue report environmental sustainability total current asset note financial statement legal proceeding total asset goodwill liability goodwill decrease year million current liability december million decrease primarily shortterm borrowing reflect impact exchange movement contingent consideration liability trade payable intangible asset intangible asset include cost intangible acquire derivative financial instrument party computer software net book value current tax payable intangible asset december million shortterm provision million decrease reflect impact total current liability exchange movement amortisation impairment exist intangible million million respectively noncurrent liability partly offset development cost capitalise year longterm borrowing million addition million corporation tax payable deferred tax liability investment associate joint venture hold investment associate joint venture carry pension postemployment benefit value december million million provision market value december million contingent consideration liability million large investment innoviva inc noncurrent liabilities book value december million total noncurrent liability million market value december total liability million note financial statement net asset investment associate joint venture equity investment share capital hold investment carry value december million million decrease share premium account carry value year primarily impact retain earning exchange movement significant investment hold reserve december theravance biopharma inc shareholders equity book value december million noncontrolling interest million investment include equity stake company research collaboration total equity provide access biotechnology development potential interest interest company arise business divestment gsk annual report strategic report governance remuneration financial statement investor information financial position resource continue derivative financial instrument asset pension postemployment benefit current derivative financial instrument hold fair value account pension postemployment million million noncurrent derivative arrangement accordance ias deficit financial instrument hold fair value million nil net surplus allow deferred taxation majority financial instrument relate foreign million million pension arrangement exchange contract designate designate million million unfunded post accounting hedge employment liability decrease deficit predominantly drive special funding contribution inventory scheme significant asset gain partly inventory million increase million offset low discount rate discount increase primarily reflect inventory build advance new value liability product launch noncurrent liability trade receivable noncurrent liability amount million trade receivables million decrease december million decrease million primarily reflect exchange movement reflect reclassification consumer healthcare partly offset impact high sale option current liability year defer tax asset contingent consideration liability defer tax asset million decrease million contingent consideration liability amount million primarily result revaluation exist defer tax december million million asset reflect low headline tax rate follow enactment million represent estimate present value tax reform partly offset increase defer tax asset amount payable shionogi relate viiv healthcare relate intragroup profit inventory million million represent estimate present value contingent consideration payable novartis relate derivative financial instrument liabilitie vaccine acquisition liability shionogi include hold current derivative financial instrument fair value million respect preferential dividend liability million million primarily relate foreign preferential dividend pfizer december exchange contract designate designate million explanation accounting treatment accounting hedge interest viiv healthcare set trade payable net debt trade payable amount million increase million reflect reclassification consumer healthcare option million noncurrent cash cash equivalent liquid investment liability relate present value estimate payable event exercise novartis right require borrowing repayable year acquire shareholde consumer healthcare borrowing repayable year joint venture option exercisable march net debt payment likely month exercise december net debt billion compare classify current liability group balance sheet billion december comprise gross debt detail provide note key accounting judgement billion cash liquid investment billion estimate decrease net debt primarily reflect improve free cash provision flow billion disposal proceed billion carry defer tax provision shortterm billion favourable exchange impact translation noncurrent provision million december nonsterling denominate debt offset cost million decrease year primarily reflect dividend pay shareholder billion reduction defer tax provision result swiss tax december cash liquid investment hold reform provision yearend include million follow million related legal dispute million million relate major restructure programme provision legal dispute bank balance deposit indemnify disposal liability employee relate liability treasury treasury repo cost restructure programme extent balance money market fund sheet date legal constructive obligation exist reliably estimate liquidity fund cash cash equivalent liquid investment government security cash liquid investment billion billion hold centrally december gsk annual report group financial review continue financial position resource continue maturity profile gross debt maturity profile gross debt equivalent gbp bonds eur bond usd bond commercial paper bank borrowing lease analysis cash gross debt effect hedge total equity follow december total equity decrease million december million primarily reflect impact dividend pay exceed total profit year offset favourable exchange translation impact cash liquid investment weak sterling rate total profit year impact gross debt fix charge respect tax reform float noninterest bear summary movement equity set net debt total equity beginning year movement net debt total comprehensive income year dividend shareholder ordinary share issue net debt begin year change noncontrolle interest decreaseincrease cash bank overdraft recognition liability noncontrolle interest increase liquid investment derecognition liability noncontrolle increase longterm loan interest net repayment ofincrease shortterm loan share acquire esop trust exchange movement sharebase incentive plan movement tax sharebase incentive plan net debt end year contribution noncontrolle interest distribution noncontrolle interest total equity end year gsk annual report strategic report governance remuneration financial statement investor information financial position resource continue share purchase enter number research collaboration develop employee share ownership plan esop trust new compound pharmaceutical company term acquire million share glaxosmithkline plc arrangement include upfront fee equity investment million share hold trust satisfy future exercise loan commitment fund specify level research option award group share option award addition agree payment future scheme proportion share hold trust milestone achieve respect award rule scheme require agreement relate compound early satisfy exercise market purchase issue stage development potential obligation milestone new share share hold trust match payment continue number year compound option award grant successfully development process generally close december esop trust hold million product marketing approval great probability million gsk share future exercise success amount show intangible asset share option share award carry value million represent maximum pay milestone million deduct reserve achieve include billion relate externalise market value share million million project discovery portfolio reduction commitment amendment exist share repurchase december agreement obligation cease hold million share treasury share million share cost million million reach agreement trustee deduct retain earning pension scheme additional contribution include assist eliminate pension deficit identify ordinary share purchase period january december actuarial funding valuation table march company expect include commitment exclude normal ongoing annual ordinary share repurchase remainder funding requirement approximately million commitment contingent liability information pension obligation note financial commitment summarise note financial financial statement pension postemployment benefit statement commitment contingent liability contingent liability obligation respect short longterm debt set follow table set contingent liability comprise note financial statement contingent liability discount bill performance guarantee letter credit note financial statement net debt item arise normal course business amount provide pension postretirement benefit expect expire set note financial statement pension postemployment benefit amount provide restructure total yrs yrs yrs programme legal environmental dispute set note financial statement provision guarantee contingent liability contractual obligation commitment total follow table set contractual obligation commitment december fall payment normal course business provide indemnification guarantee respect business disposal total yrs yrs yrs legal dispute subsequently arise provision outflow resource consider probable loan reliable estimate likely outcome dispute interest loan include note financial statement finance lease obligation provision finance lease charge provide outcome tax legal dispute operate lease outflow resource consider probable reliable estimate commitment outflow december intangible asset dispute provision possible property plant equipment reliable estimate potential outflow fund investment require settle dispute possibility purchase commitment outflow remote pension ultimate liability matter vary significantly commitment amount provide dependent outcome litigation total proceeding negotiation relevant tax authority discuss principal risk uncertaintie page commitment respect loan future interest payable loan note financial statement disclose take account effect derivative taxation legal proceeding gsk annual report group financial review continue critical accounting policy consolidate financial statement prepare accordance reconciliation gross turnover net turnover ifrs adopt use european union pharmaceutical business include puerto rico follow ifrs issue iasb follow accounting policy approve board described note financial margin margin margin statement accounting principle policy gross turnover require estimate assumption affect amount asset liability revenue expense report market drive financial statement actual amount result differ segment estimate government critical accounting policy relate follow area mandate state program turnover cash discount taxation note customer return legal dispute note prior year adjustment intangible asset impairment note item business combination note total deduction net turnover pension postemployment benefit note information judgement estimate area market drive segment consist primarily manage care give note financial statement key accounting medicare plan gsk negotiate contract pricing judgement estimate honour rebate chargeback mandate segment consist primarily medicaid federal government programme turnover receive government mandate pricing rebate respect turnover accounting policy large business chargeback pharmaceutical market complex arrangement rebate discount allowance follow increase deduction market drive segment briefly describe nature arrangement existence gross turnover net turnover reconciliation primarily reflect pharmaceutical business high rebate chargeback respiratory product advair particular advair account arrangement certain indirect customer pharmaceutical turnover approximately total customer able buy product wholesaler reduce deduction rebate return respiratory portfolio price chargeback represent difference account approximately total deduction invoice price wholesaler indirect customer year advair continue suffer pricing pressure contractual discount price accrual estimate chargeback business seek transition respiratory portfolio calculate base term agreement historical new product experience product growth rate balance sheet accrual rebate discount allowance customer rebate offer key manage care group return pharmaceutical vaccine business purchase organisation gpo direct indirect manage combined basis december customer arrangement require customer achieve total accrual amount million million certain performance target relate value product purchase formulary status predetermine market share monthly process operate monitor inventory level relative competitor accrual customer rebate wholesaler abnormal movement process use estimate base specific term agreement gross sale volume prescription volume base party historical experience product growth rate datum source information receive key wholesaler medicaid programme stateadministere programme aim maintain inventory consistent level year provide assistance certain poor vulnerable patient year base pattern consumption medicaid drug rebate program establish basis pharmaceutical vaccine inventory level reduce state federal expenditure prescription drug wholesaler distribution channel december patient protection affordable care act law estimate approximately week turnover participate provide rebate state accrual medicaid calculation use party information accuracy rebate calculate base specific term relevant totally verify believe sufficiently reliable regulation patient protection affordable care act purpose cash discount offer customer encourage prompt payment accrue time invoicing adjust subsequently reflect actual experience record accrual estimate sale return apply historical experience customer return amount invoice market relate information stock level wholesaler anticipate price increase competitor activity gsk annual report strategic report governance remuneration financial statement investor information critical accounting policy continue legal dispute like pharmaceutical company face respect accounting policy legal dispute complex product liability antitrust patent litigation follow briefly describe process determine investigation operation conduct governmental level provision necessary regulatory agency year general counsel group head group legal function senior accordance requirement ias provision vice president head global litigation group contingent liability contingent asset provide responsible litigation government investigation routinely anticipate settlement cost outflow resource brief chief executive officer chief financial officer consider probable reliable estimate board director significant litigation pende likely outcome dispute legal expense arise group governmental investigation group claim group involved significant legal proceeding respect possible meeting appropriate detail status significant litigation reliable estimate expect financial effect government investigation review matter number result ultimate resolution proceeding claim notify information potential claim notify case appropriate disclosure case include assessment validity claim progress settle claim annual report provision recent settlement level potential reimbursement insurer position change time meeting include assessment assurance loss result outcome legal sufficient information available able reliable proceeding exceed material estimate potential outcome dispute external provision report group financial statement counsel assist litigation matter investigation assist briefing board senior management follow discussion matter possible reliable estimate provision require level provision legal dispute review adjust appropriate matter discuss note financial statement legal proceeding treasury policy report sterling pay dividend sterling cash flow capital management role treasury monitor manage group external financial strategy implement group financial internal funding requirement financial risk support architecture support gsk strategic priority regularly strategic objective gsk operate global basis primarily review board manage capital structure subsidiary company manage capital ensure group appropriate mix debt equity subsidiary able operate go concern gsk longterm credit rating standard poor optimise return shareholder appropriate balance stable outlook moodys investor service moodys debt equity treasury activity govern policy stable outlook shortterm credit rating approve annually board director recently standard poor moodys respectively july treasury management group tmg meeting chair chief financial officer take place regular liquidity risk management basis review treasury activity member receive management policy borrow centrally order meet anticipate funding information relate activity requirement cash flow forecast funding requirement monitor tmg regular basis strategy diversify treasury operation liquidity source range facility maintain broad objective treasury activity minimise posttax net access financial market cost financial operation reduce volatility order benefit earning cash flow use variety financial instrument day sweep cash number global subsidiary finance operation derivative financial instrument manage central treasury account liquidity management purpose market risk operation derivative principally interest rate risk management comprise interest rate swap foreign exchange forward contract objective minimise effective net interest cost swap swap borrowing liquid asset balance mix debt fix float interest rate currency require group purpose manage exposure time policy interest rate risk management limit financial risk change foreign exchange rate float interest payment prescribe percentage interest rate operate profit hold issue derivative speculative purpose gsk treasury policy specifically prohibit activity transaction financial instrument undertake manage risk arise underlie business activity gsk annual report group financial review continue treasury policy continue foreign exchange risk management borrowing denominate swap foreign currency foreign currency transaction exposure arise external trade match investment overseas group asset treat flow normally hedge foreign currency transaction hedge relevant asset forward contract major exposure arise internal trade flow selectively hedge currency reduce exposure group objective minimise exposure overseas operating investment overseas group asset tmg review subsidiary transaction risk match local currency income ratio borrowing asset major currency regularly local currency cost possible gsk internal trading counterparty risk management transaction match centrally manage intercompany payment term reduce foreign currency risk foreign currency set global counterparty limit banking cash flow hedge selectively management investment counterpartie base longterm credit rating treasury tmg include hedge foreign moodys standard poor treasury usage limit exchange risk arise acquisition disposal asset monitor daily corporate compliance officer cco possible manage cash surplus borrowing operate independently treasury breach limit requirement subsidiary company centrally forward report cfo immediately contract hedge future repayment originate cco monitor credit rating counterpartie currency change rating occur notifie treasury change order reduce foreign currency translation exposure seek investment level authority limit appropriate denominate borrowing currencie principal asset addition relationship bank credit rating review cash flow primarily denominate dollar regularly report present annually tmg approval euro sterling borrowing swap currency require strategic report strategic report approve board director march sign behalf simon dingemans chief financial officer march ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn corporate governance section chairmans governance statement board corporate executive team leadership effectiveness nomination committee report accountability audit risk committee report relation stakeholder engagement activity science committee report corporate responsibility committee report director report gsk annual report chairman governance statement dear shareholder ceo transition please present corporate period formally take governance report rein ceo april emma working evolve governance strategy longterm company strategy support value creation guidance board meet board remain committed achieve board director solicit view high standard corporate company meeting governance integrity governance employee level business structure operate board external adviser commentator gain group believe critical emma walmsley underpinning ability deliver wide view shape thinking board evolve nonexecutive strategy create longterm value cet plan ensure director fully engage process benefit shareholder emma utilise diverse expertise company culture stakeholder investor boardroom table test shape tell value consistent detail proposal particular great need company combine board committee provide emma strategy obligation society delivery management team continuous financial performance performance objective feedback challenge review follow page set detail culminate discussion joint strategy composition board corporate meeting corporate executive governance arrangement process team cet june propose activity report innovation performance trust priority board committee scrutinise ahead board approval include new science committee july year report board emma cet lay work ceo executive management investor update july innovation succession board focus performance trust provide support emma walmsley transition platform growth new role conduct detail reaffirm commitment review company strategy threebusiness structure subject certain management condition continue review periodically commitment test board joint strategy session june term continue board oversight innovation performance trust priority board paper reshape align new business priority addition ceo report include innovation performance trust performance indicator annual strategy meeting enable board consider progress effectiveness business priority deliver longterm value investor gsk annual report strategic report governance remuneration financial statement investor information align strategy culture board evaluation government corporate governance healthy culture vital tool unlock appropriate time board reform legislation new code protecting value big evolution carry external board expect effective financial driver culture leadership evaluation ceo senior year look forward provide update company emma walmsley cet independent nonexecutive director arrangement measure plan ensure companys culture choose appoint new external new requirement year report value consistent strategy board evaluator review bring corporate governance code performance objective fresh perspective detail externally compliance board review propose strategy facilitate review conclusion please report culture feature heavily discussion set page compliance requirement board approve high corporate governance reform frc corporate governance code performance valuesbased culture board take close interest code copy code available new expectation courage government development package wwwfrcorguk accountability development teamwork legislative good practice measure guide employee behavior board commend report support initiative raise bar receive report management shareholder corporate governance practice commitment initiative effectiveness modern employer reform drive financial cet hold leadership conference reporting council frc recently october company leader consult proposal revise nonexecutive director corporate governance code philip hampton attend critical transfer submit view please note chairman ownership strategy culture frc include new measure leader company march encourage company step measure progress implement align strategy culture promote priority monitor aspect effective engagement workforce culture twice year allemployee wide stakeholder issue survey survey measure engagement describe early relation approach progress innovation performance board trust priority value expectation emma report progress board regularly culture detail company commitment modern employer drive high level employee engagement trust agenda set page strategic report gsk annual report board board composition ccoommpopsiotiosnition tteenunrue rneo nneoxnecuetixveecutive philip hampton nonexecutive chairman esx eact iavepril usp tto yperairl oenxeecxuetcivueti etoar year nonexecutive ayersar nationality ver eyeaarsr british year appoint january deputy chairman gender diversity april nonexecutive chairman board date publication april skill experience prior join gsk philip male male chair major ftse company include royal bank female female scotland group plc sainsbury plc serve group finance director lloyds tsb group group plc group executive plc british gas plc british date publication april steel plc philip previously male male appoint executive director lazard nonexecutive director rmc group plc female female belgacom chairman financial investment limit manage government nonexecutive shareholding bank date publication april male male external appointment philip senior independent director anglo american plc female female chairman remuneration committee member audit committee philip chair hamptonalexander review international experience ftse woman leader international experience independent review improve april gender balance ftse leadership global europe emap gsk annual report strategic report governance remuneration financial statement investor information emma walmsley simon dingemans hal barron patrick vallance chief executive officer chief financial officer chief scientific officer outgoing president president nationality nationality nationality nationality british british american british appoint appoint appoint appoint january chief executive january chief financial january january officer april officer april skill experience skill experience skill experience skill experience hal president calico patrick joined gsk emma join gsk prior join gsk simon llc california life company head drug discovery responsibility consumer year experience alphabetfunde company use subsequently appoint senior healthcare europe investment banking warburg advanced technology increase vice president medicine discovery subsequently appoint president goldman sachs simon advise understand lifespan biology development glaxosmithkline consumer gsk decade prior join calico hal member gsk corporate healthcare october appointment closely executive vice president head executive team member gsk involve number gsk global product development appoint president january corporate executive team key strategic project simon chief medical officer roche patrick joined gsk board appoint ceo previously chairman responsible product january gsk consumer healthcare joint group finance director combine portfolio roche prior join gsk patrick venture gsk novartis genentech genentech clinical academic professor creation march external appointment senior vice president medicine lead division appointment gsk ceo development chief medical medicine university college designate september officer hal nonexecutive london year emma join gsk board director chair science experience research clinical january succeed technology committee juno medicine general internal medicine sir andrew witty gsk ceo therapeutics inc cardiovascular medicine clinical april pharmacology elect external appointment prior join gsk emma work academy medical sciences hal associate adjunct professor loreal year patrick previously epidemiology biostatistic hold variety marketing nonexecutive director university california san general management role paris biobank limited genome francisco london new york research limit base shanghai general manager consumer external appointment product loreal china emma patrick step president nonexecutive director end diageo plc january step executive director september hold effect march classic modern language government chief oxford university scientific adviser head government office science external appointment key committee chair nomination audit risk remuneration science corporate responsibility gsk annual report board continue manvinder singh vindi banga professor sir roy anderson vivienne cox lynn elsenhans senior independent independent nonexecutive independent nonexecutive independent nonexecutive nonexecutive director director scientific director director medical expert nationality nationality nationality nationality indian british british american appoint appoint appoint appoint september senior october july july independent nonexecutive director skill experience skill experience skill experience professor sir roy world vivienne wide experience lynn wealth experience skill experience renowned medical scientist business gain energy run global business prior join gsk vindi spend advanced knowledge infectious natural resource publish significant knowledge global year unilever plc disease epidemiology sector deep market gsk operate role senior currently professor infectious understanding regulatory serve chair president position president disease faculty medicine government relationship chief executive officer sunoco global food home personal imperial college london work plc years inc prior care business fellow royal society britain continental europe join sunoco president member unilever executive academy medical science post include executive vice chief executive officer lynn board vindi sit prime royal statistical society president chief executive work royal dutch shell minister indias council trade honorary fellow institute bps gas power renewable join industry actuary foreign associate business alternative energy hold number senior role board governor member national academy unit vivienne previously include executive vice president indian institute management medicine national nonexecutive director global manufacturing iim ahmedabad vindi academy sciences french group plc rio tinto plc lynn previously recipient padma bhushan academy sciences professor sir lead independent director nonexecutive director flowserve india high civilian roy bring scientific expertise governments department corporation tee honours board deliberation international development vivienne great houston vindi nonexecutive director appoint commander thomson reuters corp external appointment order british empire external appointment member committee vindi professor sir roy member new year honour lynn nonexecutive director previously chairman holdingham international services economy baker hughes company supervisory board mauser group advisory board member sustainability chair audit committee science advisory board director texas medical external appointment natural history museum london external appointment center trustee vindi partner private equity member vaccine vivienne senior independent united way great houston investment firm clayton dubili international advisory board director pearson plc non rice chairman kalle vacciab pharma hold executive director stena gmbh senior independent director sdn bhd malaysia chairman supervisory mark spencer group plc international alzheimers consortium board vallourec supplier member nomination harvard university boston energy industry committee chairman chairman scientific advisory remuneration committee vindi board netherlands centre nonexecutive director health ncoh chairman confederation british industry oriole global health ltd cbi director high ridge brand member holdingham international advisory board chair board trustees marie curie govern board indian school business isb hyderabad member indo ceo forum gsk annual report strategic report governance remuneration financial statement investor information laurie glimcher jesse goodman judy lewent urs rohner independent nonexecutive independent nonexecutive independent nonexecutive independent nonexecutive director scientific director scientific director director medical expert medical expert nationality nationality nationality nationality american american american swiss appoint appoint appoint appoint september january april january skill experience skill experience skill experience skill experience laurie currently professor jesse previously serve senior judy extensive knowledge ur broad range business medicine harvard medical school leadership position global pharmaceutical industry legal experience serve ceo president food drug administration corporate finance join chairman number board attend physician dana fda include recently merck serve recently credit suisse farber cancer institute fdas chief scientist previously chief financial officer worldleade financial service deputy commissioner retire company prior join credit addition number senior science public health judy previously serve suisse urs serve leadership position hold director center biologic nonexecutive director dell chairman executive board harvard medical school evaluation research cber inc quaker oats company ceo prosieben harvard school public health motorola inc prosiebensat media laurie serve stephen jesse play leadership role follow number year suzanne weiss dean develop fdas board determine private practice major law firm professor medicine weill regulatory science medical judy recent relevant switzerland cornell medical college countermeasure initiative financial experience agree admit bar canton attend physician new york work collaboratively appropriate zurich switzerland presbyterian hospitalweill cornell industry academia government qualification background state new york medical center laurie step global public health regulatory audit committee financial expert board bristol partner prepare respond myers squibb bms major public health threat external appointment external appointment serve year include emerge infectious judy nonexecutive director urs currently chairman board laurie bring scientific disease disaster terrorism thermo fisher scientific inc board credit suisse group public health expertise board lead fda response west motorola solutions inc chairmans deliberations nile virus trustee rockefeller governance committee influenza pandemic serve family trust life member chairman member external appointment senior leadership team massachusetts institute board trustee credit suisse laurie member white house medical technology corporation member research institute credit suisse national academy sciences countermeasure review jesse american academy arts foundation urs appoint national academy medicine bring scientific public health sciences member vicechairman govern member scientific expertise board business advisory board board swiss bankers steering committee parker deliberations twoxar association institute cancer immunotherapy nonexecutive director external appointment water corporation jesse currently professor serve corporate governance medicine georgetown university committee addition laurie direct georgetown university cofounder chair center medical product access scientific advisory board quentis safety stewardship therapeutic inc scientific compass active advisory board member repare clinician serve attend therapeutic inc american physician infectious disease asthma foundation serve president member board united key states pharmacopeia usp member regulatory working committee chair nomination group coalition epidemic preparedness innovation cepi audit risk remuneration science corporate responsibility gsk annual report corporate executive team roger connor luc debruyne president global manufacturing supply president global vaccines roger join cet appoint luc join cet president president global manufacturing supply global vaccine role hold work year president join gsk commercial strategy designate prior vice president director lead european office ceo corporate strategy commercial centre excellence roger join gsk astrazeneca luc general manager netherland senior vice president appoint board gsk consumer healthcare joint venture general manager italy appoint senior vice president pharma europe novartis april prior current role luc member roger hold degree mechanical international federation pharmaceutical manufacturing engineering queen manufacturer association vaccines ceo university belfast masters manufacturing roundtable management committee leadership cambridge university belgian federation enterprise charter accountant hold master degree physical education university leuven emma walmsley chief executive officer simon dingemans nick hiron brian mcnamara chief financial officer senior vice president global ethic ceo gsk consumer healthcare hal barron compliance chief scientific officer president nick appoint cet senior brian join cet vice president global ethic compliance appoint ceo gsk consumer healthcare patrick vallance responsible compliance risk management join gsk head europe outgoing president corporate security investigation america gsk consumer healthcare follow creation joint venture nick join gsk international gsk novartis previously head biographical detail auditor later head audit assurance combine audit function novartiss otc division brian begin career procter gamble independent team common riskbase methodology nick relocate china chairman world selfmedication establish governance model china industry association business create consistent approach earn undergraduate degree compliance electrical engineering union college nick fellow chartered institute new york mba finance management accountant university cincinnati abbas hussain member cet leave company july gsk annual report strategic report governance remuneration financial statement investor information luke miel david redfern karenann terrell president global pharmaceutical chief strategy officer chief digital technology officer luke join gsk cet september david join cet chief strategy officer karenann join gsk cet september president global pharmaceuticals responsible corporate chief digital technology officer responsible commercial portfolio development strategic planning previously responsible technology digital data medicine vaccine senior vice president northern europe analytic strategy responsibility gsk pharmaceutical previously work astrazeneca previously work walmart chief business region prior executive vice president european information officer prior senior vice president central eastern business prior executive vice baxter international chief europe david join gsk president global product portfolio information officer daimler strategy global medical affair corporate appoint chairman board chrysler corporation karenann begin affair hold role increase viiv healthcare limit non career general motor seniority roche sanofiaventis executive director aspen pharmacare karenann member board trustee holdings limited board hold bachelor science degree new york hall science biology flinder university adelaide david bachelor science degree nonexecutive director mba macquarie university sydney bristol university charter pluralsight llc accountant earn graduate postgraduate degree electrical engineering kettere purdue university respectively claire thomas phil thomson dan troy senior vice president human resource president global affairs senior vice president general counsel claire appoint cet senior vice phil join cet appoint dan joined gsk cet senior vice president human resource president global affairs april president general counsel specific responsibility group strategic claire join company senior previously partner washington approach reputation corporate responsibility manager human resource sale marketing law firm sidley austin llp principally global health china britain withdrawal group pharmaceutical represent pharmaceutical company trade european union responsible director human resource association matter relate food engagement investor medium government pharmaceutical appoint drug administration fda government key global community partner employee senior vice president human resource regulations dan chief counsel pharmaceutical europe previously senior vice president fda senior vice president human resource communication government affair dan hold industrial labor relation pharmaceuticals international joined gsk commercial trainee cornell university columbia prior gsk work ford motor university school law chair company hold position phil chairman whitehall industry chamber commerce litigation center human resource group board member chinabritain member american law institute business council claire bachelor science degree announce january dan troy economics management industrial earn degree english history leave gsk later date relation university wale russian study durham university role relocate gsk annual report corporate governance continue leadership effectiveness corporate governance framework board establish corporate governance framework clearly define responsibility accountability framework design safeguard enhance longterm shareholder value provide platform realise group strategy gsk new innovation performance trust prioritie internal control risk management arrangement describe page integral gsk governance framework board operate effectively consideration key matter board committee establish set board chief nomination audit risk remuneration science corporate executive committee committee committee committee responsibility officer committee corporate executive read read read read read team wwwgskcom term reference board committee scheduled board committee attendance corporate board nomination audit risk remuneration science responsibility total number schedule meeting member attend attend attend attend attend attend philip hampton emma walmsley simon dingemans patrick vallance professor sir roy anderson vindi banga vivienne cox lynn elsenhans laurie glimcher appoint september jesse goodman judy lewent urs rohner sir andrew witty retired march moncef slaoui retired march total number adhoc meeting director serve year number bracket denote number meeting director eligible attend committee report attendee committee meeting chairman ceo executive director work committee year report include later corporate governance report gsk annual report strategic report governance remuneration financial statement investor information board programme board responsible longterm success company authority accountable shareholder ensure group appropriately manage achieve strategic objective set performance duty regard interest key stakeholder cognisant potential impact decision make board discharge responsibility annual programme meeting year focus number specific area outline table line new longterm priority innovation performance trust addition year ceo meet nonexecutive director discuss matter include evolution thinking company strategy succession plan ongoing sfo investigation area focus longterm priority link strategy board oversight execution strategy include receive discuss report principal business pharma vaccine consumer briefing product particular board keen oversee launch plan shingrix vaccine trelegy ellipta nucala product review background withdrawal tanzeum joint board corporate executive committee strategy day hold discuss new innovation performance trust prioritie external landscape changes business performance competitor governance arrangement evolution approach change medical engagement key external expert conduct deep dive group business strategy china receive discuss report pension insurance tax treasury strategy performance board focus performance include set new ceo objective set review agree annual budget forward look year plan receive report ceo principal business scrutinise group financial performance review brexit impact plan arrangement review progress pipeline governance board approach discharge corporate governance duty include receive report board committee approve annual report review agm preparation approve notice agm consider observation agree action internal evaluation board performance receive report corporate governance regulatory development undertake training gsk code conduct approve appointment new chief scientific officer president new nonexecutive director scientific medical expert cultural head brief board transformation align gsk culture value support strategy longterm priority link longterm priority innovation performance trust gsk annual report corporate governance leadership effectiveness continue key board role responsibilitie leadership independent oversight rigorous challenge chairman nonexecutive director philip hampton provide strong independent element board lead manage business board constructively support challenge management provide direction focus scrutinise performance meeting agree ensure clear structure effective operation deliverable board committee shape proposal strategy management set board agenda ensure sufficient time letter appointment set term allocate promote effective debate support sound condition directorship decision make devote time necessary proper ensure board receive precise timely clear performance duty information expect attend meeting require meet nonexecutive director annual independence statement basis discuss individual contribution performance training development need board consider nonexecutive director share peer feedback provide board identify page independent evaluation process include professor sir roy anderson tenure meet nonexecutive director independently year demonstrate executive director appropriate degree independence character lead discussion shareholder judgement free business responsible group performance relationship materially interfere exercise judgement independence chairman role description available wwwgskcom commitment professor sir roy anderson judy lewent serve board year chief executive officer subject rigorous review emma walmsley responsible management group senior independent nonexecutive director business vindi banga develop group strategic direction consideration approval board act sound board chairman trust intermediary director implement agree strategy support member corporate executive nonexecutive director lead team annual review chairman performance take account view executive director chief executive officer role description available wwwgskcom discuss result chairmans effectiveness review chairman lead search appointment process recommendation board new chairman act additional point contact shareholder maintain understand issue concern major shareholder briefing investor relation team company secretary senior independent nonexecutive director role description available wwwgskcom company secretary secretary board board committees victoria whyte supports board committee chair annual agenda plan set ensure information available board member timely fashion support chairman designing deliver board induction coordinate ongoing business awareness training requirement nonexecutive director undertake internal board committee evaluation request chairman advise director board practice procedure corporate governance matter chair group disclosure committee point contact shareholder corporate governance matter gsk annual report strategic report governance remuneration financial statement investor information board induction development company secretary assist chairman design new corporate executive team cet member meet board facilitate individual induction programme new director member induction ensure board design purpose orientating familiarise maintain connection cet new director industry organisation governance laurie glimcher new usbased science strategy innovation performance trust priority medical expert january hal barron highly new director receive general induction personalise experience leader join board customise induction devise individually tailor induction programme summarise new director background education experience role board induction general board induction executive nonexecutive director role executive director role nonexecutive director director duty responsibility build relationship gsk strategy competitor gsk corporate governance chairman board external environment structure fill capability gap meet cet member gsk code conduct training gsk financial structure personal executive director induction personal nonexecutive director induction hal barron laurie glimcher chief scientific officer president scientific medical expert maximise handover opportunity outgoing vaccine deep dive president briefing rd key therapy area detail review pipeline asset include site visit ware stevenage wavre governance process team brief business commercial model business development landscape inform audit risk science committee induction update strategy board business key stakeholder awareness training ensure nonexecutive director develop maintain chairman meet director annually onetoone great insight understand business key basis discuss ongoing training development stakeholder requirement board keep date legal regulatory governance matter regular paper briefing invite attend internal management meeting include company secretary presentation internal meeting cet external adviser meet employee informally visit group operation board member undertake training gsk reception hold staff board meeting code conduct receive monthly investor relation stakeholder report maintain awareness investor stakeholder view measure progress implement innovation performance trust business priority evolve culture allemployee survey undertake month report regular conversation cet directly workforce let talk programme gsk annual report corporate governance leadership effectiveness continue external evaluation board board carry evaluation performance committee year evaluation facilitate externally year market review ffion hague independent board evaluation appoint independently facilitate board committee evaluation hague independent board evaluation connection company hague meet chairman senior independent nonexecutive director sid ceo company secretary discuss agree scope evaluation exercise timetable activity secretary provide evaluation evaluation team attend board team access board committee committee meeting hold december paper material observe director preparatory work evaluation operation dynamic meeting phase phase phase phase phase preparation interview observation review outcome november december report contain output evaluation hague conduct detailed interview set draft conclusion compile board member hague discuss initially base clear agenda send chairman ceo sid report contain participant advance finding recommendation company secretary head present hague board interview gain main meeting january broader perspective separate report compile board committee present individual committee chair discuss respective committee meeting january individual board member present discuss chairman chairman initially discuss sid sid hague discuss nonexecutive director sid discuss chairman gsk annual report strategic report governance remuneration financial statement investor information external evaluation board continue board review feedback outcome response report board member highly engage hague report note context board commit good interest company feel evaluation conduct recently board work underpin mechanism establish significant change composition board support operation board takes governance seriously settle include choose work follow area new chairman appoint review strategy follow appointment new chief scientific officer president new ceo start role april enhance board focus decision make agree member join board past year clear priority focus year experience field previous list company experience succession plan senior executive board level welcome barron board january building board relationship culture line ceo culture work group time review occasion review team take input board member context board member express broad range view board settle issue identify focus action plan come year board strongly supportive new ceo please ongoing work strengthen focus science new chief scientific officer president non executive scientific medical expert creation science committee formative stage board performance progress conclusion board evaluation review internally facilitate company secretary set area focus progressachievement create opportunity deep year board consider detailed review company strategy management strategic discussion particularly context operate environment company culture industry dynamic global healthcare evolution pharmaceutical industry competitive landscape therapy area gsk culture performance identify way improve paper submit board streamline reshape align new innovation board decision make performance trust longterm business priority allow continue oversight focus decisionmake increase board oversight good progress establish science committee detail find science innovation collaboration science committee report new science committee consider datum new reporting board enhance area new innovation performance trust system contribute great longterm business priority framework dashboard aid board oversight company key understanding help evolve performance indicator business strategy gsk annual report corporate governance leadership effectiveness continue nomination committee report dear shareholder philip hampton committee work year refresh nominations committee board replace retire director follow ceo transition chair emma walmsley establish innovation performance trust longterm priority business committee focus turn support ceo establish team need lead company opportunity challenge ahead executive management succession patrick vallance president informed board intention government chief scientific adviser head government office science committee role engage korn ferry previously conduct proactive committee review recommend board desktop talent mapping exercise executive committee participation nonexecutive director compile profile leader profile contain brief structure size composition board requirement desire skill set potential successor appointment director members patrick need brief draft emphasise board committee cet importance ceo committee place identify succession board cet recruiting worldrenowne leader strong track record develop organisational capability significant new medicine review profile committee decide membership need look externally talent committee member committee member korn ferry initiate global search agree profile philip hampton chair january january pharmaceutical industry give importance professor sir roy anderson october search committee seek second opinion egon zehnder vindi banga january expert field executive search yield lynn elsenhans january pool candidate reduce shortlist judy lewent potential candidate shortlist candidate meet urs rohner january subsequently interview company designate scientific medical expert sme audit risk committee chair detail committee member skill experience chairman feedback candidate compile give biography board page committee receive ceo analysis candidate committee member separate analysis head attendance level process culminate committee meeting agree company secretary secretary committee recommendation board propose appointment attend meeting attendees committee hal barron chief scientific officer president meeting include recommendation receive unanimous board approval november announce hal join board regular attend executive director effect january patrick attendees attendee require step president end resign chief executive officer executive director cet member march head human resource board pleased hal appointment demonstrate appropriate external adviser company continue ability attract world class talent organisation world foremost leader hal advisory service possess exceptional track record develop significant year korn ferry egon zehnder provide new medicine roche genentech recently calico recruitment consultancy service committee building research organisation use cuttingedge technology addition recruitment service provide drug discovery development company signatorie voluntary committee report year report luke miel code conduct executive search firm gender recruit astrazeneca executive vice diversity good practice president european business succeed abbas hussain president global pharmaceuticals luke subsequently join gsk cet september luke hal previously work roche appointment complete team global pharmaceutical business gsk annual report strategic report governance remuneration financial statement investor information nomination committee report continue finally term senior executive appointment karenann currently meet parker report recommendation terrell appoint support korn ferry cet board director colour september gsk chief digital technology officer point wish personally acknowledge companywide remit transform new technology involve work hamptonalexander review improve performance group karenann miss dame helen sadly pass away august year previous role chief information officer walmart outstanding leader believe woman lead multiyear effort transform walmart use datum able contribute far business analytic digital engagement customer acknowledge review team continue work senior executive appointment underscore immediate memory area focus new ceo take appointment committee please progress continue build senior leadership team drive female board representation combine corporate executive innovation performance trust agenda team cet direct report target new nonexecutive director appointment gsk rank ftse summary standing year korn ferry assist committee hamptonalexander review ftse woman leader report search additional sme nonexecutive director reproduce enhance board scientific capability strengthen board female representation june scientific perspective join new science committee interview suitable sme candidate committee recommend combined executive report female committee direct laurie glimcher board potential nonexecutive representation metric board report director sme board subsequently approve glimcher ftse target appointment board effect september laurie gsk rank bring wealth expertise scientific medical innovation ftse public health invaluable assisting board focus ftse average deliver longterm innovation performance trust priority appoint member science ftse high audit risk committee currently board composition diversity woman board rise seek balance composition board april patrick vallance step committee time board leave company long serve director maintain understanding group woman cet sector whilst new appointee bring fresh external perspective insight go forward closing gap board cet gender representation increase pipeline female direct nonexecutive director experience wide range report cet achieve target area focus industry background include pharmaceutical industry support approach gsk action enhance vaccine consumer product healthcare medical development pipeline include accelerate difference research academia insurance financial service programme women leadership initiative accelerate complex organisation global reach importantly majority transition coach programme join rejoin board scientific mathematical background company extend time absence mean attuned fundamental industry operate representation woman management position illustrate gender diversity gsk global workforce gsk commit equal opportunity employee alongside initiative promote diversity inclusion level organisation board commit encourage organisation diverse inclusive culture lead cet committee evaluation key requirement effective board comprise committee annual evaluation exercise externally facilitate range balance skill experience knowledge gender ffion hague independent board evaluation conclude independence individual prepare challenge committee continue operate effectively agree work team need back diversity committee effectiveness improve personal attribute include character intellect sound judgement honesty courage refining approach longterm succession plan key additional skill capability need board committee responsible develop measurable objective support implementation board diversity policy improve dialogue board evolve area meet measurable target set focus committee parker review commission report publish october increase ethnic diversity appointment board ftse company philip hampton hamptonalexander review report work nominations committee chair late dame helen alexander publish increase number woman senior leadership position ftse march company gsk annual report accountability audit risk committee report dear shareholder judy lewent follow page report aim share insight audit risk committee activity undertake oversee audit risk committee chair committee year committee work largely recur structured programme activity devise programme company secretary agree content management external auditor start year adapt appropriate year progress oversee smooth audit transition process important focus committee year exercise detail committee continue scrutiny role enhancement simplification internal control risk management financial reporting system process committee review responsible covered external auditor financial internal reporting process year advise shareholder conclusion integrity financial statement include competitive audit contract tender board appoint annual report quarterly result announcement committee prefer choice deloitte llp deloitte system internal control company new auditor gsk financial year onwards identification management risk external committee oversee significant activity necessary internal audit process transition pricewaterhousecooper llp pwc deloitte initiate audit tender selection appointment initially require deloitte achieve independence half external auditor set remuneration year observe pwcs work statutory auditor exercise oversight work yearend audit committee receive regular report audit transition meet regularly lead audit membership partner pwc deloitte discuss progress committee member committee member pleased hear new perspective deloitte judy lewent chair january april bring audit present audit scope end vindi banga january include significant opportunity datum analytic bring report audit transition arrangement give lynn elsenhans january pages laurie glimcher september like thank pwc team professionalism detail committee member financial accounting continue deliver highquality audit particularly scientific experience expertise give backdrop transition audit firm cooperate biography board page transition smooth minimal disruption business committee member attendance level look forward report shareholder deloitte audit company secretary secretary committee gsk annual report attend meeting entire board invite attend internal framework control risk management committee meeting attendee include development regular attend core focus committee follow attendee attendee require development business unit enterprise help general counsel strengthen culture compliance risk management financial controller gsk value expectation high priority head audit assurance committee year oversaw progress drive head global ethic compliance global ethic compliance gec embed measure chief medical officer effectiveness value integrate value chief product quality officer exist control process example thirdparty oversight external auditor framework update require party confirm adherence value thirdparty code conduct accordance financial reporting council gsk value speak programme element corporate governance code board determine include general manager certification process judy lewent recent relevant financial company gm confirm adherence internal experience board agree control framework gec continue deploy appropriate qualification background audit leader lead discussion programme gsk value right committee financial expert define sarbane time culture ethical decision make workshop oxley act determine independent mean security exchange act amended committee competence relevant sector company operate gsk annual report strategic report governance remuneration financial statement investor information audit risk committee report continue value maturity assessment value assessment review monitor committee learn outcomes value maturity monitor key element internal control framework assessment vma perform target serve continuous source insight inform improvement assessment specific area implementation control environment significant focus business unit specific action plan address area business area improvement identify vma oversee local compliance activity risk management compliance board vma insight sec settlement committee continues review consider highlight overall patient focus integrity value update securities exchange commission sec employee feel affinity agree settlement sec embed positive shift perception relate compliance term settlement track final value transparency respect people note report submission sec summer result audit assurance team value assessment review assess value embed cia committee oversight company organisation responsibility cia enter office inspector general oig department health revise gsk employee survey human service year group report people take gsk employee engagement survey oig commercial practice global pharmaceutical purpose outcome discuss affirmative obligation cia expire strategic report group wait official closure oig complete write standard control work continue review group final cia annual report cia require harmonise simplify write standard part group ensure sufficient internal control mitigate risk enterprise recognise improve accessibility clarity associate commercial practice involve pharmaceutical write standard enabler improve risk product interaction healthcare professional management inform decision make group receive positive feedback oig consequently receive release month early original training communication gec function continue year term cia commitment certain focus personal development include state salesforce compensation extend ethic compliance academy gec run faceto committee continue receive quarterly cia face ethic compliance academy launch virtual assurance update head gec academy enable flexible participation virtual respond issue integrate investigation academy hold end hold process develop gec legal clarify quarter currently certify ethic accountabilitie safeguard reporter speak compliance professional inception academy channel deliver improve outcome decision improvement helped accelerate step take live value april enterprisewide substantiate allegation investigate resolution live value training issue population deliver enhancement engagement key stakeholder employee complementary worker training individual raise issue detail report include scenario explore value investigate concern gsk set application company way work include strategic report awareness enterprise risk speak arrangement enterprise risk framework strategy year focus critical risk include privacy committee consider gsk enterprise risk strategie antibribery corruption abac mandatory training abac address review undertake corporate integrity agreement cia complete target area workforce depend annual unit risk assurance update report role perform enterprise risk strategy paper significant risk annual risk review contain risk management internal control report present head gec gsk annual report corporate governance accountability continue audit risk committee report continue review committee assess key financial reporting framework enhancement enterprise risk affect unit manage mitigated committee continue improve clarity gsk external proportionate way committee examine financial reporting review company financial report satisfied control environment operation effectiveness framework committee recommendation board refinement management propose ensure approve adoption early change environment remain fit purpose appropriate assess improve way gsk report explain adjusted result commitment unit leadership maintain strong adjust item line european security market control culture authority sec requirement addition change company use adjusted performance measure committee note progress deliver improve clarity financial reporting finally free enabler drive strong risk management cash flow calculation adjust include contingent approach gsk enterprise risk provide great consistency consideration payment risk management drive efficiency include common list enterprise risk subrisk assess unit global reporting system platform single list business activity risk committee please oversee continue progress map move standardise global system support endtoend process significant party oversight programme committee please deployment multiyear programme note end december assessment complete early focus move capturing country complete thirdparty benefit new standardise system process oversight tpo programme commence generate gsk assessment currently progress assessment result issue approximately role corrective preventative action design improve finally role chair committee continue busy thirdparty engagement tpo framework continue evolve varied year significant interaction key senior efficient easy use currently executive auditor attend range management embed gsk make easy buy good service meeting programme detail work party set committee work closely emma walmsley strategic report gsk new ceo set new business priority enhance privacy compliance capability privacy centre innovation performance trust committee monitor excellence coe deliver change programme improve continue monitor evolution gsk culture sustainably manage gsk datum privacy compliance whilst company sharpen business performance ensure performance comply general data protection regulation delivered appropriately gdpr come effect coe vindi banga member remuneration committee good progress define privacy risk framework enable allow provide input committee review gsk design proportionate control prioritise deployment group performance oversight risk factor relevant effective decision risk whilst programme remuneration matter purpose increase privacy maturity globally coe remediation effort focus initially european committee evaluation operation mitigate high nearterm risk create committee annual evaluation exercise externally facilitate gdpr remediation expect deliver ffion hague independent board evaluation report december point gsk enhance privacy largely positive confirm committee cover operating model deploy globally ground detail consideration report committee conclude continue operate effectively agree implement performance improvement review format paper term accessibility consider increase focus committee time meeting allow opportunity review discussion nomination committee succession planning board committee member financial experience judy lewent audit risk committee chair march gsk annual report strategic report governance remuneration financial statement investor information committee area committee focus item discuss frequency financial review integrity draft financial statement appropriateness accounting policy go concern report assumption consider approval process confirm recommend board annual report fair balance understandable review recommend board approval annual report form review approve director expense review recommend approval quarterly preliminary result announcement dividend review significant issue relation quarterly preliminary result consider evolve market practice viability statement requirement review recommend inclusion viability statement annual report review accounting development impact key accounting issue external receive external auditor transition update management auditor review approve auditnonaudit expenditure incur consider auditor report annual result perform evidencebase assessment external auditor effectiveness external audit consider qualification expertise independence external auditor recommend board reappointment external auditor committee agree auditor remuneration approve audit plan audit fee proposal set performance expectation auditor consider initial result external audit global internal review assurance report global pharmaceutical vaccine consumer healthcare gms control viiv healthcare compliance review gsk internal control framework confirm compliance sarbanesoxley act review audit assurance work approve plan work undertake corporate integrity agreement cia training receive review cia compliance assurance report review report operational excellence programme review implementation new system group support function receive litigation report update receive report ongoing investigation abac issue risk review risk management framework compliance review risk element group treasury pension risk insurance tax policy receive status report follow enterprise risk abac ehss information protection patient safety privacy product quality research practice party oversight receive terrorism cyber security risk assessment update receive update implication brexit receive risk oversight compliance council meeting update consider emerge risk governance confirm compliance corporate governance code matter review committee term reference confirm adhere receive corporate governance update review committee performance effectiveness review approve group approach modern slavery act meet privately separately head global ethic compliance audit assurance meet privately external auditor end meeting require approve publication group tax strategy committee activity key annually quarterly periodically stand gsk annual report corporate governance accountability continue significant issue relate financial statement consider quarterly financial result announcement financial result contain annual report committee review significant issue judgement management determine result committee review paper prepare management set key area risk action undertake quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue consider relation financial statement year end december set follow table summary financial outcome appropriate addition committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis preparation committee consider outcome management halfyearly review current forecast net financial statement debt position financing facility option available group follow review risk potential impact unforeseen event committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include return committee review management approach time recognition revenue accrual rebate rar accrual customer return rebate pharmaceutical vaccine accrual return rebate billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter include committee receive detailed report actual potential litigation internal external investigation group legal counsel number detail update investigation group commercial commercial practice practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion set note financial statement provision provision uncertain tax position committee consider current tax dispute area potential risk concur management judgement level tax contingency require december tax payable liability billion include provision uncertain tax position recognise group balance sheet impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail valuation contingent consideration committee consider management judgement follow improve sale relation viiv healthcare performance tivicay triumeq necessary increase liability pay contingent consideration acquisition shionogiviiv healthcare joint venture december group balance sheet include contingent consideration liability billion relation viiv healthcare note financial statement contingent consideration liability details consumer healthcare option committee consider management judgement valuation liability billion recognise respect novartis option shareholde consumer healthcare joint venture include review impact unwind discount liability decrease liability cause significant strengthening sterling year viiv healthcare option committee review agree accounting pfizer option concur management judgement valuation option billion december gsk annual report strategic report governance remuneration financial statement investor information auditor appointment external auditor pricewaterhousecooper llp pwc auditor company group inception performance review annually audit partner rotation requirement observe gsk conduct external audit tender view replace pwc financial year onwards disclose year report pwc invite participate audit tender process comply audit firm rotation requirement audit tender process complete december board announce appoint deloitte llp deloitte gsk new external auditor effect january effectiveness quality external audit process committee commit ensure ongoing basis gsk receive high quality effective audit external auditor effectiveness pwcs performance quality external audit process formally evaluate committee early criterion agree conjunction management early committee undertake number activity year satisfy pwcs continuous external audit quality effectiveness particularly year audit firm transition pwc deloitte activity timeline set recommend pwcs pwcs formal appointment review pwcs performance accept appointment performance approve audit resignation recommend expectation set process planning deloitte appointment matter address matter address matter address effectiveness pwc expectation shareholder approve resolution appoint effectiveness pwc expectation set review pwc authorise committee set march review appropriate level challengescepticism determine remuneration appropriate level challengescepticism exhibit pwc work consider audit plan review agree exhibit pwc work consider pwcs independence appropriate level pwcs quality control procedure pwcs letter resignation receive qualification expertise resource consider deloitte independence appropriate level review statutory audit fee agree set qualification expertise resource report pwcs audit gsk review management feedback audit process annual report financial reporting survey receive cover appointment deloitte fill vacancy council audit quality team review robustness audit process recommend board approve satisfied matter quality delivery people service audit plan review agree reappointment pwc agm performance expectation deloitte perform audit auditor audit agree recommend board appointment deloitte performance expectation pwc agm perform audit auditor audit agree recommend board budget nonaudit services audit fee agree march march gsk annual report corporate governance accountability continue auditor appointment continue detailed criterion committee judging effectiveness pwc external auditor overriding responsibility deliver smoothrunne thorough efficiently execute audit set performance expectation gsk external auditor specific auditor discuss audit approach area focus advance early engagement understanding implication new operating model responsibility ensure sarbanesoxley act scope additional procedure discuss endorse management communicate timely basis gsk pwc avoid surprise timely reporting issue level company ensure clarity role responsibility local pwc gsk finance service respond issue raise management timely basis meet agree deadline provide continuity succession plan key staff member pwc provide sufficient time management consider draft auditor report respond request query ensure consistent communication local central audit team wide auditor provide timely uptodate knowledge technical governance issue include evolve market practice viability statement responsibility requirement european security market authority securities exchange commission sec guideline new ifrs standard ifrs ifrs serve industry resource communicate good practice trend report integrate reporting adhere independence policy gsk financial reporting council revise ethical standard applicable sec standard deliver focus consistent audit approach globally reflect local risk materiality liaise audit assurance avoid duplication work global ethic compliance ensure common understanding audit outcome provide consistency advice level ultimately provide high quality service board scrupulous scrutiny group act utmost integrity specific audit contribute seamless effective efficient auditor transition deloitte include follow action firm transition provide access relevant information respect audit glaxosmithkline plc subsidiary relation audit responsibility group consolidated account provide information concern gsk obtain course provide nonaudit service constitute relevant information audit group consolidated account provide factualevidence base oral write explanation timely manner aid deloitte understand audit work paper agree practical term interaction establish appropriate environmentforum arrangement provide access information include format mechanism response time liaise deloitte enable observation audit activity independent provide sufficient analysis hour spend provision relevant information complete additional adhoc handover expectation agree year competition market authority compliance statement committee consider company comply mandatory audit process audit committee responsibility provision competition market authority statutory audit service order page report describe work committee discharge responsibility nonaudit services sarbanesoxley act prohibit engagement ensure adequate safeguard place objectivity external auditor provision certain service legal independence group audit threaten actuarial internal audit outsource financial information system compromise design external auditor permit provide nonaudit ensure total fee level exceed annual service auditrelate tax service audit fee special circumstance committee ensure auditor objectivity independence clear advantage company auditor undertaking safeguard policy require preapproval committee additional work service contractual similar obligation restrict group choice external auditor exist policy review revise committee december ensure compliance financial follow core policy guideline engage external auditor reporting council frc revise ethical standard provide nonaudit service observe audit regulation new regulation new policy ensure nonaudit service implement group begin competitive tender financial service provider contain follow policy guideline external auditor line group procurement process fee cap gsk exist policy cap annual audit fee skill experience external auditor cap retain new policy stringent suitable supplier nonaudit service frc new fee cap set average fee precede consideration year period gsk annual report strategic report governance remuneration financial statement investor information nonaudit service continue prohibition gsk new policy include black list prohibit nonaudit services new regulation auditnonaudit service year comparison graph preapproval categorywide preapproval process update reflect restriction frc guidance audit committee nonaudit service preapprove committee chairman cfo delegate committee preapprove group financial controller approve designate group financial controller external audit firm transition arrangement describe deloitte subject restriction policy started require period independence july advance take statutory audit group audit assurance service financial statement january fee audit assurance service include million arise fee pay company auditor associate set novartis transaction subsequent increase complexity group approximately half expect recur detail give note financial statement service include tax regulatory compliance treasuryrelate operate profit service possible accounting firm engage undertake nonaudit service auditor transition significant activity committee year enhance understanding gsk year committee exercise oversight responsibility deloitte audit team engage extensively gsk manage transition period pwc deloitte business stakeholder primary focus finance committee satisfy smooth handover community begin engage priority local audit responsibilitie committee specific market entity identify represent high audit transition performance expectation pwc set transition complexity give local regulatory requirement entity cover group audit local introduction progress committee receive detailed transition paper schedule meeting begin primary focus oversee deloitte hold series regional academy onboard step need deloitte achieve independence july local team communicate audit vision approach firm commence audit planning activity local partner deloitte centrally coordinate introductory meeting senior finance manager deloitte involve scrutinise deloitte plan achieve partner location statutory audit require independence progress oversee termination nonaudit service prohibit deloitte continue key pwc clearance deloitte take role auditor example include meeting target pwc walkthrough leverage work deloitte stepping role remuneration exist pwc procedure deloitte team perform committee adviser end june initial audit scope risk assessment design detailed audit plan compile initial insight report present independence achieve committee december deloitte formally observe pwcs work pwc resign firm conclude external audit audit process committee recommend board prospective lead audit partner support deloitte appoint fill casual vacancy shareholder invite attend committee meeting invite appoint deloitte gsk new statutory auditor committee chair hold number meeting agm pwcs audit partner available lead partner agm answer shareholder question annual report transition process thorough minimal disruption gsk business gsk annual report corporate governance accountability continue auditor transition continue external audit firm transition process key phase preindependence readiness postindependence transition january june july december key step relationship build detailed audit knowledge transfer design audit plan january june july september october december key task achieve independence complete risk assessment scope building understand gsk organisation structure business implement audit analytic tool unit deepen understand business process undertake appropriate audit team selection onboarding walking process assess design control agree process datum extraction tool onboarde global team communicate audit approach agree collaboration term pwc incountry market introduction assess conclude key historic accounting judgement observe pwc interim review process agree term engagement fair balance understandable assessment key compliance requirement group financial code conduct report line statement annual report fair balance number wellestablishe policy include understandable coordination review groupwide code conduct available governance section contribution annual report follow wellestablishe website confidential speak reporting line document process perform parallel reporting investigation unlawful conduct update formal process undertake external auditor version code conduct publish april committee receive summary approach take management preparation gsk annual report ensure meet requirement financial reporting council corporate governance code enable committee board confirm gsk annual report take fair balanced understandable provide information necessary shareholder assess company position performance business model strategy gsk annual report strategic report governance remuneration financial statement investor information internal control framework board recognise obligation present fair balanced fit purpose framework conjunction corporate understandable assessment gsk current position value behaviour speak process ensure risk prospect board accountable evaluating approve associate gsk business activity actively effectively effectiveness internal control include financial control line agree risk appetite framework operational compliance control risk management provide reasonable absolute assurance material process operate gsk misstatement loss internal control framework framework comprehensive gsk risk oversight compliance council rocc enterprisewide risk management model mean team senior leader mandate board assist gsk ensure reliability financial reporting compliance committee oversee risk management internal control law regulation framework support continuous activity provide business unit framework process board identification evaluation management risk management upward escalation significant risk gsk principal risk require financial reporting business unit govern risk management compliance council frc corporate governance code code board rmcb report rocc business unit design enable gsk achieve business objective rmcbs responsible promote local tone risk culture ensure effective oversight internal control risk management process risk owner member senior management assign framework principal risk risk owner accountable management respective principal risk report risk management strategy rocc committee enterprise oversight year rocc rmcbs assist independent assurance foy adlo anal int iss mnd empl eia ose pis isre foib independent business monitor soe uve cnt ivo elr mpr sic ere ari iok ith inn hically organisation seek establish framework disc rce ssk nsm een cori ntt ron standards tom sem apl ree eis nbaa tso ehl uip mec ecr nolt tcee iia ttc sac eein orra oae diu dae hnh fek sun ord ricc ble mer ssp ding activity train funa lfidn inhg gee goe san krt sor te jeeh cri tii vga ehs ddn ude dise inolp grys wor itm aia tig sne mom toa ine gment communication ind cth iae fik mas ual reporting line chief committee receive regular report business unit principal risk owner gec area significant risk gsk relate internal control report provide assessment internal control environment principal risk area include enhancement strengthen gsk value expectation control environment follow consideration report committee conclude effectiveness internal control environment reports board annually accordance code provision committee board behalf conduct robust assessment group principal risk include consideration nature extent risk willing achieve group strategic objective gsk annual report internal control framework continued board committee maintain oversight information gsk risk management approach provide ensure effectiveness internal control environment risk manage risk section strategic report page management process operation gsk year management principal risk explain date approval annual report principal risk uncertainties page group viability discuss group financial review section board review focus company subsidiary strategic report extend material associate undertaking joint venture investment consider risk company participation activity establish procedure control place identify entity result consolidated group result believe process follow board committee review regularly system internal control risk management process accordance guidance risk management internal control relate financial business reporting issue frc governance structure risk management gnirotinom rof ytilibatnuocca responsibility implement corporate governance accountability continue board director responsible system corporate governance strategy risk management financial performance responsible review approve audit risk committee adequacy effectiveness risk management internal control corporate executive team support ceo manage business activity authorise board assist audit risk oversight compliance council risk committee oversee risk management internal control activity group responsible system corporate business unit governance strategy risk management financial performance ensure appropriate internal control risk management compliance board effective risk management implement complement country executive risk board ensure consistent approach risk management local geography level gsk annual report strategic report governance remuneration financial statement investor information relation stakeholder engagement activity performance duty company seek major shareholder build trust priority board listen view year publication quarterly result shareholder key stakeholder include patient emma walmsley simon dingemans give presentation consumer customer employee cognisant institutional investor analyst media webcast potential impact decision make teleconference july emma walmsley senior team hold investor update event audience principal board committee delegate power share innovation performance trust longterm priority enable indepth assessment impact conclude indepth session company engagement stakeholder provide mean identify emerge stakeholderrelate issue emma simon maintain continual active dialogue bring attention board turn enable institutional shareholder performance plan objective invest activity build trust programme regular meeting year hold total individual meeting major shareholder shareholder host total group meeting major try engage shareholder way include shareholder potential major shareholder regular communication agm investor relation activity announce result quarterly basis philip hampton meet major shareholder hear annual result include annual report shareholder view discuss issue mutual importance receive annual summary advise annual communicate view rest board year report notice annual general meeting available hold individual meeting major shareholder range issue senior independent nonexecutive director sid nonexecutive director available meet major shareholder ongoing basis investor relation department office london philadelphia act focal point communication investor company secretary act focal point communication corporate governance matter annual governance event cornerstone investor calendar annual governance align culture strategy event hold institutional shareholder key investment board stewardship stakeholder relationship industry body influential proxy advisory firm year event hold december francis crick institute brexit london host chairman sid lynn elsenhans jesse goodman judy lewent committee chair urs rohner provide overview work respective value prior engagement input investor board committee undertake year finally vindi forum member help shape agenda banga sid provide insight perspective board event chairman share update key area focus dynamic role contribution nonexecutive board include director challenge shape group strategy business model overview business performance listen view shareholder receive board cet succession skill capabilitie feedback event hold run corporate diversity report agm season help board understand new ceo shareholder views oversight new business priority innovation performance trust capital allocation gsk annual report corporate governance relation stakeholder continue engagement activity continue annual general meeting retail shareholder company secretary act focal point retail investor shareholder invite attend annual general manage key relationship company registrar meeting year hold qeii equiniti bank new york mellon london agm good level attendance administer adr programme engagement shareholder propose resolution approve shareholder level people support range provide opportunity board fully supportive group commitment question board chair progressive modern employer attract retain good talent board committee formal agm proceeding drive high level employee engagement key provide shareholder chance meet informally transformation priority emma walmsley cet board director available evolve culture company enhance business performance meet strategic success rely ability engage employee delivery company innovation performance trust longterm priority discuss length board threeday conference october attend senior leader employee engagement enhancement help enhance exist employee consultation activity board support management introduction roll follow engagement activity let talk programme employee encourage cet regular input view conversation directly let talk channel workforce feedback employee performance system engagement session share advance new performance board employee system link innovation performance trust priority business performance trust new allemployee survey undertake month regular allemployee engagement level newsletter video detail trust increase significantly ceo round priority include employee previous survey news interest engagement company provide valuable insight employee encourage approach develop employee sentiment feedback workforce safe diverse ethical environment find page gsk annual report strategic report governance remuneration financial statement investor information science committee report dear shareholder jesse goodman please present report science committee science committee committee establish main board chair consider science pipeline capital allocation priority committee core role year operation provide assurance board quality competitiveness integrity discharge role effectively require committee compose member strong scientific capability please joined committee fellow scientific medical expert professor sir roy anderson laurie glimcher judy lewent background life science role specialist commercial perspective committee committee committee focus establish role undertake periodic review strategy remit consider follow matter progress rd pharmaceutical strategy performance assess overall performance include relevant transformation programme financial metric effectiveness competitiveness review vaccine strategy science medical healthcare trend helps identify critical emerge trend science medicine potential impact company antimicrobial resistance undertake periodic review company overarch focus committee work appraisal scientific capability talent transformation proposal associate funding review scientific opportunity specific large requirement prepare new ceo emma walmsley scale investment business transaction president patrick vallance committee share review output group science advisory feedback management incorporation proposal board please note key milestone date drive focus prioritisation core therapy area membership refocus committee member committee member enhance pipeline governance committee note effect jesse goodman chair january january change strengthen portfolio governance create professor sir roy anderson january great robustness financial commercial strategic review follow introduction new portfolio strategy committee laurie glimcher september guide challenge work judy lewent january improve development significant progress detail committee member skill experience create roadmap improve company overall give biography board capability development quick win include talent page committee member development team optimisation acceleration planning attendance level partnership commercial organisation company secretary secretary committee committee evaluation attend meeting attendee committee annual evaluation committee externally facilitate meeting include ffion hague independent board evaluation conclude committee establish formalising structure regular attend way work include continue oversight attendee attendee require step company chairman committee look forward work hal chief scientific officer president oversee development plan reinvigorate president global vaccine accelerate discovery development transformational independent senior external scientific new medicine adviser finally like thank patrick vallance step chief financial officer board end march significant contribution company executive help establish committee devising remit helping develop programme activity basis committee deliberation wish future jesse goodman science committee chair march gsk annual report corporate governance continue corporate responsibility committee report dear shareholder lynn elsenhans corporate responsibility committee committee act corporate responsibility custodian policy practice define safeguard committee chair reputation company chair committee continue fellow committee member challenge shape company responsible business agenda committee member bring wide range sector experience insight stakeholder perspective help provide oversight topic help board monitor company work engage effectively key stakeholder assess company operating way seeks meet high expectation gsk global healthcare company deliver longterm value role shareholder society committee review work committee focus topic material company mission strategy value xternal issue potential committee focus review impact gsk business reputation company proposal future responsible business activity support company new longterm priority trust oversight stakeholder view engagement committee provide oversight management work nnual governance oversight progress review refocus gsk activity support global health gsk responsible business commitment move forward committee pay close attention evolve view membership expectation companys broad range key stakeholder membership committee appointment date regular report stakeholder development review set discuss meeting year committee committee member committee member receive external report hold discussion trend lynn elsenhans chair october stakeholder expectation likely influence trust professor sir roy anderson company longterm committee remuneration committee interested review preparation vivienne cox july company gender pay gap disclosure set jesse goodman committee membership refresh mid detail committee member skill experience impress way roy jesse vivienne give biography board exercise knowledge understanding issue page committee member discussion bring new challenge oversight attendance level committee stand good stead company secretary secretary committee company evolve responsible business agenda attend meeting attendee committee please invite roger connor president gms company meeting include responsibility product quality environment health regular attend safety sustainability attend committee regular basis attendee attendee require committee continue increase focus vital area chief executive officer company operation company chairman year continue enjoy positive engagement general counsel investor responsible business approach performance president global affairs particular opportunity enhance investment chief scientific officer president value create business opportunity mitigate risk alongside create social value president gms president global pharmaceuticals company position evolve responsible president global vaccine business commitment new set focus activity support delivery trust gsk longterm ceo gsk consumer healthcare business priority head human resource svp corporate affair head global corporate responsibility lynn elsenhans executive corporate responsibility committee chair independent external corporate march responsibility adviser gsk annual report strategic report governance remuneration financial statement investor information corporate responsibility committee report continue main responsibility work committee main responsibility committee set committee continue seek understand management respond expectation external committee rolling agenda receive report stakeholder seek align agenda activity member cet senior manager ensure progress support company longterm priority trust meeting responsible business commitment area focus review annual basis follow independent external corporate responsibility adviser health innovating address currently unmet health need support committee ensure sufficient improve access product irrespective people consideration view key stakeholder meet live ability pay control eliminate disease sophia tickell appoint independent external affecting world vulnerable people adviser committee position previously hold july tickell extensive experience pharmaceutical behaviour put interest patient consumer industry improve health system productivity sustainability drive value back energy supply distribution climate change policy short robust policy strong compliance process termism financial market people enable people thrive develop cofounder director meteo individual deliver mission direct pharma future series aim align well societal planet grow business reduce shareholder value hold number board environmental impact value chain advisory role addition meeting committee consider analysis tickell attend meeting committee provide management engagement expectation independent advice guidance corporate responsibility company key stakeholder bear matter committee chair ceo company reputation delivery responsible business committee evaluation agenda committee review approve responsible committee annual evaluation exercise externally facilitate business supplement available reference ffion hague independent board evaluation conclude wwwgskcomresponsibility committee continue operate effectively gsk annual report corporate governance continue director director power determine legislation change control essential contract article association contain rule appointment contract arrangement individually replacement director provide director fundamental ability business operate effectively appoint ordinary resolution member company party material agreement resolution director provide appoint board effect alter terminate change control follow director retire agm follow appointment takeover bid agreement director provide compensation loss office employment article provide director normally subject result takeover provision company reelection agm interval year annually share plan cause option award grant hold office continuous period year plan vest takeover detail termination provision board agree director wish continue executive director service contract give version member board seek reelection annually company remuneration policy report available accordance corporate governance code wwwgskcom investors section director cease director director report bankrupt purpose company act director cease director virtue company act report glaxosmithkline plc year end december article comprise page corporate governance suffer mental physical ill health board resolve report director statement responsibility page shall cease director page investor information miss director meeting continuous period strategic report set matter require disclose month permission board resolve director report consider strategic shall cease director importance prohibit director law resign offer resign board accept offer risk management objective policy page require resign board likely future development company strategic report director conflict interest research development activity page director duty company act avoid diversity inclusion situation direct indirect conflict provision information consultation employee interest possible conflict company article provide general power board authorise conflict carbon emission nomination committee authorise board follow information incorporate director report grant regularly review potential actual conflict location annual report authorisation record company secretary note board director count quorum interest capitalise financial statement note authorisation actual potential conflict publication unaudite financial information group financial review ongoing basis director responsible informing detail longterm incentive scheme remuneration report company secretary new actual potential conflict waiver emolument director applicable arise change circumstance affect authorisation previously give provide waiver future emolument director applicable authorisation director absolve statutory duty non preemptive issue equity cash applicable promote success company actual conflict arise non preemptive issue equity cash applicable postauthorisation board choose exclude director unlisted major subsidiary undertake receipt relevant information participation parent company participation place applicable debate suspend director board resort list subsidiary require director resign provision service control applicable shareholder nomination committee review register potential shareholder waiver dividend financial statement conflict authorisation january report board note conflict appropriately authorise process authorisation continue operate effectively shareholder waiver future dividend financial statement note describe note financial statement relate party transaction end financial year director agreement control shareholder applicable person closely associate material interest director report draw present contract significance group company accordance reliance english company law independent advice liability director connection report shall company agree procedure director subject limitation restriction provide law independent legal andor financial advice company expense director report approve board director deem necessary march sign behalf indemnification director qualify party indemnity provision define company act force benefit director philip hampton director hold office signing chairman annual report march ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn remuneration section chairman annual statement annual report remuneration remuneration policy summary gsk annual report remuneration report chairman annual statement dear shareholder remuneration outcome behalf board please award relation present remuneration report accordance approve include annual statement remuneration policy key decision annual report remuneration remuneration committee summary remuneration policy committee follows approve agm bonus outcome executive shareholder vote favour director determine reference annual report remuneration performance preagreed annual statement subject financial measure decision advisory vote agm committee assessment individual level performance gsk context executive remuneration gsk remuneration committee achieve performance excess see gsk perform sale relevant financial target year take year grow business conjunction assessment individual pharmaceutical vaccine consumer align performance result bonus healthcare continue good payment target remuneration policy momentum new product drive maximum opportunity strong performance tivicay receive overwhelming triumeq hiv inhale ellipta portfolio detail bonus outcome year provide nucala respiratory meningitis shareholder support vaccine see key vest performance share agm approval shingrix vaccine shingle plan psp award match trelegy ellipta oncedaily single inhaler award defer annual triple therapy copd juluca bonus plan dabp base dolutegravir rilpivirine drug preagreed measure new regimen oncedaily single pill hiv gsk product performance adjust free cash demonstrate continue cost control flow relative tsr equal year improve free cash weighting performance measure flow achieve earning growth year december deliver adjusted eps growth line threshold level tsr guidance total eps increase cash flow measure exceed finally return shareholder maximum level achieve dividend line expectation new product measure result overall vest level detail vest outcome psp dabp matching award provide remuneration committee review executive director salary emma walmsleys simon dingemans salaries increase january line increase broad employee population remain committee intention walmsley package review come year subject development performance role gsk annual report strategic report governance remuneration financial statement investor information board change look ahead financial reporting council frc november patrick vallance new product measure lti recently consult broaden announce leave plan implement recognise role remuneration committee company government importance future business propose measure pay chief scientific adviser head growth continue relevant wideranging review corporate government office science lti performance reward governance code revised code vallance voluntary leaver performance committee include view receive severance organisation successful matter company response payment leave company commercialisation launch excellence consultation revised code end march vallance continue remain important committee consider committee review current receive base salary set mean incentivise practice government leave gsk eligible commercial success group frc measure wellplace receive bonus base committee work comply look forward provide combination business individual design new lti measure base update issue year performance receive bonus pipeline replace report portion new product measure lti employ psp dabp matching award look forward share agm award vest prior detail new innovation measure finally like thank shareholder departure lapse leave year progress ongoing input engagement eligible receive lti award welcome shareholder feedback governance development report look forward receive committee take close interest support annual report november announce legislative good practice development remuneration agm appointment hal barron role director pay policy support chief scientific officer president initiative raise bar area january barron modern employer company take world foremost leader responsibilitie new gender pay spend career working regulation seriously committee usa barron package fully corporate responsibility committee urs rohner line remuneration policy approve interested review preparation remuneration committee chairman shareholder base salary company gender pay disclosure set march million incentive opportunity line approve remuneration policy aggregate total compensation government announce competitive range see package measure executive pay global pharmaceutical peer group include secondary legislation require buyout award publication pay ratio company ceo average sir andrew witty step ceo employees committee retire gsk mutual agreement support enhancement march moncef slaoui transparency shareholder step board march interested stakeholder include retire gsk mutual agreement information report june agree termination methodology calculate ratio arrangement case set finalised new regulation year report case arrangement execute line approach describe year accordingly year remuneration report provide detail final amount pay gsk annual report annual report remuneration glance highlight summary follow show breakdown total remuneration pay executive director office december respect emma walmsley ceo simon dingemans cfo patrick vallance outgoing president fix pay salary benefit pension performance pay annual bonus ltis earn respect year end emma walmsley patrick vallance appoint board january pay performance annual bonus financial performance lti outcome performance period end december overall vest maximum relative new target tsr product target threshold target core group pbit maximum performance target performance achieve adjust lapse free cash flow vest call adjust group pbit executive director shareholding audit align interest executive director share ownership sor multiple base salary shareholder require build maintain significant emma walmsley holding share gsk time executive director require continue satisfy share ownership requirement sor minimum month simon dingemans leave gsk patrick vallance executive director cet multiple base salary ceo sor december shareholde executive director corporate executive team member gsk annual report strategic report governance remuneration financial statement investor information total remuneration audit value earn annual total salary benefit pension lti bonus remuneration award fix pay pay performance total remuneration executive director set table patrick vallance moncef slaoui emma walmsley sir andrew witty simon dingemans outgoing president chairman ceo ceo cfo global vaccines janmar janmar fixed pay salary benefit pension total fix pay pay performance annual bonus page vest lti awards dabp matching awards psp total pay performance total remuneration note emma walmsley appoint board effect january succeed sir andrew witty ceo april sir andrew step ceo retired board march emma walmsleys salary ceo designate january march walmsleys salary increase april succeed sir andrew witty ceo detail defer annual bonus plan dabp bonus deferral set matching award dabp detail respect vest dabp matching awards performance share plan psp award threeyear period december provide psp dabp awards sir andrew witty moncef slaoui grant vest award vest follow oneyear anniversary termination accordance term executive financial recoupment policy sir andrew awards vest march slaoui june addition delay vest psp award twoyear hold period point normal vest disclose annual report sir andrew witty moncef slaoui left gsk mutual agreement receive termination payment outstanding incentive award treat accordance remuneration policy approve shareholder term sir andrew slaoui receive payment prorate proportion financial year work lieu performance relate bonus payment prorate amount pay month march respectively simon dingemans vest psp share subject twoyear hold period committee specific circumstance line state principle apply clawbackmalus determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect executive director gsk annual report annual report remuneration continue total remuneration audit continue follow section provide detail element total remuneration include committee implement approve remuneration policy comparator group pay tsr committee pay comparator group role consider executive pay primary group executive director follow crossindustry comparator group global pharmaceutical comparator group emma walmsley astrazeneca reckitt benckiser patrick vallance france simon dingemans bhp billiton rio tinto sanofi abbvie royal dutch shell switzerland amgen british american tobacco unilever novartis bristolmyers squibb diageo vodafone roche holdings eli lilly johnson johnson merck astrazeneca pfizer abbvie amgen include remuneration benchmarking include tsr comparator group review ceo remuneration committee reference pay group lead european company selection base size complexity fix pay audit salary benefit benefit table set base salary executive director year disclose year salary increase emma walmsley align provide wide employee benefit workforce detail salary level provide travel benefit base salary total change emma walmsley sir andrew witty january march employee benefit emma walmsley travel april december benefit sir andrew witty total simon dingemans simon dingemans patrick vallance employee benefit moncef slaoui travel benefit benefit table opposite show breakdown gross cash value total benefit receive executive director patrick vallance include employee benefit employee benefit employee share plan healthcare travel car allowance personal financial advice life assurancedeath benefit service cover total travel expense car travel spousepartn cost associate moncef slaoui accompany executive director gsk business deem taxable benefit individual employee benefit travel benefit expense incur ordinary course business deem taxable benefit benefit individual include table total moncef slaoui benefit include accommodation gsk annual report strategic report governance remuneration financial statement investor information fix pay audit continued pension executive director pension plan type member emma walmsley base salary matching contribution salary base salary lieu pension salary excess sir andrew witty define benefit simon dingemans base salary lieu pension patrick vallance base salary lieu pension moncef slaoui belgian plan member define contribution plan emma walmsley eligible receive matching award salary accordance term plan emma walmsley receive cash payment lieu pension base salary excess line gsk define contribution pension plan rate simon dingemans patrick vallance receive cash payment lieu pension base salary line gsk define contribution pension plan rate member plan moncef slaoui build pensionable service belgian plan cash balance supplemental pension plan annual employer cash contribution plan executive supplemental saving plan essp current pension entitlement product service progression gsk follow table show breakdown pension value set emma walmsley sir andrew witty simon dingemans patrick vallance moncef slaoui janmar janmar pension remuneration value define benefit define benefit define contribution belgian define benefit employer cash contribution total pension remuneration value pension remuneration figure calculate accordance methodology set large mediumsize company group account report amendment regulation remuneration regulation calculate define benefit pension value sir andrew witty slaoui difference accrue pension march accrue pension december increase inflation define benefit define benefit belgian define benefit multiply amount translate euro dollar exchange rate detail pension value define benefit plan participant set table accrue pension march dec pension remuneration sir andrew witty value fund unfunded total accrue pension march dec pension remuneration moncef slaoui value fund unfunded belgium fund total pension figure disclose sir andrew witty moncef slaoui member define benefit plan table show accrue benefit annual pension accrue date pension remuneration calculate increase accrue benefit adjust inflation multiplier reflect fact benefit receive number year movement negative year value show amount translate euro dollar exchange rate gsk annual report annual report remuneration continue pay performance audit annual bonus core group pbit individual annual bonus objective rename adjust group pbit performance target financial measure weighting follow weight performance position performance measure executive director target outcome target core group pbit call adjust group pbit individual objective threshold maximum performance target set target respectively core group pbit target outcome purpose annual bonus calculation differ core group pbit disclose annual report primarily target outcome number calculate apply gsk budget exchange rate actual exchange rate follow table show actual bonus earn compare opportunity bonus opportunity bonus outcome financial individual total total base salary target maximum performance objective bonus bonus bonus salary salary salary salary salary emma walmsley simon dingemans patrick vallance sir andrew witty moncef slaoui cease executive director year accordance remuneration policy receive prorata payment lieu variable bonus opportunity committee set role specific objective period individual cease executive director remuneration policy approve target bonus opportunity set policy approve shareholder salary sir andrew salary slaoui contractual payment show table table provide detail delivery core group pbit target call adjust group pbit financial performance core group pbit group turnover billion increase aer cer adjust group adjust operate profit million high cer basis high aer pbit adjust operate margin percentage point high percentage point high cer basis reflect improved operating leverage drive sale growth favourable mix business margin benefit continue tight control ongoing cost business restructure integration benefit vaccine consumer healthcare business partly offset continue pricing pressure particularly respiratory investment supply chain gsk annual report strategic report governance remuneration financial statement investor information pay performance audit continue follow table summarise performance scorecard individual objective agree committee executive director individual objective emma walmsley successful induction transition sir andrew witty deliver strong overall financial performance group strong performance new product sale billion aer cer track deliver billion new product sale cer basis sale billion cer build corporate executive team outstanding new hire new chief scientific officer president president global pharmaceuticals chief digital technology officer role new hire internal promotion successfully complete strategic review pharmaceutical business key area portfolio footprint operating model implementation ongoe significant pipeline reprioritisation new portfolio governance process commercial new year pharmaceutical supply chainstrategy reduce complexity improve productivity whilst maintain compliance innovation performance trust priority kpi define communicate basis employee objective business performance management improve cash cost discipline newly establish capital allocation process integrate business cash flow management new employee expectation incentive system launch key enablers culture change significant improvement reliability quality supply pharmaceutical consumer health business gsk rank access vaccine index antimicrobial resistance benchmark cent improvement comparable employee engagement score simon dingemans deliver strong financial leadership group improve cash flow generation improve cash cost discipline newly establish capital allocation process integrate business cash flow management restructure synergy programme deliver combined benefit billion billion cer develop capital allocation framework support strategy include business development requirement strong support new ceo appointment new chief digital technology officer patrick vallance strong performance new product sale billion aer cer include strong performance tivicay triumeq hiv inhale ellipta portfolio nucala respiratory key approval pharmaceutical pipeline include trelegy ellipta daily single inhal triple therapy copd juluca drug regimen oncedaily single pill hiv continue strong delivery organisation pipeline complete performance review lead significant pipeline reprioritisation operational change area diagnosis early implementation strengthen partnership commercial pharmaceutical particular attention pay pipeline prioritisation malus clawback policy detail policy malusclawback refer remuneration policy report annual report available wwwgskcom investors section january respect financial year committee decide disclose recoupment committee exercise malus clawback disclosure matter subject public report misconduct fully resolve legally permissible disclose unduly prejudice company shareholders line disclosure guideline committee recoupment committee exercise malus clawback policy detail policy recruitment remuneration loss office termination payment refer remuneration policy report page annual report available wwwgskcom investor section gsk annual report annual report remuneration continue pay performance audit continue value earn longterm incentive ltis follow table set performance achieve management target set company lti plan include update performance outstanding award line committee agree principle measure applicable lti awards actual performance target review adjustment appropriate reflect impact novartis transaction business ensure vest outcome reflect genuine underlie business performance detail adjustment provide time vest award performance period end december committee review performance psp dabp matching award grant executive director target set performance achieve year december vest level set table outcome vest level performance measure relative weighting performance target outcome maximum award new product new product sale performance measure aggregate threeyear sale new performance product launch threeyear performance period precede year original target adjust target vest maximum threshold adjust free line company agree principle afcf figure include adjustment cash flow afcf number material distort item include legal settlement exchange rate performance movement special pension contribution target vest maximum threshold afcf target set announce follow close novartis transaction target adjust relative tsr rank tsr ranking comparator group vest performance maximum threshold median comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company total vest respect award gsk annual report strategic report governance remuneration financial statement investor information pay performance audit continued historical vest gsk ltis year grant performance measure total vest level lapse dabp matching award onwards dabp matching award wholly subject tsr performance total vest level award subject measure psp vest line figure show chart performance measure key new product adjust free cash flow tsr business diversification lapse update performance ongoing lti awards committee review performance psp dabp matching award grant executive director follow chart provide estimate vest level take account performance december actual vest level determine base performance threeyear performance period indication regard prediction final vest level award performance update award performance update rank rank threshold threshold maximum maximum commercially commercially median sensitive median sensitive threshold threshold tsr adjust free new tsr adjust free new cash flow product cash flow product estimate vest level estimate vest level threshold performance award vest respect new product afcf measure tsr element tsr comparator group remain unchanged show respect award adjust free cash flow target award revise reflect additional investment key project priority review voucher juluca launch refer page annual report committee intend disclose target follow end performance period annual report remuneration lti awards level participation dabp respect bonus deferral show table table detail matching award show maximum vest potential respect bonus table show psp award detail dabp matching awards psp award total bonus number face value award level number face value defer share award base salary share award emma walmsley share share sir andrew witty simon dingemans share share patrick vallance share share moncef slaoui face value dabp award calculate base share price closing price february face value psp award calculate base share price closing price july performance period awards january december gsk annual report annual report remuneration continue ceo pay comparison ceo total remuneration position historic ceo remuneration single figure crossindustry remuneration group annual bonus award global pharmaceutical maximum group vest lti awards european maximum crossindustry group bonus include amount pay operational efficiency bonus place year overall maximum bonus receivable subject limit base salary low quartile median upper emma walmsley percentage change remuneration ceo median quartile current position remuneration include salary expect value incentive base gsk ceo employee committee agree benchmarke methodology change change performance graph ceo emma walmsley sir andrew witty follow graph set performance company relative salary ftse index pharmaceutical performance benefit comparator group nineyear period december annual bonus index select comparison purpose reflect primary index gsk constituent industry wide employee population salary increase include operate annual salary review additional change year promotion employee benefit unchanged previous year change benefit policy level reflect change level benefit individual receive result change role promotion population consider relevant comparison closely reflect economic environment encounter ceo ceo ratio committee intend disclose pay ratio gsk ceo average employee annual report methodology calculating ratio finalise legislation gsk total return gsk pharma peer ftse total return index total return index index comprise astrazeneca bristolmyers squibb eli lilly johnson johnson merck novartis pfizer roche holding sanofi gsk annual report strategic report governance remuneration financial statement investor information additional remuneration disclosure relative importance spend pay shareholder vote remuneration matter table show total employee pay group dividend pay table provide detail shareholder vote shareholder recent resolution respect annual remuneration remuneration policy report vote total employee pay total vote total vote total vote withhold agm cast billion million dividend remuneration report figure table reflect payment remuneration policy year impact movement exchange rate set page dividend declare external appointment executive director respect million million executive director hold remunerated external appointment increase exclude special dividend million hal barron director juno therapeutics inc declare pay company expect retain fee receive role ordinary share repurchase payment past director audit total employee pay base employee average number people employ payment loss office audit service contract table set relevant date executive director service contract available review company register office office hour gskcom executive director service contract contain month notice period set remuneration policy date contract effective date expiry date emma walmsley simon dingemans patrick vallance hal barron remuneration governance role committee membership role committee set company remuneration member committee appointment policy gsk able recruit retain motivate date set executive committee member committee member remuneration policy regularly review ensure consistent company scale scope operation urs rohner january chair chair support business strategy growth plan help drive creation shareholder value vindi banga january term reference vivienne cox january committees term reference available judy lewent january company website term reference review annually revise january reflect good committee meeting usually include closed session practice corporate governance development members committee present individual invite attend committee meeting year governance executive committee attendee involve board consider member committee decision present discussion independent nonexecutive director accordance remuneration corporate governance code details committee member skill experience give biography board page committee member attendance level gsk annual report annual report remuneration continue remuneration governance continue company secretary secretary committee attend willis tower watson member remuneration consultant meeting attendee committee include group voluntarily operate code conduct relation executive remuneration consulting code committee attendee conduct find wwwremunerationconsultantsgroupcom regular attend attendee attendee require deloitte provide independent commentary matter ceo consideration committee update market practice cfo legislative requirement prior willis tower watson appointment fee advice period head human resource fee charge time material basis head reward deloitte provide consult tax assurance service committee adviser deloittewilli tower watson gsk year committee satisfy judy lewent vindi banga member audit risk compromise deloitte independence remuneration committee provide input audit risk willis tower watson fee advice provide committee review group performance oversight willis tower watson provide additional market datum risk factor relevant remuneration decision committee adviser committee committee evaluation company undertake tender process appoint committee annual evaluation externally facilitate willis tower watson independent adviser committee ffion hague independent board evaluation conclude effect july committee chairman agree committee continue operate effectively term protocol willis tower watson provide advice enhancement committee work agree board committee satisfied advice objective member provide detailed update matter independent consider committee committee area committee focus item discuss remuneration policy propose remuneration policy committee set broad structure remuneration policy engagement shareholder determine remuneration executive director chairman shareholder feedback propose remuneration policy corporate officer board approval salary review remuneration environment include wide employee trend committee periodically review consider remuneration executive director cet benchmarking competitiveness gsk environment executive director cet approve annual amendment comparator group necessary executive director cet salary recommendation increase set remuneration hal barron annual bonus ceo executive director cet bonus recommendation committee responsible set specific performance measure bonus objective annual bonus annual bonus target metric lti plan review defer annual bonus plan performance share plan rule committee responsible approve lti plan rule change grant lti performance outcome vest lti awards cet assessment performance vest lti awards executive lti grant cet directors cet governance areas focus committee evaluation process committee adhere robust remuneration governance framework remuneration report ensure alignment internal action external reporting remuneration consideration compliance requirement agm remuneration report feedback external remuneration environment performance target disclosure incentive plan chairmans fee remuneration report disclosure remuneration committee external adviser tender process gender pay group reporting gsk annual report strategic report governance remuneration financial statement investor information nonexecutive director fee chairman nonexecutive director nonexecutive director fee apply set company aim provide chairman nonexecutive table director fee competitive pay annum company equivalent size complexity subject limit standard annual fee contain gsk article association supplemental fee chairman fee chair audit risk committee chairman philip hampton pay fee annum senior independent director elect gsk share chairman scientificmedical expert fee review year change chair remuneration corporate responsibility science committee nonexecutive director fee nonexecutive director fee review year nonexecutive director undertake intercontinental meet travel meeting follow increase january agree increase supplemental fee chair remuneration corporate responsibility committee january chair new science committee receive supplementary fee fee remain unchanged minimum fee continue deliver share ad defer nonexecutive director step board audit table set value fee benefit receive nonexecutive director form cash share ad detail nonexecutive director share allocation plan set nonexecutive director fee pay currency gbp convert average exchange rate review time time nonexecutive director fix fee fix fee emolument audit cash sharesad benefit total pay cash sharesad benefit total pay professor sir roy anderson vindi banga vivienne cox lynn elsenhans laurie glimcher jesse goodman philip hampton judy lewent urs rohner director stephanie burn stacey cartwright sir deryck maughan daniel podolsky jing ulrich han wijers laurie glimcher appoint board effect september stephanie burn sir deryck maughan daniel podolsky hans wijer retire board stacey cartwright retire board december jing ulrich retired board figure restate remove tax gross flight non ukdomicile director travel board meeting reflect fact tax flight income tax year time publish annual report believe income tax gsk annual report annual report remuneration continue director interest share audit interest director company office person closely associate pca show table total share plan interest december date retirement total director interest sharesad option december aunveste unvested aunveste unvested march date january subject subject subject subject vest exercise retirement performance performance performance performance exercise year executive director share emma walmsleyabcdh sir andrew wittyabcfh simon dingemansabcdfh patrick vallanceabcdfh moncef slaoui ad hal barroni moncef slaouiacegh share allocation plan nonexecutive director total director interest number share ad december january dividend dividend reinveste reinveste march date date year december allocate december retirement appointment end pay year elect nonexecutive director sharesj professor sir roy anderson vindi banga vivienne cox philip hampton urs rohner stacey cartwright adsj lynn elsenhans laurie glimcher jesse goodman judy lewent daniel podolsky unvested option subject performance emma walmsley represent bonus deferral unveste share subject performance sir andrew witty represent share award end threeyear performance period psp grant subsequent reinveste dividend share subject twoyear hold period sir andrews unvested option subject performance represent bonus deferral share save option unvested option subject performance simon dingemans represent bonus deferral share save option unvested option subject performance patrick vallance represent bonus deferral share save option unvested ad subject performance moncef slaoui represent bonus deferral deferral psp plan share value plan award pca total director interest include share purchase glaxosmithkline share reward plan emma walmsley simon dingemans patrick vallance award share plan total number share hold plan follow share reward plan share march december january emma walmsley sir andrew witty simon dingemans patrick vallance hal barron moncef slaoui eligible participate share reward plan open employee gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continue total director interest include option share ad result deferral bonus subsequent reinvestment dividend dabp total show table include bonus deferral exclude unvested matching award subject ongoing performance criterion amount represent gross share ad balance prior sale share ad satisfy tax liability december defer annual bonus plan bonus deferral march date retirement january emma walmsley share sir andrew witty shares simon dingemans share patrick vallance share moncef slaoui ad total director interest march include share ad vest performance meet element dabp psp award sell satisfy tax liability vest amount page detail moncef slaoui total director interest include ad purchase plan executive supplemental saving plan essp ad award slaouis pca share value plan svp relevant balance follow moncef slaoui ad march march january retirement saving plan share value plan executive director slaoui eligible receive award svp svp award show reflect holding slaouis pca employee gsk award subject threeyear vest period vest contingent continue employment gsk gain arose vest include slaouis total remuneration figure slaouis total share plan interest include psp award hold pca award subject performance criterion relevant employee cet share save plan sir andrew witty simon dingemans patrick vallance unvested option subject performance include holding respectively share save plan sir andrew participate dingemans vallance participate term employee dingemans grant option plan november ad vest unexercised option totalling moncef slaoui represent ad option hold pca gsk annual report annual report remuneration continue director interest share audit continue follow table set detail option include nilcost option dabp exercise executive director moncef slaoui exercise option year number share market gain exercise type award date grant option date exercise grant price price exercise emma walmsley dabp deferral dabp match sir andrew witty share save dabp deferral dabp match simon dingemans share save dabp deferral dabp match patrick vallance dabp deferral dabp match respect option share save plan remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share total value share vest date executive director choose exercise option vest date subsequent increase decrease realise movement share price vest date date exercise increase decrease value result investment decision executive director record remuneration respect nilcost option dabp bonus defer director record remuneration annual bonus year relate gain record exercise nilcost option comprise remuneration total amount receive reinveste dividend prior vest gain loss result movement share price date grant exercise initial bonus defer date dividend reinvestment exercise reinveste dividend matching element dabp remuneration executive director record year performance period end represent number vest share multiply price vest gain record exercise nilcost option comprise total remuneration gain loss result movement share price vest exercise emma walmsley gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment gain relate movement share price vest exercise date sir andrew witty gain result exercise option grant share save plan number share reduce sir andrew retire march way share save contract gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment gain relate movement share price vest exercise date gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continued simon dingemans gain result exercise option grant share save plan gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment gain relate movement share price vest exercise date patrick vallance gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment gain relate movement share price vest exercise date hal barron appoint board january nonexecutive director total interest include share ad receive fee nonexecutive director share allocation plan note dividend receive share ad plan january convert share ad february gsk annual report annual report remuneration continue director interest share audit continue deferred annual bonus plan matching award follow table provide detail executive director office respect dabp matching awards market price grant vest represent closing share price business day prior date performance period emma walmsley share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration performance period sir andrew witty share market price grant unvested december dividend reinveste vested lapse unvested december dividend reinveste unvested march vest share number share market price vest gain remuneration gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continue deferred annual bonus plan matching award continue performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration performance period patrick vallance share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration gsk annual report annual report remuneration continue director interest share audit continue deferred annual bonus plan matching award continue performance period moncef slaoui ad market price grant unvested december dividend reinveste vested lapse unvested december dividend reinveste unvested march vest ad number ad market price vest gain remuneration gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continued performance share plan award follow table provide detail executive director office respect psp award market price grant vest represent closing share price date performance period emma walmsley share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest share number share market price vest total gain remuneration remuneration performance period sir andrew witty share market price grant unvested december dividend reinveste vested lapse unvested december dividend reinveste unvested march vest share number share market price vest gain remuneration gsk annual report annual report remuneration continue director interest share audit continued performance share plan award continue performance period simon dingemans share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december grant face value grant dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration performance period patrick vallance share market price grant unvested december grant face value grant dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march vest share number share market price vest gain remuneration remuneration gsk annual report strategic report governance remuneration financial statement investor information director interest share audit continued performance share plan award continue performance period moncef slaoui ad market price grant unvested december dividend reinveste vested lapse unvested december dividend reinveste unvested march vest ad number ad market price vest gain remuneration remuneration hal barron appoint board january follow table provide detail psp award grant february performance period hal barron grant ad number ad market price grant face value grant unvested march gsk annual report annual report remuneration continue director senior management information provide compensation interest director senior management group group purpose group define nonexecutive executive director members cet company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group pca employee gsk award share ad company executive share plan set table award dividend reinvestment award award share ad share ad defer annual bonus plan performance share plan defer investment awardsa share value planb march group pcas follow interest share ad company interest award executive share plan describe note financial statement employee share scheme interest march share ad own unexercised option defer annual bonus plan performance share plan defer investment awardsa share value planb notional share ad executive director eligible receive defer investment award participate share value plan gsk annual report strategic report governance remuneration financial statement investor information share plan dilution limit allemployee share plan dilution limit executive director participate allemployee share award plan incorporate dilution plan include share save share reward revenue limit consistent guideline publish investment custom approve plan association limit roll tenyear period plan roll tenyear period executive share participant share save plan save month plan estimate dilution exist award net salary fix term year end year december follow saving period option buy gsk share discount market price set launch saving contract gsk employee share plan participant share reward plan contribute month gross salary purchase gsk share company match number gsk share buy month monthly saving share save share reward emma walmsley executive share plan simon dingemans patrick vallance actual limit gsk annual report annual report remuneration continue implementation remuneration policy salary long term incentive plan committee determine follow salary increase take defer annual bonus plan dabp awards account average increase wide workforce table provide detail mandatory deferral dabp respect annual bonus payment associate change award grant wide workforce emma walmsley total bonus dabp award defer share number share simon dingemans emma walmsley patrick vallance simon dingemans hal barron patrick vallance base average increase budget employee level cet performance share plan psp award benefit table provide detail award grant psp significant change provision benefit propose detail policy relation benefit psp award psp award refer detail remuneration policy report page salary number share annual report available wwwgskcom emma walmsley investors section simon dingemans hal barron pension table provide overview pension arrangement ward form ad ongoing executive director detail hal barron pension arrangement set performance measure metric psp award remain unchanged pension contribution award continue base equally weight emma walmsley base salary matching contribution measure simon dingemans base salary lieu pension new product performance member define contribution plan eligible receive matching adjust free cash flow contribution salary accordance term plan relative tsr annual bonus tsr continue measure global pharmaceutical significant change operation annual bonus plan peer prior year target new product accordance shareholder approve remuneration commercially sensitive time grant policy propose committee intend disclose target follow end performance period target maximum emma walmsley addition committee continue provide shareholder simon dingemans interim performance update element course performance period hal barron adjust free cash flow target disclose shareholder financial measure adjust group pbit previously core prospective basis time grant group pbit inevitably target link directly financial report annual report remuneration strategic plan commercially sensitive committee consider appropriate disclose annual bonus target year result competitive harm detail performance target disclose retrospective basis annual report gsk annual report strategic report governance remuneration financial statement investor information implementation remuneration policy continue termination arrangement patrick vallance remuneration arrangement new executive director announce patrick vallance leave board hal barron join gsk chief scientific officer president march january executive director summary remuneration set vallance voluntary leaver receive severance payment leave company salary bonus outstanding note incentive award treat accordance shareholder base salary comparator group pay approve remuneration policy position global pharmaceutical comparator group disclosure payment cessation include annual bonus ontarget bonus annual report remuneration maximum outgoing president remuneration element summary treatment award ltis assume expect value annual bonus receive bonus award performance share psp dabp grant psp award company performance share plan defer bonus dabp multiple base salary outstanding psp award vest prior vallance outgoing president dabp matching awards departure lapse leave gsk share ownership line gsk dabp defer bonus award respect bonus defer requirement base salary remuneration policy award respect prior year vest sor normal vest date pension pension line gsk remuneration policy arrangement addition vallance require maintain executive base shareholde equal respective share ownership requirement benefit benefit line gsk month leave company remuneration policy gsk annual report remuneration policy summary executive director remuneration policy company remuneration policy approve gsk annual general meeting policy available wwwgskcom investor section follow summary policy value earn annual total salary benefit pension lti bonus remuneration award fix pay pay performance salary provide core reward role set level appropriate secure retain high calibre individual need deliver group strategic priority operation opportunity performance measure individual role experience performance formal maximum limit ordinarily salary overall performance independently source datum relevant comparator group increase broadly line average increase individual key consideration consider determine salary level wide gsk workforce determine salary increase increase higher reflect change scope individual role responsibility experience salary adjustment reflect wide market condition geography individual operate detail current salary level set annual report remuneration page benefit level set recruit retain high calibre individual execute business strategy operation opportunity performance measure executive director generally eligible receive formal maximum limit benefit cost benefit line policy employee fluctuate depend change provider cost vary location include travel allowance individual circumstance include spousepartn travel healthcare life detail current benefit cost set annual assurancedeath service provide report remuneration individual pension arrangement personal financial advice contractual postretirement benefit pension pension arrangement provide competitive level retirement income operation opportunity performance measure pension arrangement structure accordance policy current executive director new external plan operate country recruit individual likely retire individual choose salary contribution define member pension plan cash lieu contribution plan match relevant pension contribution pay instead contribution subject relevant cap line implementation principle new executive director entitle member plan join define contribution pension plan receive salary cash payment lieu pension cash payment lieu pension contribution contribution individual member gsk legacy define benefit eligible benefit senior plan define contribution plan alternative executive pension plan arrangement subsequently ash balance pension plan supplemental appoint board remain cash balance pension plan include executive member plan pension credit provide maximum contribution base salary pension plan gsk plan retirement saving plan executive supplemental saving plan core contribution salary bonus match contribution salary bonus gsk annual report strategic report governance remuneration financial statement investor information executive director remuneration policy summary continue annual incentivise recognise execution business strategy annual basis reward achievement stretch annual bonus financial strategic business target delivery personal objective operation opportunity performance measure financial operational business target set maximum bonus opportunity executive director base combination start year committee bonus salary threshold performance bonus financial target individual level determine committee base payout nil strategic performance performance target objective majority target performance bonus payout bonus assess individual objective set start year maximum opportunity financial measure committee performance objective weight different assess committee measure determine executive director require defer year accord bonus earn share ad appropriate business priority year defer share vest end year lti awards incentivise recognise delivery long term business priority financial growth increase shareholder value compare pharmaceutical company provide alignment shareholder interest retention element encourage longterm shareholding discourage excessive risk take psp operation opportunity performance measure conditional award annually vest normal maximum award limit grant base combination dependent achievement performance psp individual year set financial share price relate condition year subject table strategic performance additional twoyear hold period condition align salary company strategic committee adjust formulaic vest ceo plan award outcome ensure cfo vest threshold overall outcome reflect underlying business executive director performance performance vest period dabp current operation bonus payment onwards executive director require defer bonus earn share year dabp legacy pre operation opportunity performance measure bonus payment executive director defer share match maximum outstanding matching require defer bonus earn share subject achievement performance award subject year voluntarily defer condition year matching award measure award additional bonus earn conditional share nilcost option eligible psp dividend equivalent give year share ownership requirement sor align interest executive director shareholder executive director require continue satisfy requirement require build maintain significant holding share minimum month follow retirement gsk gsk time sor requirement ceo salary sor requirement executive director salary detail policy clawbackmalus recruitment remuneration loss office termination payment refer remuneration policy report page annual report available wwwgskcom investor section gsk annual report remuneration policy summary continue scenario future total remuneration chart opposite provide illustration future total remuneration executive director respect emma walmsley ceo remuneration opportunity grant policy range potential outcome provide executive director underlie assumption set scenario base salary benefit pension figure ceo cfo outgoing president base actual amount receive respect ongoing policy new chief scientific officer president role benefit value role base value benefit exclude benefit travel include pension contribution base policy fix expect maximum amount show value psp award base relevant multiple include amount simon dingemans cfo respect dividend reinveste factor change share price vest period fix pay performance annual bonus psp payable expect annual bonus assume target performance achieve psp award threshold level vest assume fix expect maximum maximum hal barron chief scientific officer president assume annual bonus payable maximum level award psp vest fix expect maximum patrick vallance outgoing president fix fix fix fix pay annual bonus psp outgoing president leave gsk march eligible bonus psp award figure represent actual remuneration january march gsk annual report strategic report governance remuneration financial statement investor information nonexecutive director remuneration policy company remuneration policy nonexecutive director set approve gsk annual general meeting chairman provide inclusive flat rate fee competitive pay company equivalent size complexity subject fee limit contain gsk article association operation opportunity performance measure committee responsible evaluating make formal maximum fee review recommendation board fee payable annually set reference review chairman chairman chairman participate discussion performance independently source market datum respect fee detail current fee set annual report fee pay combination cash andor gsk remuneration share ad nonexecutive director share allocation plan basic fee operation opportunity performance measure chairman ceo responsible evaluate chairman fee review annually set make recommendation board fee payable reference independently source data company nonexecutive director detail current fee set annual report minimum deliver form gsk share remuneration ad nonexecutive director share allocation plan deliver share ad nonexecutive director follow retirement board supplemental compensate nonexecutive director chairman take additional board responsibility undertake fee intercontinental travel operation opportunity performance measure additional fee committee chairman senior detail supplemental fee set annual report independent nonexecutive director science medical remuneration expert intercontinental travel benefit facilitate execution responsibility duty require role operation opportunity performance measure travel subsistence cost nonexecutive director formal maximum limit benefit cost incur normal course business relation fluctuate depend change provider cost meetings board committee matter individual circumstance gskhoste event overseasbase nonexecutive detail current benefit cost set director include travel meeting annual report remuneration event necessary business purpose whilst normal practice nonexecutive director accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director gsk annual report remuneration policy summary continue operation scope remuneration policy remuneration policy policy set page performance share plan defer annual bonus plan award annual report intend policy gsk subject term relevant plan rule executive nonexecutive director operate period award grant committee adjust amend year date approval company annual award accordance provision plan rule general meeting include make adjustment reflect oneoff corporate event change company capital structure committee write policy principally relation remuneration arrangement executive director whilst committee minor amendment policy take account possible recruitment replacement regulatory exchange control tax administrative purpose additional executive director operation policy account change legislation obtain shareholder committee intend policy operate period set approval amendment entirety consideration seek statement consideration shareholder view change policy period believe committee engage regular dialogue shareholder appropriate longterm success company hold annual meeting gsk large investor discuss consultation shareholder seek shareholder feedback remuneration policy governance matter approval general meeting annual meeting hold december urs committee reserve right remuneration rohner committee chairman share update remuneration payment andor payment loss office include exercise matter month proposal onwards discretion available connection payment notwithstanding line policy term payment agree agm date company shareholderapprove director remuneration policy come effect policy come effect provide term payment consistent shareholderapprove remuneration policy force time agree iii time relevant individual director company opinion committee payment consideration individual director company purpose payment include committee satisfy awards variable remuneration relation award share ad term payment agree time award grant basis preparation annual report remuneration prepare annual report remuneration approve board accordance company act large director sign behalf mediumsize company group account report amendment regulation regulation accordance regulation follow part annual report ur rohner remuneration subject audit total remuneration figure remuneration committee chairman executive director include detail element remuneration salary benefit pension annual bonus longterm march incentive awards nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section annual report remuneration subject audit page refer audit section ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap gsk annual report director statement responsibility director responsible prepare annual report strategic report risk section annual report remuneration report group financial statement represent management report include fair review accordance applicable law regulation development performance business position group description principal risk company law require director prepare financial uncertainty face statement financial year law director require prepare group financial statement accordance disclosure information auditor international financial reporting standard ifrs adopt director office date annual report european union prepare group financial statement confirm director elect comply ifrs issue far aware relevant audit information international accounting standard board iasb company company auditor unaware law director approve group financial statement satisfied true fair view state take step ought take affair group profit loss period director aware relevant audit information establish company auditor aware prepare financial statement director information require confirmation give interpret accordance select suitable accounting policy apply provision section company act consistently go concern basis judgement accounting estimate page contain information performance reasonable prudent group financial position cash flow net debt position state group financial statement comply ifrs borrowing facility information include treasury risk adopt european union ifrs issue iasb management policy exposure market credit risk subject material departure disclose explain hedging activity give note financial statement group financial statement financial instrument relate disclosure assess principal risk matter consider connection prepare financial statement go concern basis viability statement director consider appropriate adopt inappropriate presume group continue go concern basis accounting prepare financial business statement director responsible keep adequate accounting internal control record sufficient explain companys board audit risk committee review transaction disclose reasonable accuracy time assessment risk internal control framework operate financial position group enable ensure gsk consider effectiveness system group financial statement remuneration report comply internal control operation group year cover company act article ias regulation annual report date approval board responsible safeguarding asset group director take reasonable step prevention detection fraud irregularity corporate governance code board consider glaxosmithkline plc apply principle group financial statement year end december complie provision corporate governance comprise principal statement support note code maintain financial reporting council describe set financial statement page corporate governance section page board report responsibilitie auditor relation group consider annual report take fair financial statement set independent auditor report balanced understandable provide information page necessary shareholder assess group position group financial statement year end december performance business model strategy include annual report publish require financial conduct authority list rule print form available website director auditor consider director statement compliance responsible maintenance integrity annual report relation point corporate governance code website accordance legislation govern specified review preparation dissemination financial statement access website available outside comparable annual report legislation different annual report year end december comprising report director remuneration report current director name function list financial statement additional information investor corporate governance section annual report approve board director sign behalf confirm good knowledge group financial statement prepare philip hampton accordance ifrs adopt ifrs chairman issue iasb true fair view asset liability financial position profit group march gsk annual report strategic report governance remuneration financial statement independent auditor report investor information member glaxosmithkline plc report group financial statement opinion take component audit work opinion glaxosmithkline plcs group financial statement perform account consolidated revenue financial statement consolidated profit tax profit tax adjust certain item determine materiality true fair view state group affair cover component individually contribute december profit cash flow year revenue profit tax profit tax adjust end certain item determine materiality properly prepare accordance international area focus financial reporting standard ifrss adopt european union rebate discount allowance return pharmaceutical vaccine business prepare accordance requirement company act article ias regulation carry value goodwill intangible asset acquisitionrelate liability audit financial statement include annual report comprise consolidated balance sheet uncertain tax position transfer pricing impact december consolidated income statement tax reform consolidate statement comprehensive income year litigation end consolidated cash flow statement year end finance transformation consolidate statement change equity year end note financial statement include investigation group commercial operation description significant accounting policy scope audit opinion consistent reporting audit risk design audit determine materiality committee assess risk material misstatement financial statement particular look director separate opinion relation ifrss issue iasb subjective judgement example respect significant explain note financial statement group accounting estimate involve make assumption addition apply ifrss adopt european union consider future event inherently uncertain apply ifrss issue international accounting standard board iasb gain understand legal regulatory framework applicable group industry operate opinion group financial statement properly consider risk act group contrary prepare accordance ifrss issue iasb applicable law regulation include fraud design audit basis opinion procedure group significant component level respond conduct audit accordance international risk recognise risk detect material standard audit isas applicable law misstatement fraud high risk detect responsibility isa describe result error fraud involve deliberate concealment auditor responsibility audit financial statement example forgery intentional misrepresentation section report believe audit evidence collusion design audit procedure focus law obtain sufficient appropriate provide basis regulation rise material misstatement event opinion noncompliance particularly relate limited defence product pricing practice legislation taxation anti independence bribery corruption legislation test include remain independent group accordance limited enquiry management review relate work ethical requirement relevant audit financial perform component audit team review relevant internal statement include frc ethical standard audit report discussion inhouse legal counsel applicable list public interest entity fulfil supplement review external legal counsel correspondence ethical responsibility accordance requirement certain case discussion external legal counsel good knowledge belief declare nonaudit inspect underlying support calculation service prohibit frc ethical standard provide assess test design operating effectiveness group relate control inherent limitation audit procedure describe remove noncompliance law disclose note financial statement regulation event transaction reflect provide nonaudit services group period financial statement likely aware january december audits address risk management audit approach override internal control include evaluate overview evidence bias director represent risk material materiality misstatement fraud risk fraud revenue overall group materiality million million recognition procedure design execute address base profit tax add certain item risk include use datum enable auditing technique test journal entry postclose adjustment test evaluate audit scope management key accounting estimate reasonableness audit include scope audits report component consistency undertake cutoff procedure verify proper cutoff specific audit procedure perform reporting revenue expense test existence accuracy component revenue transaction addition incorporate element unpredictability audit work year gsk annual report independent auditor report continue report group financial statement continue key audit matter key audit matter matter auditor professional judgement significance audit financial statement current period include significant assess risk material misstatement fraud identify auditor include great effect overall audit strategy allocation resource audit direct effort engagement team matter comment result procedure thereon address context audit financial statement form opinion thereon provide separate opinion matter complete list risk identify audit key audit matter audit address key audit matter rebate discount allowance return obtain management calculation accrual applicable pharmaceutical vaccine business scheme validate assumption reference refer note group financial statement group state commercial policy term applicable contract party datum relate patient enrolment group make sale customer fall government fund benefit scheme historical level certain commercial government mandate contract product return reimbursement arrangement significant medicaid medicare group provide right compare assumption contract price historical rebate return customer certain product discount allowance return level relevant current payment trend consider historical accuracy arrangement result deduction gross sale arrive group estimate previous year impact competitive turnover rise obligation group provide pricing pressure great discount market customer rebate discount allowance right generally form independent expectation large return unsettle amount recognise accrual element accrual december party datum focus area rebate discount allowance compare expectation actual accrual recognise return arrangement complex establish group appropriate accrual require significant judgement base procedure perform identify material estimation director judgement particularly complex difference independent expectation accrual healthcare environment competitive pricing pressure product discount increasingly prevalent director determine accrual million necessary december million carrying value goodwill intangible asset deploy valuation specialist obtain group refer note group financial impairment analysis test reasonableness key statement assumption include profit cash flow growth decline terminal value impact expiry patent potential product group billion intangible asset december obsolescence selection discount rate challenge billion comprise significant licence patent management substantiate assumption include compare acquire trademark exclude computer software addition relevant assumption industry economic forecast group billion goodwill december billion verify integrity support calculation corroborate certain information party source include carry value goodwill intangible asset expectation performance certain asset component recover future cash flow risk business obtain evaluated management sensitivity asset impair cash flow meet analysis ascertain impact change key assumption group expectation impairment review perform perform independent sensitivity calculation quantify group contain number significant judgement downside change management model require result estimate include revenue growth success new product impairment launch genericisation exist product follow patent expiry profit margin cash conversion terminal value result work determine carry value discount rate change assumption lead goodwill intangible asset appropriate context impairment carry value intangible asset goodwill group financial statement take focused intangible asset acquire historical acquisition significant individually aggregate number indefinite life include significant intangible asset acquire novartis group recognise goodwill number acquisition include threepart transaction novartis gsk annual report strategic report governance remuneration financial statement investor information report group financial statement continue key audit matter audit address key audit matter acquisitionrelate liability deploy valuation specialist evaluate certain key refer note group financial assumption include growth projection discount rate statement integrity mechanical accuracy management valuation model evaluation include lookback test assess recent year group complete number significant historical accuracy group forecast assumption transaction include perform sensitivity analysis key assumption determine threepart transaction novartis significant impact value record certain establishment viiv healthcare procedure specific individual liability include acquisition viiv healthcare remain follow interest shionogiviiv healthcare joint venture consumer healthcare option redemption value transaction result recognition agree gsk novartis estimate gsk base measurement material acquisitionrelate liability multiple consumer healthcare profit verify integrity necessitate significant management judgement balance model compare certain key assumption include sheet date exchange rate multiple party source gsk obtain valuation party bank support estimate significant acquisitionrelate liability obtain consider work compare outlined earning forecast approve consumer healthcare board consumer healthcare option group record director management model actual earning liability present value expect redemption price understand reason change consider write option novartis noncontrolle interest appropriateness assume exercise date consider consumer healthcare december liability impact different exercise date discount redemption carry value million million value option viiv healthcare contingent consideration acquisition viiv healthcare contingent consideration compare remain interest shionogiviiv healthcare projection group dolutegravir product party joint venture million record expectation growth consider potential upside contingent consideration represent fair value downside impact product launch expect launch expect payment shionogi contingent group competitor future sale dolutegravir product liability require viiv healthcare option certain assumption relate forecast remeasure fair value reporting date revenue dolutegravir product valuation initial recognition increase response actual liability consistent viiv healthcare contingent future sale significantly exceed original expectation consideration valuation component valuation december liability million consider appropriateness assumption million forecast growth rate margin reference historical viiv healthcare option pfizer grant performance board approve budgets party write option group enable forecast datum noncontrolle interest group future acquisitionrelate liability subject significant december liability respect pfizer estimation uncertainty range possible outcome write option carry value million broad base procedure perform million comfortable value liability december addition liability group record certain reasonable context group financial statement take acquisitionrelate liability december reflect management good estimate time include million relation contingent consideration payable acquisition novartis vaccine business review disclosure acquisitionrelate liability include management commentary estimation uncertainty range alternative outcome satisfy focused area carry value disclosure appropriate financial liability material determined management judgement estimate include projection future sale product potential impact competitor product delivery anticipate synergy addition valuation sensitive change assumption include discount rate tax rate tax reform significant impact valuation gsk annual report independent auditor report continue report group financial statement continue key audit matter audit address key audit matter uncertain tax position transfer pricing impact conjunction international tax transfer price tax reform specialist evaluate challenge management judgement refer note group financial statement respect estimate tax exposure contingency order assess adequacy group tax provision include group operate complex multinational tax environment obtain evaluate certain party tax advice group open tax transfer pricing matter obtain assess appropriateness assumption overseas tax authority addition time time group enter commercial transaction complicate accounting understanding evaluate management judgement tax consequence consider status recent current tax authority audits enquiry outturn previous claim judgemental position take judgement require assess level provision require tax return current year estimate development tax respect uncertain tax position december environment note assumption judgements group record provision million respect require formulate provision mean range possible uncertain tax position million outcome broad base evidence obtain number change tax law consider level provision relate disclosure switzerland result material impact acceptable context group financial statement take group current defer tax balance december significant impact respect tax deploy tax specialist evaluate key judgement cut job act substantively enact assumption interpretation management assess yearend aggregate total adjust item account impact tax reform undertake procedure validate impact amount million tax line main material corporate tax rate change adjustment current change include reduction corporate tax rate defer tax balance apply defer taxation balance introduction toll tax deem repatriation certain defer foreign respect million toll tax charge deem earning change complex repatriation foreign earning subsidiary entity number area uncertainty relate manner group evaluate documentation prepare management law apply account certain area assess underlying calculation advice party advisor undertake procedure validate key input underpin estimate charge confirm liability appropriately present group balance sheet give complexity uncertainty relate tax reform expect trueup update estimate guidance issue satisfied accounting position take group december represent management good estimate impact tax reform time litigation discuss status significant know actual potential refer note group financial litigation inhouse legal counsel obtain substantively statement test evidence support decision rationale provision hold decision record provision include correspondence pharmaceutical industry heavily regulate increase external legal counsel monitor consider external inherent litigation risk group engage number legal information source identify potential legal action action include product liability antitrust relate private litigation significant disclose note develop independent expectation litigation provision base product litigation history available evidence challenge valuation completeness provision recognise focused area eventual outcome claim group include obtain confirmation external legal uncertain position take director base counsel confirm understanding settle outstanding application material judgement estimation accordingly litigation assert claim evaluate significant adjustment unexpected adverse outcome significantly impact legal provision record year group report profit balance sheet position disclose note group financial statement december group hold provision million eventual outcome legal proceeding dependent respect legal action million outcome future event position take group significant reduction provision result group inherently judgemental find context group financial settle large individual case relate paxil statement take judgement management continue focus area give possibility reasonable disclosure respect adverse outcome provision contingent liability appropriate gsk annual report strategic report governance remuneration financial statement investor information report group financial statement continue key audit matter audit address key audit matter finance transformation centrally manage work perform component audit team group continue rationalise simplify finance bpos bsc consist control substantive testing process include rollout enterprisewide resource conduct oversight visit key bsc bpo site group planning system erp migration accounting service audit scope india malaysia romania inhouse business service centre bsc party direct work perform business process outsourcing location bpos number evaluate design test operating effectiveness key market migration central erp system low automate manual control migration number market migrate centralised processing environment include general control pose particular complexity position group control respect datum migration erp system supply chain continue focus area substantively test accuracy completeness datum change represent financial reporting risk migration migration new erp control process happen control process establish embed number year update migrate new environment increase risk breakdown internal financial control transition increase risk inaccurate incomplete migration financial datum turn increase risk material misstatement group financial statement investigation group commercial operation meet director management inhouse legal counsel refer note group financial speak group external advisor assess risk statement occurrence inappropriate activity status ongoing investigation potential fine penalty group remain subject ongoing investigation include understand evaluate group internal commercial operation sfo december investigation process assess risk allegation report group conclude sufficient clarity channel include whistleblowe hotline likely time completion investigation evaluate ongoing enhancement change able sufficiently reliable estimate fine penalty control process business practice recent year sfo impose group completion investigation result group state note deploy forensic specialist assess scope finding unable recognise provision estimate investigative work perform group risk eventual outcome assessment exercise management perform party addition group continue carry investigation interaction engagement broadly output number market ascertain inappropriate assessment instruct component team include certain market commercial operation take place include group audit scope undertake riskfocuse audit procedure address audit risk group financial focus follow risk material statement materially misstate potential financial impact group financial statement implication allege illegal act fine penalty forthcoming respect respect sfo investigation independently circularise ongoing investigation group commercial operation speak external legal counsel engage group obtain sfo rise need material view status investigation ascertain provision reasonableness management assertion respect likely inappropriate activity occur outcome relate disclosure group financial statement rise material fine penalty result asset impairment satisfy group provision decision december context group financial statement take adequacy disclosure give status investigation gsk annual report independent auditor report continue report group financial statement continue tailor audit scope specific audit procedure central function group tailor scope audit ensure perform consolidation area significant judgement include taxation work able opinion financial statement goodwill intangible asset treasury postretirement benefit take account structure group elimination unrealise intercompany profit inventory accounting process control industry directly lead group audit team operate take territory function perform group financial statement consolidation audit work account consolidated revenue reporting component identify reporting component consolidated profit tax profit tax adjust view require audit complete financial information certain item determine materiality size risk characteristic exclude central consider contribution audit evidence perform adjustment entity audit group level specific audit audit work divisional group level include test procedure significant balance transaction monitor control disaggregate analytical review procedure perform report component appropriate cover significant portion group small low coverage material balance report risk component directly include group audit component support share financial service centre scope addition obtain indirect audit evidence certain centre include group audit scope outofscope component procedure undertake reporting component include group audit scope group share service centre encompass bpos individually contribute consolidated revenue bsc centralise infrastructure process profit tax profit tax adjust certain item standardised determine materiality work perform component auditor determine level involvement need audit work report component unit result overseas component visit senior member group audit team include group financially significant component visit annually japan india switzerland italy brazil korea germany belgium addition visit overseas share service centre support reporting component group audit scope component group audit scope site visit undertaken involvement include regular dialogue component team review component auditor work paper gsk annual report strategic report governance remuneration financial statement investor information report group financial statement continue materiality scope audit influence application materiality set certain quantitative threshold materiality qualitative consideration help determine scope audit nature timing extent audit procedure individual financial statement line item disclosure evaluate effect misstatement individually aggregate financial statement base professional judgement determine materiality financial statement follow overall group materiality million million determined profit tax add certain item include remeasurement charge shionogiviiv healthcare contingent consideration million vaccine contingent consideration million remeasurement charge consumer healthcare option liability million viiv option remeasurement credit million remeasurement acquisition relate liability result tax reform million major restructuring cost million significant legal cost million impairment intangible asset million deduct net income relate gain disposal asset million rationale benchmark apply group principal measure earning comprise adjust result add statutory result number item income expenditure include detailed management use measure believe eliminate material unusual nonoperational item obscure key trend factor determine group operational performance take measure account determine materiality adjust profit tax add amortisation intangible asset certain small adjust item view recur item introduce volatility group earning component scope group audit allocate materiality overall group materiality range materiality allocate component million million certain component audit local statutory audit materiality overall group materiality agree audit risk committee report misstatement identify audit million million misstatement view warrant reporting qualitative reason go concern accordance isas report follow report obligation outcome require report material add material add draw attention draw attention respect director statement future event condition predict financial statement director consider statement guarantee group ability continue appropriate adopt go concern basis accounting going concern prepare financial statement director identification material uncertainty group ability continue go concern period month date approval financial statement require report director statement relate report go concern accordance list rule materially inconsistent knowledge obtain audit gsk annual report independent auditor report continue report information report information director assessment prospect group information comprise information annual principal risk threaten solvency report financial statement auditor report liquidity group thereon directors responsible information material add draw attention opinion financial statement cover director confirmation annual report information accordingly express audit opinion carry robust assessment principal risk extent explicitly state report face group include threaten business form assurance thereon model future performance solvency liquidity connection audit financial statement disclosure annual report describe risk responsibility read information explain manage mitigated consider information materially inconsistent financial statement knowledge obtain audit director explanation annual report appear materially misstate identify assess prospect group apparent material inconsistency material misstatement period consider period require perform procedure conclude appropriate statement material misstatement financial statement material reasonable expectation group able continue misstatement information base work operation meet liability fall period perform conclude material misstatement assessment include related disclosure draw information require report fact attention necessary qualification assumption report base responsibility report perform review respect strategic report director report director statement carry robust assessment consider disclosure require company principal risk face group statement relation act include longerterm viability group review substantially scope audit consist make inquiry base responsibility describe work consider director process support statement undertake course audit company act check statement alignment relevant isa list rule financial conduct provision corporate governance code code authority fca require report certain opinion matter consider statement consistent describe require isa state knowledge understanding group environment obtain strategic report director report course audit list rule opinion base work undertake course code provision audit information give strategic report director report respect responsibility report report year end december consistent financial statement prepare accordance applicable legal requirement statement give director consider annual report take fair balanced light knowledge understanding group understandable provide information necessary environment obtain course audit identify member assess group position performance material misstatement strategic report director business model strategy materially inconsistent report knowledge group obtain course perform audit section annual report page describe work audit risk committee appropriately address matter communicate audit risk committee director statement relate parent company compliance code properly disclose departure relevant provision code specify list rule review auditor gsk annual report strategic report governance remuneration financial statement investor information responsibilitie financial statement audit responsibility director financial statement use report explain fully director statement responsibility report include opinion prepare set director responsible preparation parent company member body accordance financial statement accordance applicable chapter company act framework satisfied true fair view purpose give opinion accept assume director responsible internal control responsibility purpose person determine necessary enable preparation financial report show hand come save statement free material misstatement expressly agree prior consent writing fraud error company act exception reporting prepare financial statement director responsible company act require report assess group ability continue go concern opinion disclose applicable matter relate going concern receive information explanation go concern basis accounting director require audit intend liquidate group cease operation realistic alternative certain disclosure director remuneration specify law auditor responsibility audit financial statement objective obtain reasonable assurance exception report arise responsibility financial statement free material appointment misstatement fraud error issue auditor audit group inception report include opinion reasonable assurance high legacy firm previously auditor certain group legacy level assurance guarantee audit conduct component far record accordance isa detect material obtain period total uninterrupted engagement misstatement exist misstatement arise fraud year cover minimum year end december error consider material individually aggregate december year end december reasonably expect influence economic final year engagement follow group decision rotate decision user take basis financial statement external audit description responsibility audit financial statement locate frc website wwwfrcorg ukauditorsresponsibilitie description form auditor report matter report separately parent company financial statement glaxosmithkline plc year end december parent company pass resolution accordance section company act senior statutory auditor state pricewaterhousecooper llp charter accountant statutory auditor london march gsk annual report consolidated income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operate profit finance income finance expense profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profitloss attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny consolidate statement comprehensive income year end december profit year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement share comprehensive expense associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gainslosse define benefit plan tax remeasurement define benefit plan comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report strategic report governance remuneration financial statement consolidate balance sheet investor information december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing contingent consideration liability trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing corporation tax payable deferred tax liability pension postemployment benefit provision contingent consideration liability noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board march sign behalf philip hampton chairman gsk annual report consolidate statement change equity year end december shareholder equity share share retain noncontrolle total capital premium earning reserve total interest equity january profitloss year comprehensive expenseincome year total comprehensive incomeexpense year distribution noncontrolle interest dividend shareholder gain transfer net asset consumer healthcare joint venture consumer healthcare joint venture option change noncontrolle interest loss transfer equity investment investment associate ordinary share issue ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive income year total comprehensive income year distribution noncontrolle interest dividend shareholder recognition liability noncontrolle interest derecognition liability noncontrolle interest change noncontrolle interest ordinary share issue ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive income year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest dividend shareholder change noncontrolle interest ordinary share issue ordinary share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report strategic report governance remuneration financial statement consolidate cash flow statement investor information year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment contingent consideration pay purchase business net cash acquire disposal business investment associate joint venture proceeds disposal subsidiary interest associate decreaseincrease liquid investment interest receive dividend associate joint venture equity investment net cash outflowinflow investing activity cash flow financing activity share acquire esop trust issue share capital purchase noncontrolle interest increase longterm loan repayment ofincrease shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder distribution noncontrolle interest contribution noncontrolle interest finance cash flow net cash outflow financing activity decreaseincrease cash bank overdraft cash bank overdraft begin year exchange adjustment decreaseincrease cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report note financial statement presentation financial statement description business financial statement prepare accordance gsk major global healthcare group engage group accounting policy approve board creation discovery development manufacture marketing describe note accounting principle policy pharmaceutical product vaccine overthecounter otc information application accounting policy medicine healthrelate consumer product gsk principal include area estimation judgement give note pharmaceutical product include medicine follow key accounting judgement estimate therapeutic area respiratory hiv immunoinflammation antiviral preparation financial statement conformity central nervous system cardiovascular urogenital metabolic generally accept accounting principle require management antibacterial dermatology rare disease estimate assumption affect report compliance applicable law ifrs amount asset liability disclosure contingent financial statement prepare accordance asset liability date financial statement company act article ias regulation report amount revenue expense report international financial reporting standard ifrs relate period actual result differ estimate interpretation adopt european union implementation new accounting standard interpretation financial statement compliance ifrs issue agenda decision ifrs interpretation committee international accounting standard board september clarify charge interest tax report finance expense certain penalty tax composition financial statement settlement report administrative expense consolidate financial statement draw sterling previously gsk report charge overall tax functional currency glaxosmithkline plc accordance charge income statement comprehensive income ifrs accounting presentation financial statement appropriate comprise gsk adopt revise basis report consolidated income statement result number settlement year record consolidated statement comprehensive income credit interest tax million finance expense consolidated balance sheet material charge penalty settlement require adjustment consolidate statement change equity accrue interest payable tax december consolidate cash flow statement million include trade payable note financial statement group balance sheet impact prior year material prior year amount restate composition group list subsidiary associate opinion financial period director principally affect profit net asset financial statement cover financial year january group give note principal group company december comparative figure financial year january december appropriate accounting principle policy january december financial statement prepare historical cost convention modify revaluation certain item parent company financial statement state accounting policy go concern basis financial statement parent company glaxosmithkline plc prepare accordance gaap accounting presentation company balance sheet present accounting policy give accounting principle policy consolidation group ability exercise joint control consolidated financial statement include right net asset entity entity account joint venture group ability exercise joint asset liability result cash flow control arrangement right specify asset company subsidiary include esop trust obligation specify liability arrangement group share result net asset associate arrangement account joint operation group joint venture ability exercise significant influence entity group share asset liability revenue expense account associate result asset liability joint operation associate joint venture incorporate consolidated financial statement equity method account financial statement entity consolidate group right asset liability revenue expense joint december year operation include consolidated financial statement entity group power direct relevant accordance right obligation activity affect return group generally interest acquire entity consolidated date control financial operating policy account group acquire control interest sell deconsolidate subsidiary date control cease gsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue transaction balance subsidiary eliminate revenue profit tax take sale subsidiary revenue recognise income statement good product sell customer outside group relevant service supply available external customer proportion profit transaction joint venture joint order receive title risk loss pass customer operation associate defer product reliable estimate relevant deduction relevant sell party transaction noncontrolle interest obligation fulfil earning process record directly equity defer tax relief unrealise intra regard complete group profit account extent consider turnover represent net invoice value deduction recoverable discount allowance give accrual estimate future business combination rebate return methodology assumption business combination account acquisition estimate rebate return monitor adjust regularly accounting method identifiable asset liability contingent light contractual legal obligation historical trend past liability acquire measure fair value acquisition date experience project market condition market condition consideration transfer measure fair value evaluate wholesaler thirdparty analysis market include fair value contingent consideration research datum internally generate information value add tax consideration transfer noncontrolle interest sale taxis exclude revenue exceed fair value net asset liability contingent group copromote product counterparty liability acquire excess record goodwill cost record sale group records share revenue acquisition charge income statement period promotion income turnover nature copromotion incur activity group record cost sale goodwill capitalise separate item case subsidiarie pharmaceutical turnover include copromotion revenue cost investment case joint venture million million million addition initial associate goodwill denominate currency operation eventbase milestone income exclude royalty income arise acquire development marketing collaboration group compound product party recognise turnover cost acquisition fair value net asset income include turnover period present acquire difference recognise directly income statement royalty income recognise accrual basis accordance term relevant licensing agreement equity subsidiary acquire non control interest recognise fair value non expenditure control interest share net asset subsidiary expenditure recognise respect good service receive casebycase basis change group ownership percentage supply accordance contractual term provision subsidiary account equity obligation exist future liability respect past event obligation reliably foreign currency translation estimate manufacturing startup cost validation foreign currency transaction book functional currency achievement normal production expense incur group company exchange rate ruling date advertising promotion expenditure charge income transaction foreign currency monetary asset liability statement incur shipment cost intercompany transfer retranslate functional currency rate exchange rule charge cost sale distribution cost sale customer balance sheet date exchange difference include include sell general administrative expenditure income statement restructuring cost recognise provide consolidation asset liability include related goodwill appropriate respect direct expenditure business overseas subsidiary associate joint venture translate reorganisation plan sufficiently detail sterling rate exchange rule balance sheet date advance appropriate communication affect result cash flow overseas subsidiary associate undertake joint venture translate sterling average rate exchange exchange adjustment arise open net asset profit year retain overseas subsidiary associate joint venture translate sterling exchange difference arise related foreign currency borrowing hedge group net investment operation take separate component equity translating sterling asset liability result cash flow overseas subsidiary associate joint venture report currency hyperinflationary economy adjustment material reflect current price level loss net monetary asset charge consolidated income statement gsk annual report note financial statement continue accounting principle policy continue research development employee share plan research development expenditure charge income incentive form share provide employee statement period incur development share option share award scheme expenditure capitalise criterion recognise asset fair value option award calculate meet usually regulatory filing major grant date blackschole option pricing model charge market approval consider highly probable property plant income statement relevant vest period equipment research development capitalise depreciated accordance group policy group provide finance esop trust purchase company share meet obligation provide share employee environmental expenditure exercise option award costs run esop trust environmental expenditure relate exist condition result charge income statement share hold esop past current operation current future trust deduct reserve transfer benefit discernible charge income statement group reserve retain earning vest period recognise liability sitebysite basis reliably relate share option award reflect ultimate proceed estimate liability include group portion total cost receivable employee exercise portion potentially responsible party cost probable able satisfy respective property plant equipment share cleanup obligation recovery reimbursement property plant equipment ppe state cost record asset virtually certain purchase construction provision depreciation impairment financing cost capitalise cost legal dispute qualify asset construction provision anticipate settlement cost legal dispute group outflow resource depreciation calculate write cost residual value consider probable reliable estimate likely ppe exclude freehold land straightline basis outcome addition provision legal expense expect useful life residual value life review arise claim receive dispute respect product appropriate adjust annually normal expect useful liability claim relate certain product sufficient history live major category ppe claim settlement enable management reliable estimate provision require cover unasserted claim freehold building year certain case incur report ibnr actuarial leasehold land building lease term year technique determine estimate plant machinery year group involved legal proceeding respect equipment vehicle year possible reliable estimate expect financial effect result ultimate resolution disposal ppe cost relate accumulate depreciation proceeding case appropriate disclosure impairment remove financial statement case include provision cost net proceed take income statement associate claim group party lease charge income statement incur leasing agreement transfer group substantially pension postemployment benefit benefit risk ownership asset treat finance cost provide pension define benefit scheme lease asset purchase outright asset calculate project unit credit method spread include ppe computer software capital element period benefit expect derive leasing commitment show obligation finance employee service consistent advice qualified actuary lease asset hold finance lease depreciate basis pension obligation measure present value estimate consistent similar own asset lease term short future cash flow discount rate reflect yield high interest element lease rental include income quality corporate bond pension scheme asset measure statement lease operating lease rental cost fair value balance sheet date charge income statement straightline basis lease term cost postemployment liability calculate similar way define benefit pension scheme spread goodwill period benefit expect derive goodwill state cost impairment goodwill deem employee service accordance advice qualified indefinite useful life test impairment actuary annually actuarial gain loss effect change actuarial fair value interest acquire entitys asset assumption recognise statement comprehensive liability contingent liability exceed consideration pay income year arise excess recognise immediately gain income statement group contribution define contribution plan charge income statement incur gsk annual report strategic report governance remuneration financial statement investor information accounting principle policy continue intangible asset availableforsale investment intangible asset state cost provision amortisation liquid investment investment classify available impairment forsale investment initially record fair value plus transaction cost remeasure subsequent reporting licence patent knowhow marketing right separately date fair value unrealised gain loss availableforsale acquire acquire business combination investment recognise directly comprehensive income amortise estimate useful life generally exceed impairment arise significant prolong decline fair year straightline basis time available value equity investment reduce carrying asset use estimate useful life determine amortisation directly charge income statement charge account patent live applicable value obtain period nonexclusivity asset live disposal impairment investment gain review appropriate adjust annually contingent loss defer comprehensive income milestone payment recognise point contingent reclassify income statement dividend equity event probable development cost incur investment recognise income statement group associate acquire licence patent knowhow group right receive payment establish equity investment marketing right write income statement record noncurrent asset expect incur criterion recognition internally generate sell year intangible asset meet usually regulatory filing purchase sale equity investment account major market approval consider highly probable trade date purchase sale availableforsale acquire brand value independently fair value investment account settlement date business acquire party brand value inventory substantial long term brand inventory include financial statement low contractual legal nature sell separately rest cost include raw material direct labour direct cost business acquire brand amortise related production overhead net realisable value cost estimate useful life year consider generally determine basis prelaunch inventory useful economic life indefinite hold asset high probability regulatory cost acquire develop computer software internal approval product point provision use internet site external use capitalise intangible carrying value recoverable provision fix asset software site support significant reverse point high probability regulatory business system expenditure lead creation approval determine durable asset erp system software amortise seven trade receivable year computer software year trade receivables carry original invoice impairment noncurrent asset provision doubtful debt provision carry value noncurrent asset review evidence risk nonpayment take account age impairment standalone basis large cash previous experience general economic condition trade generating unit indication asset receivable determine uncollectable write firstly impair additionally goodwill intangible asset indefinite provision available income statement useful live intangible asset available use subsequent recovery amount previously provide test impairment annually provision impairment credit income statement longterm receivables charge income statement year concern discount effect material impairment goodwill reverse impairment loss borrowing noncurrent asset reverse change borrowing initially record proceed estimate determine recoverable amount receive net transaction cost borrowing subsequently extent revise recoverable amount exceed carry amortise cost difference proceed carry value exist net depreciation net transaction cost redemption amortisation impairment recognise recognise charge income statement period investment associate joint venture joint operation relevant borrowing investment associate joint venture carry consolidated balance sheet group share net asset date acquisition postacquisition retain profit loss goodwill arise acquisition group recognise right asset liability revenue expense joint operation gsk annual report note financial statement continue accounting principle policy continue taxation derivative financial instrument classify heldfortrade current tax provide amount expect pay apply carry balance sheet fair value derivative tax rate enact substantively enact designate hedge instrument classify inception balance sheet date cash flow hedge net investment hedge fair value hedge defer tax provide temporary difference arise change fair value derivative designate cash flow tax basis asset liability carry hedge recognise comprehensive income amount financial statement defer tax asset extent hedge effective ineffective portion recognise extent probable future taxable profit recognise profit loss immediately amount deferred available temporary difference comprehensive income reclassify income utilise defer tax provide temporary difference arise statement hedge item affect profit loss investment subsidiary associate joint venture net investment hedge account similar way cash timing reversal temporary difference flow hedge control probable temporary difference reverse foreseeable future defer tax provide rate change fair value derivative designate fair value tax enact substantively enact hedge record income statement balance sheet date change fair value hedge asset liability derivative financial instrument hedge change fair value derivative instrument derivative financial instrument manage exposure qualify hedge accounting recognise immediately market risk principal derivative instrument gsk income statement foreign currency swap interest rate swap foreign exchange discount forward contract option group hold issue time value money material balance derivative financial instrument trading speculative discount current value appropriate discount rate purpose unwind discount record finance income finance expense key accounting judgement estimate prepare financial statement management require taxation judgement item tax charge year million million recognise financial statement estimate december current tax payable million assumption affect amount asset liability revenue million noncurrent corporation tax payable expense report financial statement actual million nil current tax recoverable million amount result differ estimate million defer tax liability million follow consider key accounting judgement million defer tax asset million estimate million turnover defer tax asset recognise judgement reported group turnover million probable future taxable profit available million temporary difference utilise base management assumption relate amount time future taxable gross turnover reduce rebate discount allowance profit factor affect tax charge future year particular product return give expect give vary product tax reform set note taxation change arrangement buy group arrangement group effective tax rate change total tax purchasing organisation dependent submission charge year approximately million claim time initial recognition sale accrual time sale estimate rebate discount group open tax issue number revenue authority allowance payable return base available market management make judgement outflow fund information historical experience probable reliable estimate outcome dispute provision good estimate liability amount estimate fully reflect estimate liability gsk apply riskbased approach final outcome amount subject change dependent take account appropriate probability thing type buy group product group able obtain compensatory adjustment sale mix international tax treaty estimate account level accrual rebate return review adjust specific circumstance dispute relevant external advice regularly light contractual legal obligation historical inherently judgemental change substantially time trend past experience project market condition market dispute progress new fact emerge condition evaluate wholesaler thirdparty analysis market research datum internally generate information future event cause assumption accrual base change affect future result group gsk annual report strategic report governance remuneration financial statement investor information key accounting judgement estimate continue gsk continue believe adequate provision contingent consideration option liability liability likely arise open assessment december income statement charge contingent consideration group recognise provision million option liability million million respect uncertain tax position million december liability contingent consideration open issue exist ultimate liability matter vary amount million million amount provide dependent outcome million million related acquisition negotiation relevant tax authority necessary litigation shionogiviiv healthcare joint venture proceeding million million relate acquisition legal dispute vaccine business novartis legal cost year million million contingent consideration include consideration payable december provision legal dispute business combination record fair value date amount million million acquisition fair value generally base riskadjuste group provide anticipate settlement cost future cash flow discount appropriate posttax discount management make judgement outflow resource rate fair value review regular basis probable reliable estimate likely outcome annually change reflect income statement dispute legal expense arise claim note contingent consideration liability group estimate provision account specific group grant option novartis respect circumstance dispute relevant external advice novartis shareholde consumer healthcare joint venture inherently judgemental change substantially time certain circumstance novartis right require gsk dispute progress new fact emerge detail status acquire shareholde consumer healthcare joint uncertainty involve significant unresolved venture marketbase valuation right exercisable dispute set note legal proceeding certain window exercise company director take legal advice respect novartis entire shareholding instalment establish provision take account relevant fact gsk recognise financial liability million circumstance matter accordance accounting december million represent requirement respect product liability claim relate certain present value redemption value estimate gsk event product sufficient history claim settlement exercise right novartis calculate apply enable management reliable estimate provision relevant public company multiple premium discount require cover unasserted claim group involved forecast future profit accordance shareholder legal proceeding respect possible agreement sensitivity analysis give note trade reliable estimate expect financial effect payable result ultimate resolution proceeding case pfizer request ipo viiv healthcare time appropriate disclosure case provided gsk consent ipo offering complete provision contingent liability quantify month pfizer require gsk acquire ultimate liability legal claim vary amount shareholde liability option recognise provide dependent outcome litigation group balance sheet initial value proceeding investigation possible settlement negotiation million gsk recognise liability future preferential position change time dividend anticipate payable pfizer shionogi assurance loss result outcome legal group balance sheet liability pfizer proceeding exceed provision report option derive internal valuation viiv group financial statement material healthcare business utilise discount forecast future cash flow multiplesbase methodology amount million intangible asset impairment december million sensitivity analysis december intangible asset million give note trade payable million impairment test intangible asset undertake event occur question carry value asset addition intangible asset indefinite useful life available use subject annual impairment test valuation impairment test base established market multiple riskadjuste future cash flow estimate useful life asset limit discount appropriate discount rate set note intangible asset assumption relate future cash flow estimate useful life discount rate base business forecast inherently judgemental future event cause assumption impairment test change consequent adverse effect future result group gsk annual report note financial statement continue key accounting judgement estimate continue pension postemployment benefit discount rate derive rate corporate bond yield cost provide pension postemployment benefit country deep market corporate assess basis assumption select management bond government bond yield sensitivity analysis assumption include future earning pension increase provide note pension postemployment discount rate expect longterm rate return asset benefit reduction discount rate lead mortality rate disclose note pension increase net pension deficit approximately million postemployment benefit surplus define benefit increase annual pension cost approximately million scheme arise potential surplus arise selection different assumption affect future result commit future contribution right trustee prevent group group obtain refund surplus future consider determine necessary restrict surplus recognise new accounting requirement follow new amend accounting standard new standard expect material impact issue iasb likely affect future annual report report result financial statement gsk adopt ifrs retrospectively certain permit exception ifrs revenue contract customer issue result prior year result restate implement group january cumulative adjustment decrease equity january standard provide single principlesbased approach approximately million recognition revenue contract customer focus identification performance obligation contract ifrs lease issue january require revenue recognise performance implement group january standard obligation satisfy replace ias lease require lease liability right use asset recognise balance sheet new standard expect material impact lease expect result significant increase timing recognition report revenue financial asset liability recognise cost operating statement gsk adopt ifrs apply modify lease currently include operating cost split retrospective approach cumulative adjustment decrease financing element charge report finance equity january approximately million accordance expense finance lease obligation december requirement standard modify set note net debt undiscounte commitment retrospective approach adopt prior year result noncancellable operating lease set note restate commitment ifrs financial instrument issue final form july group assess potential impact ifrs implement group january standard replace majority ia cover ifric uncertainty income tax treatment issue june classification measurement derecognition financial asset implement group january financial liability introduce new impairment model interpretation clarifie consider probable tax financial asset base expect loss incur authority accept uncertain tax treatment tax charge loss provide new hedge accounting model calculate basis consider probable effect uncertainty estimate reflect tax charge assess uncertainty assume tax authority knowledge information relate matter group continue assess potential impact new interpretation exchange rate group use average exchange rate prevail period translate result cash flow overseas average rate subsidiary joint venture associate sterling period end rate translate net asset entity currency euro influence translation relevant exchange rate follow yen period end rate euro yen gsk annual report strategic report governance remuneration financial statement investor information segment information operating segment report base financial information provide chief executive officer responsibilitie corporate executive team cet gsk report result segment pharmaceutical pharmaceutical vaccine consumer healthcare individual member cet responsible segment group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis explain january significant legal charge exclude segment profit report reconcile item segment profit operating profit segment profit revise comparable basis corporate unallocated turnover cost include result vaccine consumer healthcare product hold sale number market order meet antitrust approval requirement cost corporate function turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover pharmaceutical turnover therapeutic area respiratory hiv immunoinflammation establish pharmaceutical operation pharmaceutical vaccine business sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler vaccine turnover category meningitis influenza shingle establish vaccine consumer healthcare turnover category wellness oral care nutrition skin health gsk annual report note financial statement continue segment information continue revise revise segment profit pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring charge significant legal charge expense settlement litigation government investigation disposal business product associate certain item relate major acquisition disposal activity pretax impact enactment tax cut job act depreciation amortisation segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statement investor information segment information continue ppe intangible asset goodwill impairment segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment reconcile item segment impairment total impairment include million relate progressive withdrawal tanzeum ppe intangible asset impairment reversal segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal net asset segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset pharmaceutical segment include shionogiviiv healthcare contingent consideration liability million million pfizer option million million consumer healthcare segment include option liability million million gsk annual report note financial statement continue segment information continue geographical information regard group country domicile turnover location customer international external turnover noncurrent asset location subsidiary international noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables operating incomeexpense impairment equity investment disposal equity investment disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement viiv healthcare option liability preferential dividend remeasurement consumer healthcare option liability fair value adjustment derivative financial instrument incomeexpense disposal business asset include profit million disposal anaesthesia business aspen disposal include milestone income million relation divestment ofatumumab number small divestment include disposal oncology business novartis million initial million divestment ofatumumab fair value remeasurement contingent consideration recognise business combination include million related acquisition shionogiviiv healthcare joint venture million payable novartis relate vaccine acquisition fair value remeasurement contingent consideration remeasurement viiv healthcare option liability preferential dividend remeasurement consumer healthcare option liability include additional charge arise tax reform million gsk annual report strategic report governance remuneration financial statement investor information operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset net reversal net foreign exchange loss inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration net foreign exchange loss include net loss million nil nil exchange arise reclassification exchange liquidation disposal overseas subsidiary include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidated financial statement audit company subsidiary attestation sarbanesoxley act audit auditrelated service taxation compliance taxation advice assurance service service assurance service provide auditor relate agree procedure assurance service outside statutory audit requirement service provide auditor primarily relate advisory service year end december addition fee pay respect gsk pension scheme audit service gsk annual report note financial statement continue employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity increase wage salary include impact movement exchange rate group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan cash settle plan average monthly number person employ group include director year number number number manufacturing sell general administration research development average monthly number group employee exclude temporary contract staff number group employee end financial year give financial record monthly average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan gsk annual report strategic report governance remuneration financial statement investor information major restructuring cost major restructuring cost charge arrive operating profit include restructure cost arise major change programme initiate pharmaceutical restructuring programme announce october follow novartis transaction complete ceo strategic initiative programme announce july total restructuring cost million incur follow area restructure organisation predominantly unite kingdom north america project simplify eliminate process lead staff reduction support function restructuring pharmaceutical commercial operating model supply chain lead staff reduction sale force administration transformation manufacture vaccine business deliver step change quality cost productivity cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost provision reversal million million million reflect release legacy support function novartis integration provision asset impairment million million million noncash charge total million million million noncash item principally fix asset write down support function manufacture research facility accelerate depreciation asset live manufacturing shorten result major restructure programme charge settle cash include termination lease site closure cost consultancy project management fee finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables fair value adjustment derivative fair value profit loss derivative account fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ias gsk annual report note financial statement continue finance expense interest expense arise financial liability amortise cost derivative fair value profit loss fair value movement derivative fair value profit loss reclassification cash flow hedge comprehensive income unwind discount provision finance expense derivative account fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest expense arise derivative fair value profit loss relate swap interest expense finance expense include million credit interest relate income taxis note presentation financial statement amount material comparative restate associate joint venture group share tax profit loss associate joint venture set share tax profit associate share tax loss joint venture december group hold significant associate innoviva inc summarise income statement information respect innoviva set periods group account investment innoviva associate group share tax profit associate comprehensive income include profit million comprehensive income nil respect innoviva september turnover profit taxation comprehensive income total comprehensive income result innoviva include summarise income statement information represent estimate earning innoviva relevant period innovivas turnover royalty income gsk relation relvarbreo ellipta anoro ellipta trelegy ellipta sale aggregate financial information respect gsk share associate undertaking joint venture set share turnover share tax lossesprofit share comprehensive income share total comprehensive expenseincome group sale associate joint venture million million million gsk annual report strategic report governance remuneration financial statement investor information taxation group tax charge sum total current defer tax expense taxation charge base profit year current year charge rest world current year charge credit respect prior period total current taxation total defer taxation total tax gsk payment million corporation tax hmrc amount corporation tax include business taxis bear gsk year defer tax credit reflect revaluation exist defer tax liability reflect low swiss tax rate applicable follow swiss tax reform increase defer tax asset relate intragroup profit inventory impact item partly offset revaluation exist defer tax asset reflect low headline tax rate follow enactment tax reform comparison net defer tax credit impact great extent remeasurement contingent consideration relation shionogiviiv healthcare joint venture credit include unwind defer tax liability disposal group oncology business novartis follow table reconcile tax charge calculate statutory rate group profit tax actual tax charge year reconciliation taxation group profit profit tax statutory rate taxation difference overseas taxation rate benefit intellectual property incentive credit remeasurement nontaxable option liability loss recognisedpreviously unrecognise loss permanent difference disposal acquisition permanent difference reassessment prior year estimate respect current defer taxis swiss tax reform tax unremitte earning tax chargetax rate gsk substantial business presence country globe impact difference overseas taxation rate arise profit earn country tax rate high statutory rate significant belgium india adverse impact partly offset increase benefit intellectual property incentive patent box belgian patent income deduction regime regime provide reduce rate corporate income tax profit earn qualifying patent group tax rate influence impact swiss tax reform transactionrelate charge arise group option liability relation viiv healthcare consumer healthcare joint venture reassessment estimate uncertain tax position follow settlement number open issue tax authority jurisdiction include permanent difference million charge arise follow enactment belgium tax reform future tax charge group effective tax rate affect factor acquisition disposal restructuring location research development activity tax regime reform resolution open matter continue bring tax affair date world gsk annual report note financial statement continue taxation continue tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan defer taxation sharebase payment define benefit plan exchange movement fair value movement cash flow hedge fair value movement availableforsale investment total chargecredit equity statement comprehensive income item charge statement comprehensive income tax share base payment follow enactment belgian tax reform group recognise defer tax charge million million respectively equity statement comprehensive income amount include million net defer tax charge present international tax reform group tax charge influence impact international tax reform enact year tax cut job act act expect positive impact future tax earning gsk business enactment new law result number nonrecurre charge addition enactment swiss tax reform result nonrecurre tax credit arise revaluation defer tax liability relate certain consumer healthcare brand acquire novartis reflect reduction headline swiss tax rate charge associate tax reform base information currently available guidance treasury implementation act available particularly regard repatriation tax provision assumption underlying estimate change result adjustment charge take material impact result group impact tax reform profit attributable shareholder set swiss tax tax reform reform operating expense current tax defer tax impact profit taxation year profit attributable noncontrolle interest profit attributable shareholder valuation hiv consumer healthcare business increase low tax rate result increase related liability contingent consideration option additional operating cost million current tax charge respect tax reform relate primarily introduction repatriation tax accumulate reserve nonus subsidiary entity group cash impact spread year onwards defer tax charge relate primarily revaluation exist balance sheet tax asset hold future liability pension tax charge associate tax reform partly offset allocation noncontrolle interest amount million adjustment relate viiv healthcare consumer healthcare joint venture tax credit associate swiss tax reform similarly offset million charge allocation noncontrolle interest relate consumer healthcare joint venture impact tax charge arise tax reform follow current tax defer tax total revaluation asset liability repatriation tax group incur charge million follow enactment belgian tax reform predominantly relate revaluation exist defer tax asset continue focus tax reform expect future year drive oecds base erosion profit shift bep project european commission initiative include fiscal state aid investigation domestic initiative world result significant change establish tax principle increase tax authority dispute turn adversely affect gsk effective tax rate result high cash tax liability gsk annual report strategic report governance remuneration financial statement investor information taxation continue issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket line current oecd guideline group base transfer pricing policy arm length principle different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation group open item jurisdiction concern matter deductibility particular expense tax treatment certain business transaction gsk apply riskbased approach determine transaction likely subject challenge probability group able obtain compensatory adjustment international tax treaty calculation group total tax charge necessarily involve degree estimation judgment respect certain item tax treatment finally determine resolution reach relevant tax authority appropriate formal legal process december group recognise provision million respect uncertain tax position million decrease recognise provision drive reassessment estimate utilisation provision uncertain tax position follow settlement number open issue tax authority jurisdiction transfer accrue interest payable tax balance payable foreign exchange impact revalue overseas exposure contribute reduction recognise provision whilst ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate group continue believe appropriate provision period open agree tax authority currently anticipate material change amount provide transfer pricing tax contingency month provision defer tax liability million million respect withholding taxation arise distribution profit certain overseas subsidiary whilst aggregate unremitte profit balance sheet date approximately billion billion majority unremitted profit subject tax include withhold tax repatriation legislation relate company distribution provide exemption tax overseas profit subject certain exception prior year temporary difference arise accumulate reserve nonus subsidiary entity group time reversal temporary difference control consider probable foreseeable future defer tax provide result tax cut job act temporary difference reverse group record oneoff repatriation tax charge million accordingly unremitte profit defer tax provide nil billion movement defer tax asset liability pension share accelerate post option net capital intangible contingent intragroup employment tax award temporary allowance asset consideration profit benefit loss scheme difference total january exchange adjustment creditcharge income statement creditcharge income statement associate tax reform credit income statement associate swiss tax reform chargecredit statement comprehensive income equity december net defer tax credit million income statement include million credit associate swiss tax reform million credit relation origination reversal temporary difference credit partly offset million charge relation tax reform net credit income statement million include million charge relate incentive recognise operate profit taxation charge income statement defer tax liability provide relation intangible asset predominately relate temporary difference arise asset liability acquire historic business combination group continue recognise defer tax asset future obligation respect contingent consideration amount payable minority shareholder payment tax deductible point time payment deferred tax asset recognise intragroup profit arise intercompany inventory eliminate consolidated financial statement intragroup profit eliminate individual entity tax return temporary difference arise reverse point time inventory sell externally defer tax asset recognise tax loss million relate trading loss million relate trading loss million relate capital loss net temporary difference include accrue expense tax deduction available pay basis rebate defer tax asset liability recognise balance sheet follow defer tax asset defer tax liability gsk annual report note financial statement continue taxation continue defer tax asset recognise foreign tax credit possible future taxable profit available gross foreign tax credit defer tax recognise million december defer tax asset recognise probable future taxable profit available utilise loss unrecognise tax loss follow unrecognised unrecognised defer tax defer tax tax loss asset tax loss asset unrecognised tax loss trading loss expire year year available indefinitely december capital loss december earning share pence pence pence basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total special dividend april ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder gsk annual report strategic report governance remuneration financial statement investor information property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year disposal writeoff year include number asset nil net book value long use business gsk annual report note financial statement continue property plant equipment continue net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate depreciation million million impairment nil million net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million impairment million nil net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost disposal value use fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate relevant specific risk value use calculation impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately net impairment loss charge cost sale million million million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale carrying value december asset impairment charge reverse year million million million million computer software reclassify asset construction intangible asset ready use goodwill cost january exchange adjustment addition business combination note transfer asset hold sale cost december net book value january net book value december goodwill allocate group segment follow pharmaceutical vaccine consumer healthcare net book value december gsk annual report strategic report governance remuneration financial statement investor information goodwill continue recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate region period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical vaccines consumer healthcare terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill goodwill monitor segmental level pharmaceutical cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million million consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset gsk annual report note financial statement continue intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment capitalise development cost capitalise borrowing cost addition business combination addition disposal asset writeoff transfer asset hold sale reclassification cost december exchange adjustment capitalise development cost capitalise borrowing cost addition disposal asset writeoff transfer asset hold sale reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff transfer asset hold sale impairment december exchange adjustment impairment loss disposal asset writeoff transfer asset hold sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year net book value computer software include million million internally generate cost charge impairment year include million relate progressive withdrawal pharmaceutical product tanzeum fully impaired carrying value december intangible asset impairment charge reversed year follow impairment reversal million million patent expiry date group significant asset relevant set page gsk annual report strategic report governance remuneration financial statement investor information intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow meningitis portfolio dolutegravir benlysta fluarixflulaval hiv asset acquire bms selzentry okairos technology platform meningitis portfolio include menveo bexsero man abcwy indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow voltaren otrivin fenistil theraflu panadol sensodyne lamisil breathe right stiefel trade excedrin physiogel polident brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate specific country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction exchange rate assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply nil management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment intangible asset gsk annual report note financial statement continue investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal distribution receive movement lossprofit tax recognise consolidated income statement december group hold significant associate december innoviva inc december group own million share innoviva biopharmaceutical company list nasdaq innoviva partner gsk development long act beta agonist vilanterol currently receive royalty income sale product contain component relvarbreo ellipta anoro ellipta trelegy ellipta remain economic interest royalty theravance biopharma inc company spin innoviva group hold common stock investment innoviva market value million december million group divest shareholding associate note acquisition disposal summarise balance sheet information base result information respect innoviva set december december noncurrent asset current asset current liability noncurrent liability net liability interest associate undertake goodwill fair value adjustment carry value december gsk annual report strategic report governance remuneration financial statement investor information investment january exchange adjustment addition net fair value movement impairment loss disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument discount cash flow underlie net asset investment include list investment million million significant investment hold december theravance biopharma inc group hold common stock investment fair value december million million investment include equity stake company gsk research collaboration company provide access biotechnology development potential interest disposal investment fair value movement reclassify equity income statement base average cost share acquire different time impairment loss record recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement carry value december investment impaired follow original cost cumulative impairment recognise income statement subsequent fair value increase carry value december noncurrent asset amount receivable insurance contract pension scheme surplus receivables inventory raw material consumable work progress finish good gsk annual report note financial statement continue trade receivable trade receivables net provision bad doubtful debt accrue income prepayment interest receivable employee loan advance receivables trade receivable include million million associate joint venture receivables include million million associate joint venture bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit asset hold sale property plant equipment goodwill intangible inventory include asset hold sale million intangible impairment million ppe impairment million intangible impairment reversal million ppe impairment reversal noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell include asset hold sale asset write fair value cost sell million million valuation methodology use significant input base observable market datum valuation classify level fair value hierarchy gsk annual report strategic report governance remuneration financial statement investor information trade payable trade payable wage salarie social security consumer healthcare option viiv healthcare option payable defer income customer return rebate accrual accrual trade payable include million million associate joint venture customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine fully describe group financial review accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption accrual base change affect future result group consumer healthcare option liability relate ability novartis share consumer healthcare joint venture gsk certain point future option exercisable march payment likely month exercise classify current liability liability record present value estimate redemption value apply discount rate calculate apply average relevant public company multiple approach premium discount base forecast profit earning consumer healthcare joint venture form gsk consumer healthcare segment remeasurement charge year million include impact tax reform million note operate incomeexpense table show indicative basis income statement balance sheet sensitivity reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast sale multiple apply decrease sale forecast sale multiple apply cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro pfizer option shareholding viiv healthcare recognise currently exercisable table show indicative basis income statement balance sheet sensitivity pfizer option reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report note financial statement continue pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate white collar table adjust reflect recent experience rate project allow future improvement life expectancy gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue average life expectancy assume individual age project apply individual age follow male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment group review investment strategy plan asset allocation plan adjust approximately return seek asset liability match asset target asset allocation plan update return seek asset liability match asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix return seek asset generate future return liability match asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liability define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal group apply follow financial assumption assess define benefit liability rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate gsk annual report note financial statement continue pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit rest world group group amount charge operating profit current service cost past service cost net interest cost expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service cost net interest cost gain settlement expense remeasurement loss record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest cost lossesgain settlement expense remeasurement gainslosse record statement comprehensive income amount include past service cost include million million million augmentation cost million arise major restructuring programme note provision gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow rest world group december equity list unlisted multiasset fund property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset multiasset fund comprise investment pool investment vehicle invest range asset class increase diversification growth portfolio indexlinke gilt hold repo programme include government bond relate loan include asset value million million million rest world group december equity list unlisted multiasset fund property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net obligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report note financial statement continue pension postemployment benefit continue rest world group december equity list unlisted multiasset fund property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net obligation include noncurrent asset include pension postemployment benefit actual return plan asset postretirement pension benefit rest world group group movement fair value asset asset january exchange adjustment addition business combination interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december group special funding contribution pension scheme total million million million million nil million scheme gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation base funding agreement follow valuation additional contribution eliminate pension deficit expect million contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue postretirement pension benefit rest world group group movement define benefit obligation obligation january exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million postretirement benefit unfunded gsk annual report note financial statement continue pension postemployment benefit continue movement net define benefit liability follow january exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement return plan asset exclude amount include interest gain change demographic assumption lossgain change financial assumption experience lossesgain employer contribution expensesother movement december remeasurement include postretirement benefit detailed gain change demographic assumption lossgain change financial assumption experience gainslosse gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation gsk annual report note financial statement continue provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement transfer pension obligation december settle year settle year december legal dispute pharmaceutical restructuring programme announce group involve substantial number legal october focus rescale commercial dispute include notification possible claim set operation global support function certain rdmanufacturing note legal proceeding provision legal dispute operation pharmaceutical addition integration include amount relate product liability antitrust government restructure programme initiate follow investigation contract termination self insurance completion novartis transaction ceo strategic environmental cleanup initiative programme announce july restructure integration programme report charge year million net reversal combine major restructure programme estimate insurance recovery primarily relate provision product liability case paxil product provision staff severance payment management commercial dispute government investigation formal decision eliminate certain position communicate group employee affect discount provision increase million appropriate consultation procedure complete appropriate increase million discount calculate provision staff severance payment riskadjuste project cash flow riskfree rate return immediately respect product liability claim relate certain product pension augmentation arise staff redundancie sufficient history claim settlement enable million million charge management reliable estimate provision require year transfer pension obligation provision cover unasserted claim ultimate liability matter show note pension postemployment benefit vary amount provide dependent outcome asset writedown recognise impairment litigation proceeding investigation possible settlement property plant equipment note property plant negotiation equipment majority amount provide expect nature group business number utilise year matter subject negotiation litigation employee relate provision year litigation proceeding include appeal employee relate provision include obligation certain medical procedure year reach resolution benefit disabled employee spouse outofcourt settlement discussion protract december provision benefit amount group potential settlement discussion number million million employee benefit reflect dispute amount provide base variety provision severance cost jubilee awards current assessment progress dispute longservice benefit estimate million provide december provision settle year december include provision insurance provision million expect nil million nil provision legal million onerous property lease provision dispute reimburse party insurer million million number provision discussion legal issue note legal proceeding include vehicle insurance regulatory matter major restructuring programme group initiate major change restructure programme focus opportunity simplify supply chain process build group capability manufacture restructure european pharmaceutical business gsk annual report strategic report governance remuneration financial statement investor information noncurrent liability accrual defer income consumer healthcare option liability payable net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing commercial paper bank loan overdraft obligation finance lease medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange longterm borrowing medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange obligation finance lease long term borrowing net debt gsk annual report note financial statement continue net debt continue current asset liquid investment classify availableforsale investment december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float rate million million liquid investment balance december earn interest fix rate nil million nil effective interest rate cash cash equivalent december approximately approximately cash cash equivalent december earn interest float fix rate million million respectively million million gsk policy credit quality cash cash equivalent refer note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme billion billion issue december billion billion gsk billion year commit facility billion billion day commit facility fiveyear commit facility agree september extend year september day commit facility agree august liquid investment cash cash equivalent show table weight average interest rate commercial paper borrowing december weight average interest rate current bank loan overdraft december average effective preswap interest rate note classify short term december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year average effective preswap interest rate note issue december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range pledge asset group hold pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision addition million million asset include note noncurrent asset form net debt pledge collateral future rental payment operate lease arrangement enter human genome sciences inc prior acquisition group finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december million million financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant tax legal dispute group party set note taxation note legal proceeding gsk annual report strategic report governance remuneration financial statement investor information share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue employee share scheme december issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme gsk annual report note financial statement continue movement equity retain earning reserve amount million december million million million million million relate joint venture associate undertaking cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset december exchange movement overseas net asset december exchange movement overseas net asset reclassification exchange liquidation disposal overseas subsidiary december analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax fair value movement availableforsale investment defer tax reverse reclassification available sale investment fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive incomeexpense year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge defer tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement loss define benefit plan tax remeasurement loss define benefit plan comprehensive income year gsk annual report strategic report governance remuneration financial statement investor information movement equity continue non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment reclassification cash flow hedge income statement fair value movement cash flow hedge share comprehensive expense associate joint venture item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive expenseincome year analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report note financial statement continue related party transaction december gsk own million share innoviva inc biopharmaceutical company list nasdaq gsk begin recognise innoviva associate september royalty gsk innoviva year million million december balance payable gsk innoviva million million december gsk hold interest japan vaccine ltd jvc subsidiary glaxosmithkline joint venture daiichi sankyo ltd primarily responsible development marketing certain prophylactic vaccine japan gsk sell million million vaccine product joint venture december trading balance gsk jvc million million balance payable gsk jvc nil million nil loan million jvc million medicxi venture million index venture life jersey remain gsk december aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance expense net finance income depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profit sale investment associate profit sale equity investment change work capital increasedecrease inventory increasedecrease trade receivables increase trade payable decreaseincrease receivables contingent consideration pay note noncash increase contingent consideration liability increase payable decreaseincrease pension provision sharebase incentive plan fair value adjustment cash generate operation gsk annual report strategic report governance remuneration financial statement investor information reconciliation net cash flow movement net debt net debt begin year decreaseincrease cash bank overdraft decreaseincrease liquid investment net increase longterm loan net repayment ofincrease shortterm loan net repayment obligation finance lease exchange adjustment noncash movement movement net debt net debt end year january profit reclass december exchange loss ification disposal cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper european medium term note debt year european medium term note net debt analysis change liability finance activity debt year debt year hedge borrowing derivative financial instrument finance item interest payable total liability financing activity information significant change net debt note net debt gsk annual report note financial statement continue acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give business acquisition business acquisition business disposal gsk number small business disposal year net cash consideration million include contingent consideration receivable million profit disposal determine follow total consideration include currency forward purchase adjustment net asset sell goodwill intangible asset property plant equipment inventory cash cash equivalent net asset transaction cost reclassification exchange comprehensive income profit disposal investment associate joint venture year gsk cash investment million associate joint venture addition gsk sell holding associate million cash total cash consideration net book value share reclassification exchange comprehensive income transaction cost profit disposal cash flow associate associate business disposal investment disposal cash consideration net defer consideration receive cash cash equivalent divest transaction cost pay cash inflow business acquisition gsk complete small business acquisition cash consideration million pay year acquire hiv preclinical discovery stage portfolio bristol myers squibb consideration contingent commercial milestone future sale performance initial estimate million recognise contingent consideration intangible asset acquire value million goodwill million recognise gsk form galvani bioelectronic limited year acquire intangible asset million cash cash equivalent million verily life sciences llc return shareholding galvani bioelectronic fair value shareholde million gsk recognise credit million noncontrolling interest represent verilys share net asset contribute business disposal gsk number small business disposal year net cash consideration million addition defer consideration receivable million recognise gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue cash flow business business acquisition disposal cash consideration paidreceive purchase adjustment cash cash equivalent acquire cash inflow addition gsk cash investment million associate joint venture business acquisition novartis consumer healthcare vaccine business threepart interconditional transaction novartis involve consumer healthcare vaccine oncology business complete march gsk novartis contribute respective consumer healthcare business consumer healthcare joint venture noncash transaction gsk equity interest majority control joint venture addition gsk acquire novartis global vaccine business exclude influenza vaccine initial cash consideration billion billion contingent consideration represent subsequent potential milestone payment billion billion arise achievement specify development target ongoing royalty base future sale performance certain product total payable unlimited milestone million million pay march business acquisition addition gsk complete small vaccine business acquisition cash consideration million net cash acquire fair value exist investment million represent goodwill million intangible asset million net liability million fair value asset acquire business combination include goodwill set table novartis consumer novartis healthcare vaccine business business net asset acquire intangible asset property plant equipment inventory trade receivables asset include cash cash equivalent trade payable defer tax liability liability noncontrolle interest goodwill consideration settle share gsk consumer healthcare holding cash consideration pay purchase adjustment fair value equity investment disposal contingent consideration defer tax contingent consideration loss settlement preexist relationship total consideration gsk annual report note financial statement continue acquisition disposal continue noncontrolle interest consumer healthcare joint venture calculate apply goodwill method represent novartis share net asset contribute joint venture attributable goodwill goodwill business acquire represent potential synergy arise combine acquire business gsk exist business value workforce acquire majority goodwill recognise expect deductible tax purpose total transaction cost recognise acquisition novartis amount million march december turnover million arise novartis consumer healthcare vaccine business include group turnover business acquire beginning year estimate group turnover approximately million high business integrate group exist activity practical identify impact group profit period business disposal oncology gsk divest market oncology business relate activity right akt inhibitor grant commercialisation partner right future oncology product novartis consideration billion million purchase adjustment business disposal gsk number small business disposal period net cash consideration million profit disposal business determine follow oncology cash consideration include currency forward purchase adjustment net asset sell goodwill intangible asset property plant equipment inventory cash net asset loss currency forwards book disposal cost profit disposal associate joint ventures year gsk cash investment million associate joint venture addition march gsk sell half shareholding aspen represent issue share capital company million cash result sale group long consider ability exert significant influence aspen group remain investment transfer investment associate investment cash consideration net book value share reclassification exchange comprehensive income transaction fee item profit disposal business business associate acquisition disposal disposal total cash flow cash consideration paidreceive purchase adjustment cash cash equivalent acquireddiveste defer cash proceed contingent consideration pay transaction cost cash outflowinflow gsk annual report strategic report governance remuneration financial statement investor information contingent consideration liability consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogi viiv novartis healthcare vaccine total january addition business combination remeasurement income statement cash payment operate cash flow cash payment invest activity movement december addition business combination remeasurement income statement cash payment operate cash flow cash payment invest activity movement december remeasurement income statement cash payment operate cash flow cash payment invest activity december contingent consideration payable december million million expect pay year contingent consideration payable respect novartis vaccine business include sale milestone million settle january consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccine business expect pay number year result total estimate liability discount present value show shionogi viiv healthcare contingent consideration liability discount novartis vaccine contingent consideration liability discount partly partly shionogiviiv healthcare contingent consideration liability calculate base forecast sale performance specify product principally dolutegravir life product table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation contingent consideration liability shionogi novartis viiv healthcare vaccine increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report note financial statement continue noncontrolle interest group subgroup material noncontrolle interest viiv healthcare limited subsidiary gsk consumer healthcare holding limit subsidiary summarise financial information respect viiv healthcare group gsk consumer healthcare joint venture set viiv healthcare turnover profitloss taxation comprehensive income total comprehensive incomeexpense noncurrent asset current asset total asset current liability noncurrent liability total liability net liability net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity increase cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend profit taxation million loss taxation million loss taxation million state charge preferential dividend payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year follow amount attributable viiv healthcare group include gsk consolidate statement comprehensive income consolidate statement change equity consolidate balance sheet total comprehensive incomeexpense year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report strategic report governance remuneration financial statement investor information noncontrolle interest continue consumer healthcare joint venture turnover profitloss taxation comprehensive income total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net asset net cash inflow operating activity net cash inflowoutflow investing activity net cash outflow financing activity decrease cash bank overdraft year financial information relate consumer healthcare joint venture standalone basis impact grouprelate adjustment major restructuring charge follow amount attributable consumer healthcare joint venture include gsk consolidate statement comprehensive income consolidate statement change equity consolidate balance sheet total comprehensive income year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report note financial statement continue commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount decrease intangible commitment attributable amendment agreement adaptimmune therapeutic plc reduction commitment party ionis pharmaceuticals inc gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation payment million subsequent year include table include commitment exclude normal ongoing annual funding requirement approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease disclose million million provide commitment group balance sheet commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure gsk use variety financial instrument finance operation market risk derivative financial instrument manage market risk interest rate risk management operation derivative principally comprise interest gsk objective minimise effective net interest cost rate swap foreign exchange forward contract swap balance mix debt fix float interest rate swap borrowing liquid asset currency require time policy interest rate risk management limit group purpose manage exposure financial risk float interest payment prescribe percentage change foreign exchange rate interest rate operating profit gsk hold issue derivative speculative purpose foreign exchange risk management gsk treasury policy specifically prohibit activity foreign currency transaction exposure arise external trade transaction financial instrument undertake manage flow normally hedge foreign currency transaction risk arise underlie business activity exposure arise internal trade flow selectively hedge group objective minimise exposure overseas operating capital management subsidiary transaction risk match local currency income gsk financial strategy support group strategic priority local currency cost possible gsk internal trading regularly review board gsk manage capital transaction match centrally intercompany payment term structure group appropriate mix debt equity manage reduce foreign currency risk foreign currency cash capital structure group consist net debt flow hedge selectively include hedge foreign billion note net debt total equity include exchange risk arise acquisition disposal asset provide noncontrolle interest billion possible gsk manage cash surplus borrow consolidated statement change equity requirement subsidiary company centrally forward total capital include provide noncontrolle interest contract hedge future repayment originate billion currency longterm credit rating standard poor stable order reduce foreign currency translation exposure group outlook moodys investor service moodys seek denominate borrowing currency principal stable outlook group shortterm credit rating asset cash flow primarily denominate standard poor moodys respectively dollar euro sterling borrowing swap currency require liquidity risk management gsk policy borrow centrally order meet anticipate borrowing denominate swap foreign currency funding requirement strategy diversify liquidity source match investment overseas group asset treat range facility maintain broad access financial hedge relevant asset forward contract major market currency reduce exposure group investment overseas asset net investment hedge december gsk billion borrowing section note detail repayable year hold billion cash cash equivalent liquid investment billion hold centrally gsk access shortterm finance billion billion commercial paper programme billion billion issue december billion gsk billion year commit facility billion billion day commit facility fiveyear commit facility agree september extend year september day commit facility agree august facility undrawn december gsk consider level committed facility adequate give current liquidity requirement gsk billion european medium term note programme december billion note issue programme group billion billion note issue december shelf registration gsk borrowing mature date option own minority interest partner viiv healthcare consumer healthcare business exercisable review liquidity requirement gsk consider sufficient financing option available option exercise gsk annual report note financial statement continue financial instrument relate disclosure continue credit risk december million cash categorise hold group consider maximum credit risk december unrated subinvestment grade rate counterpartie low million december million bbbbaa million cash transit total group financial asset exception remain exposure concentrate overseas bank local investment comprise equity investment bear cash management investment purpose include million equity risk credit risk detail nigeria hold united bank africa zenith bank stanbic group total financial asset december gsk great ibtc bank bank nigeria million btv concentration credit risk billion citibank austria million bank balance deposit hold billion wholesaler bbbbaa bbbbaa rate counterpartie million hold bbb billion citibank baa rate counterpartie include balance deposit million hdfc bank india million state treasuryrelate credit risk bank india bank local investment purpose gsk set global counterparty limit gsk banking investment counterpartie base longterm credit rating moodys standard poor usage limit monitor daily gsk actively manage exposure credit risk reduce surplus cash balance possible gsk strategy regionalise cash management concentrate cash centrally possible table set credit exposure counterpartie rate liquid investment cash cash equivalent derivative gross asset position derivative contract consider purpose table isda agreement risk net position counterparty table set group financial asset liability offset basis bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue gsk centrally manage cash reserve amount billion follow method assumption estimate december available month include fair value billion centrally manage cash hold viiv healthcare cash cash equivalent approximate carry own subsidiary group invest centrally manage liquid asset bank deposit aaaaaa rate treasury treasury liquid investment base quote market price calculate repo money market fund aaaaaa rate liquidity fund base observable input case marketable security base principal amount case nonmarketable wholesale retail credit risk security short repricing period outside customer account group trade receivable balance investment equity investment trade active market determine reference relevant stock exchange quote bid line pharmaceutical company group price equity investment determine reference sell product small number wholesaler addition current market value similar instrument reference hospital pharmacie physician group sale discount cash flow underlie net asset large wholesaler amount approximately sale pharmaceutical vaccine business shortterm loan overdraft commercial paper december group trade receivable approximate carry short maturity wholesaler total million instrument million group expose concentration credit risk longterm loan base quote market price case respect wholesaler european medium term note fix rate encounter financial difficulty materially adversely borrowing level fair value measurement approximate affect group financial result carry case float rate bank loan group credit risk monitoring activity relate loan wholesaler include review quarterly financial information contingent consideration business acquisition base standard poor credit rating development gsk internal present value expect future cash flow risk rating establishment periodic review credit limit group believe credit risk provision interest rate swap foreign exchange forward contract swap require excess normal provision bad doubtful debt option base present value contractual cash note trade receivables flow option valuation model market source datum exchange rate interest rate balance sheet date fair value financial asset liability table present carry amount fair receivables payable include option approximate value group financial asset liability december carrying december companyowne life insurance policy base cash fair value financial asset liability include surrender value price receive sell asset pay transfer lease obligation approximate carry liability orderly transaction market participant fair value investment gsk share measurement date december employee share ownership plan esop trust hold gsk share carry value million million fair value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning gsk annual report note financial statement continue financial instrument relate disclosure continue carry fair carry fair value value value value note availableforsale investment liquid investment government bond investment loan receivables cash cash equivalent trade receivable noncurrent asset scope ia financial asset fair value profit loss trade receivables noncurrent asset scope ias derivative designate fair value profit loss ade derivative classify held trading ia ade total financial asset financial liability measure amortise cost borrowing exclude obligation finance lease bond designate hedge relationship bond bank loan overdraft commercial paper borrowing total borrowing exclude obligation finance lease obligation finance lease total borrowing trade payable provision certain noncurrent liability scope ias financial liability fair value profit loss contingent consideration liability derivative designate fair value profit loss ade derivative classify held trading ia ade total financial liability net financial asset financial liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision noncurrent liability contingent consideration liability reconcile relevant note gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company level level level total december financial asset fair value availableforsale financial asset liquid investment investment noncurrent asset financial asset fair value profit loss noncurrent asset trade receivables derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss contingent consideration liability derivative designate fair value profit loss derivative classify held trading ias level level level total december financial asset fair value availableforsale financial asset liquid investment investment noncurrent asset financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss contingent consideration liability derivative designate fair value profit loss derivative classify hold trading ia movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income contingent consideration business divestedacquire year payment contingent consideration liability addition disposals transfer level exchange december gsk annual report note financial statement continue financial instrument relate disclosure continue net loss million million attributable level financial instrument recognise income statement attributable financial instrument hold end year loss million million report operating income income million nil record finance income million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture million million arise remeasurement contingent consideration payable acquisition novartis vaccine business net gain million million attributable level financial instrument report comprehensive income fair value movement availableforsale investment include net loss million net gain million respect financial instrument hold end year financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line future performance specify product movement certain foreign currency include million million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target movement certain foreign currency sensitivity analysis balance provide note contingent consideration liability trade receivables noncurrent asset scope ias follow table reconcile financial instrument trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset balance include companyowne life insurance policy nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ias fair value non fair value non loan financial financial loan financial financial profit loss receivables instrument instrument total profit loss receivables instrument instrument total trade receivable note noncurrent asset note follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day trade payable provision noncurrent liability contingent consideration liability scope ias follow table reconcile financial instrument trade payable provision noncurrent liability contingent consideration liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ia fair value fair value financial nonfinancial financial nonfinancial profit loss liability instrument instrument total profit loss liability instrument instrument total trade payable note provision note noncurrent liability note contingent consideration liability note gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue derivative financial instrument hedge programme follow table set fair value derivative hold gsk derivative liability million million derivative asset maturity year fair value fair value asset liability asset liabilitie net investment hedge foreign exchange contract principal million million cash flow hedge foreign exchange contract principal million million derivative designate fair value profit loss foreign exchange contract principal million million embed derivative derivative classify hold trading ia total derivative instrument foreign exchange contract classify held trading ia principal foreign exchange contract absolute total outstanding position balance sheet date group foreign exchange contract period month december group hold outstanding foreign exchange contract net asset fair value million million asset million liability december fair value million net asset million asset million liability overall decrease net asset fair value weaken sterling euro strengthen sterling dollar impact portion hedge portfolio designate accounting hedge fair value movement take income statement period offset exchange gain loss relate underlying balance fair value hedge december group designate fair value hedge net investment hedge year certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro foreign operation show table carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge hedge foreign exchange exposure arise euro denominate coupon payment relate note issue group european medium term note programme number highly probable forecast transaction denominate dollar addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue prior year balance reclassify finance cost life bond gsk annual report note financial statement continue financial instrument relate disclosure continue offset financial asset liability financial asset liability offset net report balance sheet legally enforceable right offset recognise amount intention settle net basis realise asset settle liability simultaneously arrangement meet criterion offset allow related amount offset certain circumstance bankruptcy termination contract follow table set financial asset liability offset subject enforceable master netting arrangement similar agreement offset december december column net show impact group balance sheet offset right exercise gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset balance december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party presently legally enforceable right offset amount offset balance sheet present separately table gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bear sensitivity analysis table illustrate estimate impact income statement equity result hypothetical market movement foreign exchange interest rate relation group financial instrument range variable choose sensitivity analysis reflect management view change reasonably possible oneyear period foreign exchange sensitivity group operate internationally primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen foreign exchange risk arise translation financial asset liability functional currency entity hold base group net financial asset liability december weaken strengthen sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation euro yen depreciation yen gsk annual report note financial statement continue financial instrument relate disclosure continue equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro foreign operation cash flow hedge foreign exchange exposure arise euro denominate coupon payment relate note issue group european medium term note programme number highly probable forecast transaction denominate dollar increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation euro table present group sensitivity weakening strengthen sterle relevant currency base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent depreciation dollar cent depreciation euro yen depreciation yen interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro float rate financial asset liabilitie interest rate applicable float rate financial asset liability increase basis point assume variable remain constant estimate group finance income increase approximately million million increase basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis group use interest rate swap manage interest rate risk purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december contractual cash flow respect operating lease vacant space provision exclude table include commitment noncancellable operating lease table note commitment obligation finance charge trade payable interest finance obligation liability debt debt lease finance lease net debt total december year year year year year year great year gross contractual cash flow finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow increase contractual cash flow nonderivative financial liability year billion decrease cash flow year billion principally reflect consumer healthcare option amount year option relate ability novartis share consumer healthcare joint venture gsk certain point commence march payment likely month exercise note trade payable information consumer healthcare option anticipate contractual cash flow repayment debt debt interest decrease billion year reduction issuance commercial paper favourable exchange rate movement dollar denominate debt table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument amount receivable payable year decrease compare december result reduce hedge commercial paper programme receivables payable receivables payable year year gross contractual cash flow gsk annual report note financial statement continue employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share glaxosmithkline plc discount price grant restrict share award normally exercisable end year vest performance period award normally grant employee acquire share ad glaxosmithkline plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detail glaxosmithkline share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant performance condition base equally weight measure year performance period adjust free cash flow tsr new product performance fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award million share weight fair value million ad weight fair value december outstanding award million share million ad gsk annual report strategic report governance remuneration financial statement investor information employee share scheme continue share option savingsrelate option purpose value savingsrelated option arrive share base payment charge blackschole option pricing model assumption model follow grant grant grant riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year year year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable share option ad option currently exercisable expire exercise july change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution treasury share carry value million purchase esop trust satisfy future award cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report note financial statement continue principal group company follow represent principal subsidiary country incorporation group december equity share capital entity wholly own group percentage interest show company incorporate principal country operation state england glaxo group limited block drug company inc glaxo operation limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare glaxosmithkline consumer healthcare trading limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited gsk consumer health inc novartis consumer health inc glaxosmithkline research development limited limited glaxosmithkline service unlimited stiefel laboratories inc glaxosmithkline limited viiv healthcare company setfirst limited smithkline beecham limited viiv healthcare limited viiv healthcare limited europe glaxosmithkline biological belgium glaxosmithkline argentina argentina glaxosmithkline pharmaceuticals belgium glaxosmithkline australia pty ltd australia glaxosmithkline biological sas france glaxosmithkline consumer healthcare australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline brasil limitada brazil laboratoire glaxosmithkline france glaxosmithkline consumer healthcare inc canada viiv healthcare sas france glaxosmithkline inc canada glaxosmithkline consumer healthcare gmbh biomedical corporation quebec canada germany glaxosmithkline limited china hong kong glaxosmithkline gmbh germany sinoamerican tianjin smith kline french laboratories ltd china gsk vaccines gmbh germany glaxosmithkline consumer healthcare limited india glaxosmithkline consumer healthcare spa italy glaxosmithkline pharmaceuticals limited india glaxosmithkline spa italy glaxosmithkline consumer healthcare japan japan gsk vaccines srl italy glaxosmithkline japan glaxosmithkline netherlands viiv healthcare kabushiki kaisha japan glaxosmithkline consumer healthcare spzoo poland glaxosmithkline pakistan limited pakistan glaxosmithkline pharmaceuticals poland glaxo wellcome manufacturing pte ltd singapore gsk service poland glaxosmithkline korea limited republic korea glaxosmithkline trading services limited republic ireland glaxosmithkline llaclari sanayi ticaret turkey glaxosmithkline healthcare russia glaxosmithkline spain laboratorios viiv healthcare spain novartis consumer health switzerland xempt provision section company act ireland accordance exemption note section act subsidiary disclose page exempt provision consolidate group financial statement directly hold wholly own subsidiary glaxosmithkline plc subsidiary associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc page complete list subsidiary undertaking associate joint venture form financial statement gsk annual report strategic report governance remuneration financial statement investor information legal proceeding group involve significant legal administrative intellectual property proceeding principally product liability intellectual property tax intellectual property claim include challenge validity antitrust governmental investigation relate private enforceability group patent product litigation significant matter tax process assertion noninfringement matter describe group make provision patent loss case result loss patent proceeding regular basis summarise note protection product issue consequence accounting principle policy note provision loss significant decrease sale product materially affect future result operation group group involved significant legal proceeding respect possible reliable estimate flovent hfa expect financial effect result ultimate february group receive paragraph resolution proceeding case appropriate certification teva flovent hfa paragraph disclosure case include note certification group receive generic provision case pharmaceutical company seek rate version respect legal proceeding describe flovent hfa patent issue teva allege generic provision group version flovent infringe patent direct actuation unable reliable estimate expect financial effect indicator meter dose list orange book teva stage group believe information allege patent patent claim seek plaintiff know meaningful method treatment formulation contain active respect legal proceeding number medication propellant know substantially free factor include limited stage proceeding surfactant use hydrofluoroalkane hfa meter dose entitlement party appeal decision clarity theory inhaler flovent valid reviewing teva complaint liability damage govern law group sue teva patent ask fda remove patent orange book teva produce legal expense incur provision relate legal claim evidence show infringe dose counter patent charge sell general administration cost provision june group withdraw case teva take appropriate legal specialist advice outflow resource consider probable reliable bexseroman vaccines estimate likely outcome dispute certain follow acquisition novartis vaccine business product liability claim group provision group take patent litigation originally file novartis sufficient history claim settlement enable pfizer inc pfizer italy united states relate management reliable estimate provision require meningococcal man vaccine case novartis cover unasserted claim december group allege european patent own pfizer infringe aggregate provision legal dispute include tax group vaccine bexsero invalid novartis matter describe note taxation million file suit pfizer patent infringement allege pfizer ultimate liability legal claim vary amount provide sale vaccine trumenba infringe novartis patent relate dependent outcome litigation proceeding man vaccine pfizer file suit group investigation possible settlement negotiation seek invalidate patent own group group position change time relevance trumenba canada infringement patent assurance loss result outcome cover trumenba april group pfizer enter legal proceeding exceed material confidential global settlement resolving matter permit provision report group financial company manufacture sell respective man statement happen material adverse vaccine impact result operation group report period judgement incur settlement enter gsk annual report note financial statement continue legal proceeding continue dolutegravirtivicaytriumeq doc generici file action september court september october viiv healthcare receive patent rome seek declaration italian spc cover kivexa challenge letter hatchwaxman act lupin mylan invalid base invalid lamivudine cipla reddys labs triumeq cipla reddys abacavir combination patent viiv healthcare counterclaim apotex sandoz tivicay triumeq viiv healthcare list infringement italian spc trial action hear patent dolutegravir active ingredient tivicay active ingredient triumeq fda orange book patent june biogaran commence proceeding france seek cover molecule dolutegravir expire october revocation french spc cover kivexa trial date second patent claim certain crystal form dolutegravir expire set action december letter challenge patent crystal form generic company allege crystal portugal viiv healthcare initiate arbitration proceeding form patent valid challenge validity assert farmoz spc cover kivexa farmoz file propose product infringe crystal form patent marketing approval generic version kivexa arbitration february viiv healthcare file patent infringement suit date schedule action generic company district court february kyowa pharmaceutical file nullity action district delaware additionally viiv healthcare file suit relate kivexa japan oral hearing trial hold certain generic company district court japan patent office january decision japan district new jersey district court district patent office expect west virginia trial date set lexiva february viiv healthcare file patent infringement patent covering lexiva expire december litigation gilead sciences inc gilead bictegravir product paediatric exclusivity june pursuant district court district delaware patent settlement litigation confidential licence agreement mylan canadian federal court canadian patent presently sell generic version lexiva viiv healthcare allege gilead triple combination hiv drug contain hiv integrase inhibitor bictegravir infringe product liability viiv healthcare patent cover dolutegravir compound preclinical clinical trial conduct development include dolutegravir unique chemical scaffold potential product determine safety efficacy product canada viiv healthcare seek financial redress use human follow approval regulatory body injunctive relief trial date set notwithstanding effort drug vaccine kivexa introduce marketplace unanticipated safety issue viiv healthcare reached claim evident group confidential agreement vale pharmaceutical lupin currently defendant number product liability lawsuit relate sandoz stada zentiva settle challenge group pharmaceutical vaccine consumer healthcare validity supplementary protection certificate spc product group able reliable estimate patent cover combination lamivudine abacavir expect financial effect matter discuss category kivexa certain counterclaim bring viiv healthcare include provision appropriate matter infringement spc settlement bring end provision legal dispute matter litigation arbitration proceeding viiv healthcare group provision note note lupin germany portugal viiv healthcare provision stada germany italy viiv healthcare sandoz austria germany portugal spain sweden viiv healthcare vale pharmaceutical portugal viiv healthcare zentiva portugal gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue avandia seroxatpaxil paxil group name product liability lawsuit behalf group receive numerous lawsuit claim allege individual assert personal injury claim arise use use paxil paroxetine cause variety injury avandia economic loss action file seek lawsuit contain follow allegation restitution penaltie consumer protection law use paxil pregnancy cause congenital malformation federal case file group multidistrict persistent pulmonary hypertension autism paxil treatment litigation proceed pende district court eastern cause patient commit suicidal violent act iii district pennsylvania mdl court case group fail warn patient experience certain file number state court addition county santa symptom discontinue paxil treatment clara california bring action behalf california pregnancy resident pende mdl court allege violation group reach agreement settle majority california false advertising act seek restitution damage claim relate use paxil pregnancy february civil penalty number claim relate use pregnancy february remain personal injury case pende court remain lawsuit appeal summary judgement decision favour group case pende state court california federal court pennsylvania california state federal court california case state court court kentucky state court oklahoma lawsuit join claim plaintiff state court illinois matter purport class action seek economic dismiss payment damage behalf party payer assert claim racketeer influence corrupt organization act rico singh action alberta canada propose national class consumer protection law plaintiff voluntarily dismiss action seek certify class relate birth defect generally action december mdl court grant group group await hearing motion singh certify motion summary judgement remain plaintiff case class action canadian class action jensen claim plaintiff file appeal decision allege claim paxil ssri use autism file court appeal circuit briefing schedule saskatchewan january march court approval set receive settlement bartram class action suit british columbia santa clara county action group file motion summary judgement basis preemption act violence seek partial summary judgement county restitution february pende claim case claim december mdl court grant group concern allegation patient take paroxetine paxil motion county claim civil penalty remain pende commit attempt commit suicide act violence mdl court claim case case canada case dolin involve suicide man allegedly purport class action canada take generic paroxetine manufacture mylan result active active case class certification hearing million verdict plaintiff group appeal hold ontario action proceeding adjourn verdict court appeal seventh circuit december nova scotia court issue order certify nationwide class user avandia group file appeal class certification decision gsk annual report note financial statement continue legal proceeding continue discontinuation secdoj sfo anticorruption enquirie longpende group action allege seroxat cause fraud office sfo begin formal severe discontinuation symptom legal service criminal investigation group commercial operation commission lsc withdraw public funding hundred number country include china group cooperate claimant cause termination claim legal responding request sfo inquiry follow aid agency lsc discharge public funding investigation initiate chinas ministry public security june certificate follow recommendation special case china investigation result rule review panel case poor prospect success accord chinese law gsk china investment ltd recently fortitude law engage gskci offer money property nongovernment purpose resurrect seroxat group action obtain personnel order obtain improper commercial gain gskci thirdparty funding expert remain claimant find guilty bribing nongovernment personnel group ask court require thirdparty funder september group reach global resolution provide security litigation cost event plaintiff lose securities exchange commission sec december high court rule favour group sec investigation foreign corrupt practice act application order claimant litigation funder fcpa group commercial practice country outside security cost sum excess total funding include china resolution group agree commit case trial action schedule pay civil penalty million government commence department justice doj confirm conclude zofran investigation group commercial practice plaintiff allege child suffer birth defect result action group resolution sec mothers ingestion zofran andor generic ondansetron group agree certain undertaking include period pregnancyrelate nausea vomit plaintiff assert selfmonitore report group obligation group sell zofran know unsafe pregnant woman fail resolution continue september warn risk illegally market zofran offlabel use course current inquiry sfo request additional pregnant woman february group defendant information group party adviser engage personal injury lawsuit case company course china investigation sec multidistrict litigation proceeding mdl district doj investigate matter follow group massachusetts report sfos inquiry group cooperate mdl case discovery mdl continue monthly respond request status conference issue sufficiency group unable reliable estimate expect pleading scope discovery address group financial effect investigation provision continue seek dismissal individual case appropriate brown case pende oregon discovery schedule vaccines subpoena trial october remain state court case february group receive subpoena california early day attorney office southern district new york request group defendant propose class action document relate group vaccine business group canada significant activity respond subpoena group unable reliable canadian class action estimate expect financial effect matter sale marketing regulation provision group market promotion pharmaceutical vaccine product subject certain governmental subpoena relate imitrex amerge investigation private lawsuit bring litigant march group receive subpoena theories law group able reliable estimate attorney office southern district new york request expect financial effect matter discuss document relate group contract imitrex category include provision matter amerge group complete response subpoena provision legal dispute note group unable reliable estimate expect financial effect matter provision matter group provision note note provision gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue average wholesale price lamictal attorney general illinois file suit group purport class direct indirect purchaser file suit number pharmaceutical company claim damage district court district new jersey allege restitution average wholesale price awp andor wholesale group teva pharmaceuticals unlawfully conspire delay acquisition cost wac price report pharmaceutical product generic competition lamictal result overcharge cover states medicaid programme case allege purchaser enter allegedly anticompetitive reverse group report caused report false awp wac payment settlement resolve patent infringement litigation price turn allegedly cause state medicaid agency separate count accuse group monopolise market reimburse provider money cover medicine june court appeal reverse trial court agency intend state seek recovery behalf decision dismiss case remand action payer behalf instate patient consumer case trial court trial court deny indirect ongoing trial date set group purchaser class plaintiff motion reconsideration result cidra thirdparty payer litigation indirect purchaser class representative agree settlement july number major healthcare insurer file suit exit case resolve remain claim term group philadelphia pennsylvania county court settlement confidential case continue forward common plea seek compensation reimbursement document production witness depositions regard medicine manufacture group cidra plant claim direct purchaser puerto rico insurer claim group knowingly wellbutrin illegally market sell adulterate drug manufacture plaintiff claim antitrust injury relate allegedly sham patent condition noncompliant cgmp current good manufacturing litigation file biovail generic company pursue anda practice thirdparty insurer unlawfully generic wellbutrin plaintiff allege conspiracy delay induce pay suit allege federal generic approval exist biovail group state law cause action court deny group motion district court grant summary judgement favour group dismiss discovery schedule complete claim sole remain claim matter relate case schedule trial late plaintiff allegation group enter anticompetitive antitrustcompetition reverse payment settlement resolve patent infringement certain governmental action private lawsuit bring litigation district court grant summary judgement favour group allege violation competition antitrust law group claim august court appeal group able reliable estimate expect circuit court affirm trial court dismissal financial effect matter discuss category plaintiff case summary judgement august plaintiff include provision matter provision legal file motion rehear banc circuit dispute note matter group deny september plaintiff file petition provision note note provision certiorari ask united states supreme court review decision dismissal action final competition market authority investigation commercial corporate february competition market authority cma issue decision fine group group defendant certain case allege violation pharmaceutical company infringement competition federal security erisa law group able act cma impose fine million group reliable estimate expect financial effect fine total million company matter discuss category include provision relate agreement settle patent dispute group matter provision legal dispute matter potential supplier generic paroxetine formulation enter group provision note note group terminate agreement provision issue group believe strong ground appeal cma find competition appeal tribunal cat order overturn fine substantially reduce appeal conclude april cat deliver initial judgement appeal march refer principle point issue court justice preliminary ruling matter return cat final judgement provision matter gsk annual report note financial statement continue legal proceeding continue securitieserisa class action stiefel environmental matter december securities exchange group notify potential responsibility relate commission sec file formal complaint stiefel past operation past waste disposal practice certain laboratory inc charles stiefel district court site primarily matter subject district florida allege stiefel principal violate litigation include proceeding initiate federal state federal security law induce stiefel employee sell government waste disposal site remediation cost tort share employee stock plan company greatly action bring private party undervalue price disclose employee group advise responsible party company sell group case stay approximately site appear national priority private action bring stiefel employee list create comprehensive environmental response proceed court return active status compensation liability act superfund proceeding early summer unclear case ultimately seek require operator hazardous waste facility schedule trial transporter waste site generator hazardous waste addition sec case private matter martinolich dispose site clean site reimburse case remain pende federal district court florida government cleanup cost instance group stay pende trial sec matter involve allege generator hazardous waste allegation martinolich case largely track sec superfund provide defendant jointly matter plaintiff stiefel employee allege stiefel severally liable cleanup cost proceeding frequently officer director violate employee retirement resolve basis nature quantity waste dispose income security act erisa federal state security generator site group proportionate liability law induce stiefel employee sell share cleanup cost substantially determine site employee stock plan stiefel greatly undervalue price refer disclose employee stiefel sell group group potential liability vary greatly site site cost investigation study remediation site time significant group provision matter note note provision gsk annual report strategic report governance remuneration financial statement investor information financial statement glaxosmithkline plc prepare gaap include frs reduce disclosure framework director statement responsibility relation company financial statement director responsible prepare parent company disclosure information auditor glaxosmithkline plc financial statement remuneration director office date annual report report accordance applicable law regulation confirm company law require director prepare financial far aware relevant audit information statement financial year law director company auditor unaware elect prepare parent company financial statement take step ought take accordance united kingdom accounting standard director aware relevant audit applicable law united kingdom generally accept accounting information establish company auditor aware practice company law director approve information parent company financial statement satisfied true fair view state affair parent confirmation give interpret accordance company profit loss period provision section company act prepare financial statement director require go concern basis assess principal risk matter consider select suitable accounting policy apply connection viability statement director consider consistently appropriate adopt go concern basis accounting judgement accounting estimate reasonable prepare financial statement prudent corporate governance code state regard parent company financial statement board consider glaxosmithkline plc apply principle applicable accounting standard follow subject complie provision corporate governance material departure disclose explain parent code maintain financial reporting council describe company financial statement corporate governance section page board consider annual report take fair prepare financial statement go concern basis balanced understandable provide information inappropriate presume parent company necessary shareholder assess group position continue business performance business model strategy director responsible keep adequate accounting require financial conduct authority list rule record sufficient explain companys auditor consider director statement compliance transaction disclose reasonable accuracy time relation point corporate governance code financial position company enable ensure specified review parent company financial statement remuneration report page comply company act responsible safeguarding asset company take reasonable step prevention detection fraud irregularity philip hampton parent company financial statement year end chairman december comprise balance sheet year march end december support note set page report responsibility auditor relation parent company financial statement set independent auditor report page financial statement year end december include annual report publish print form available website director responsible maintenance integrity annual report website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different strategic report risk section annual report represent management report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report independent auditor report members glaxosmithkline plc report parent company financial statement opinion audit approach opinion glaxosmithkline plcs parent company financial overview statement financial statement materiality true fair view state parent company overall materiality million million base affair december total asset cap allocation group materiality properly prepare accordance united kingdom scope generally accept accounting practice united kingdom parent company single entity operate location accounting standard comprise frs reduce area focus disclosure framework applicable law carry value investment subsidiary prepare accordance requirement vaccine contingent consideration liability company act audit financial statement include scope audit annual report comprise company balance sheet designing audit determine materiality december company statement change equity assess risk material misstatement financial year end note financial statement statement particular look director include description significant accounting policy subjective judgement example respect significant accounting estimate involve make assumption opinion consistent reporting audit risk consider future event inherently uncertain committee gain understand legal regulatory framework basis opinion applicable company pharmaceutical industry conduct audit accordance international standard operate consider risk act company audit isas applicable law contrary applicable law regulation include fraud responsibility isa describe auditor design audit procedure respond risk recognise responsibility audit financial statement section risk detect material misstatement fraud report believe audit evidence obtain high risk detect result error fraud sufficient appropriate provide basis opinion involve deliberate concealment example forgery independence intentional misrepresentation collusion focus remain independent group accordance law regulation rise material misstatement ethical requirement relevant audit financial company financial statement event noncompliance statement include frc ethical standard include limited company act list applicable list public interest entity fulfil rule taxation legalisation test include ethical responsibility accordance requirement limited review financial statement disclosure underlie support documentation review correspondence good knowledge belief declare nonaudit legal advisor enquiry management review internal service prohibit frc ethical standard provide audit report far relate financial statement group parent company inherent limitation audit procedure describe disclose note group financial remove noncompliance law statement provide nonaudit service group regulation event transaction reflect subsidiary period january financial statement likely aware december identify key audit matter relate irregularity include fraud audits address risk management override internal control include test journal evaluate evidence bias director represent risk material misstatement fraud gsk annual report strategic report governance remuneration financial statement investor information report parent company financial statement continue key audit matter key audit matter matter auditor professional judgement significance audit financial statement current period include significant assess risk material misstatement fraud identify auditor include great effect overall audit strategy allocation resource audit direct effort engagement team matter comment result procedure thereon address context audit financial statement form opinion thereon provide separate opinion matter complete list risk identify audit key audit matter audit address key audit matter carry value investment subsidiary evaluate management assumption indicator refer note parent company financial statement impairment exist compare net asset subsidiary december parent company investment carry parent company hold fix asset investment comprise value investment subsidiary million december million investment net asset lower carry value consider recoverable value reference investment subsidiary account cost group market capitalisation december impairment company balance sheet december valuation imply model include valuation model prepare investment test impairment impairment indicator acquisitionrelate liability goodwill impairment review exist indicator exist recoverable amount purpose subject audit procedure investment subsidiary estimate order determine group audit extent impairment loss impairment loss recognise income statement result work agree management carry value investment hold parent company supportable management judgement require area impairment context parent company financial statement take test particularly determine impairment trigger arisen trigger need impairment review assess carry value asset support recoverable determine reference group market capitalisation valuation imply acquisitionrelate liability vaccine contingent consideration liability deploy valuation specialist consider reasonableness refer note parent company financial management assumption include growth projection statement probability success integrity accuracy management model compare sale forecast independent acquisition vaccine business novartis market analysis board approve long range forecast parent company recognise contingent consideration liability verify projection consistent represent certain future milestone royalty payment estimate include intangible asset impairment model liability include milestone payment acquire product reach set revenue development target consider appropriateness management judgement probability achieve milestone relation liability require remeasure fair value development progress quantify sensitive liability reporting date base late forecast expectation different assumption probability success probability successful product launch value liability probability success change verify drive december million million comparative change stage development vaccine carry value liability base assumption liability subject significant estimation uncertainty forecast cash flow discount rate taxation rate base procedure perform comfortable value probability certain vaccine achieve development milestone liability december reasonable context parent company financial statement take reflect management good estimate time review disclosure liability include group financial statement satisfy disclosure appropriate gsk annual report independent auditor report members glaxosmithkline plc continue report parent company financial statement continue tailor audit scope tailor scope audit ensure perform work able opinion financial statement take account structure parent company accounting process control industry operate materiality scope audit influence application materiality set certain quantitative threshold materiality qualitative consideration help determine scope audit nature timing extent audit procedure individual financial statement line item disclosure evaluate effect misstatement individually aggregate financial statement base professional judgement determine materiality financial statement follow overall group materiality million million determine total asset cap allocation group materiality rationale benchmark applied parent company hold group investment profitoriente strength balance sheet key measure financial health important shareholder primary concern parent company payment dividend benchmark total asset appropriate cap million follow allocation group audit materiality parent company component group audit agree audit risk committee report misstatement identify audit million million misstatement view warrant reporting qualitative reason go concern accordance isas report follow report obligation outcome require report material add material add draw attention draw attention respect director statement future event condition predict financial statement director consider statement guarantee parent company ability appropriate adopt go concern basis accounting continue go concern prepare financial statement director identification material uncertainty parent company ability continue go concern period month date approval financial statement require report director statement relate report go concern accordance list rule materially inconsistent knowledge obtain audit gsk annual report strategic report governance remuneration financial statement investor information report information information comprise information annual report perform review report financial statement auditor report director statement carry robust assessment thereon director responsible information principal risk face parent company statement opinion financial statement cover relation longerterm viability parent company review information accordingly express audit opinion substantially scope audit consist extent explicitly state report form make inquiry consider director process support assurance thereon statement check statement alignment relevant provision corporate governance code connection audit financial statement code consider statement consistent responsibility read information knowledge understand parent company consider information materially inconsistent environment obtain course audit list rule financial statement knowledge obtain audit appear materially misstate identify code provision apparent material inconsistency material misstatement report respect responsibility report require perform procedure conclude material misstatement financial statement material statement give director misstatement information base work consider annual report take fair balanced perform conclude material misstatement understandable provide information necessary information require report fact member assess parent company position report base responsibility performance business model strategy materially respect strategic report director report inconsistent knowledge parent company obtain consider disclosure require company course perform audit act include section annual report page describe base responsibility describe work work audit risk committee appropriately undertake course audit company act address matter communicate audit risk isa list rule financial conduct committee authority fca require report certain opinion matter director statement relate parent company describe require isa state compliance code properly disclose departure strategic report director report relevant provision code specify list opinion base work undertake course rule review auditor audit information give strategic report director director remuneration report year end december consistent opinion director remuneration report financial statement prepare accordance audit properly prepare accordance applicable legal requirement company act light knowledge understand parent company environment obtain course audit identify material misstatement strategic report director report director assessment prospect parent company principal risk threaten solvency liquidity parent company material add draw attention director confirmation annual report carry robust assessment principal risk face parent company include threaten business model future performance solvency liquidity disclosure annual report describe risk explain manage mitigated director explanation annual report assess prospect parent company period consider period appropriate statement reasonable expectation parent company able continue operation meet liability fall period assessment include related disclosure draw attention necessary qualification assumption gsk annual report independent auditor report members glaxosmithkline plc continue responsibility financial statement audit responsibility director financial statement use report explain fully director statement responsibility report include opinion prepare set director responsible preparation parent company member body accordance chapter financial statement accordance applicable company act purpose framework satisfied true fair view give opinion accept assume responsibility director responsible internal control purpose person report determine necessary enable preparation financial show hand come save expressly agree statement free material misstatement prior consent write fraud error company act exception reporting prepare financial statement director responsible company act require report assess parent company ability continue go concern opinion disclose applicable matter relate going concern receive information explanation go concern basis accounting director require audit intend liquidate parent company cease operation realistic alternative adequate accounting record keep parent company return adequate audit receive auditor responsibility audit financial statement branch visit objective obtain reasonable assurance financial statement free material misstatement certain disclosure director remuneration specify law fraud error issue auditor report include opinion reasonable assurance high level financial statement director assurance guarantee audit conduct remuneration report audit agreement accordance isa detect material misstatement accounting record return exist misstatement arise fraud error consider material individually aggregate exception report arise responsibility reasonably expect influence economic decision user appointment take basis financial statement audit financial statement parent company year end december follow parent company description responsibility audit financial inception period total uninterrupted engagement year statement locate frc website wwwfrcorguk cover year end december december auditorsresponsibilitie description form auditor year end december final year engagement report follow company decision rotate external audit matter report separately group financial statement glaxosmithkline plc year end december parent company pass resolution accordance section company act senior statutory auditor state pricewaterhousecooper llp charter accountant statutory auditor london march gsk annual report strategic report governance remuneration financial statement company balance sheet investor information gaap include frs reduce disclosure framework december note fix asset investment current asset trade receivable cash bank total current asset bank overdraft trade payable total current liability net current asset total asset current liability provision liability noncurrent liability net asset capital reserve share capital share premium account reserve retain earning january profitloss year change retain earning equity shareholder fund financial statement page approve board march sign behalf philip hampton chairman glaxosmithkline plc register number company statement change equity year end december share share premium retain total capital account reserve earning equity january loss attributable shareholder dividend shareholder share issue employee share scheme treasury share transfer esop trust december profit attributable shareholder dividend shareholder share issue employee share scheme treasury share transfer esop trust december gsk annual report note company balance sheet gaap include frs reduce disclosure framework presentation financial statement accounting policy description business foreign currency transaction glaxosmithkline plc parent company gsk major global foreign currency transaction record exchange rate healthcare group engage creation discovery ruling date transaction foreign currency asset development manufacture marketing pharmaceutical liability translate rate exchange rule balance product include vaccine overthecounter otc medicine sheet date healthrelate consumer product dividend pay receive preparation financial statement dividend pay receive include financial statement financial statement prepare historical period relate dividend actually pay cost convention modify include revaluation certain receive financial instrument go concern basis prepare accordance financial reporting standard reduce expenditure disclosure framework accounting presentation expenditure recognise respect good service receive company act december comparative supply accordance contractual term provision figure december obligation exist future liability respect past event obligation reliably permit section company act estimate income statement company present annual report investment subsidiary company investment subsidiary company hold cost company include group financial statement provision impairment adjust movement glaxosmithkline plc publicly available contingent consideration follow exemption requirement ifrs apply preparation financial statement impairment investment accordance frs carrying value investment review impairment indication investment impaired paragraph ifrs sharebase payment provision result impairment review charge ifrs financial instrument disclosure income statement year concern paragraph ifrs fair value measurement share base payment paragraph ias presentation financial statement issuance company subsidiary grant comparative information requirement respect company share represent additional capital contribution paragraph ias company subsidiary additional investment paragraph subsidiary result correspond increase shareholder ia presentation financial statement equity additional capital contribution base fair value ias statement cash flow grant issue allocate underlying grant vest period paragraph ias accounting policy change accounting estimate error taxation current tax provide amount expect pay apply paragraph ias relate party disclosure tax rate enact substantively enact requirement ia disclose related party transaction balance sheet date enter member group defer tax provide liability method temporary difference arise tax basis asset accounting convention standard liability carry amount financial statement balance sheet prepare historical defer tax asset recognise extent cost convention complie applicable accounting consider recoverable future taxable profit standard defer tax measure average tax rate expect accounting principle policy apply period temporary difference preparation balance sheet conformity generally expect realise settle defer tax liability asset accept accounting principle require management discount estimate assumption affect report amount asset liability disclosure contingent asset financial guarantee liabilitie date balance sheet actual amount liability relate guarantee issue company behalf differ estimate subsidiary initially recognise fair value amortise life guarantee balance sheet prepare accordance company accounting policy approve board legal dispute describe note policy consistently apply company provide anticipate settlement cost state outflow resource consider probable reliable estimate likely outcome dispute legal expense arise claim company december provision legal dispute amount million million gsk annual report strategic report governance remuneration financial statement investor information key accounting judgement estimate ultimate liability legal claim vary amount legal dispute provide dependent outcome litigation company provide anticipate settlement cost proceeding investigation possible settlement negotiation management make judgement outflow resource position change time probable reliable estimate likely outcome assurance loss result outcome legal dispute legal expense arise claim proceeding exceed provision report company estimate provision account company financial statement material specific circumstance dispute relevant external advice operating profit inherently judgemental change substantially time fee relate audit dispute progress new fact emerge company charge operate profit company director take legal advice dividend establish provision take account relevant fact circumstance matter accordance accounting director declare interim dividend result dividend requirement december provision legal year penny line dividend dispute amount million million detail note group financial statement dividend fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment contribution relate contingent consideration trade receivables amount year corporation tax recoverable receivables amount owe group undertaking amount year amount owe group undertaking trade payable amount year creditor contingent consideration payable amount owe group undertaking company guarantee debt issue subsidiary company receive fee aggregate company outstanding guarantee billion debt instrument billion amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note gsk annual report note company balance sheet gaap include frs reduce disclosure framework continue provision liability january exchange adjustment charge year utilise december provision relate number legal dispute company currently involve noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable share capital share premium account share premium ordinary share account number share capital authorise december december share capital issue fully pay january issue employee share scheme treasury share transfer esop trust december issue employee share scheme treasury share transfer esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme retain earning profit glaxosmithkline plc year million million loss dividend million million give retain profit million million loss treasury share purchase year nil effect million treasury share transfer subsidiary company million retain earning december stand million million million unrealise million addition billion dividend receive company distributable annual report file april group company page complete list subsidiary associate joint venture form financial statement ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn investor information section quarterly trend pharmaceutical vaccine turnover year record product development pipeline product competition intellectual property principal risk uncertainty share capital share price dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term gsk annual report financial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month report report report report report cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating incomeexpense operate profitloss net finance cost profit disposal associate share tax profitslosse associate joint venture profitloss taxation taxation tax rate profitloss taxation period profit attributable noncontrolle interest profitloss attributable shareholder basic earningsloss share penny dilute earningsloss share penny income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation adjust result describe gsk annual report strategic report governance remuneration financial statement investor information quarterly trend quarterly trend continue unaudite analysis group result provide quarter sterle financial year income statement total month report report report report report cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating incomeexpense operate profitloss net finance cost profit disposal associate share tax profitslosse associate joint venture profitloss taxation taxation tax rate profitloss taxation period profit attributable noncontrolle interest profitloss attributable shareholder basic earningsloss share penny dilute earningsloss share penny income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation adjust result describe gsk annual report financial record continued pharmaceutical turnover therapeutic area total europe international revise growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory anoro ellipta arnuity ellipta avamysveramyst flixotideflovent incruse ellipta nucala relvarbreo ellipta seretideadvair trelegy ellipta ventolin hiv epzicomkivexa juluca selzentry tivicay triumeq immunoinflammation benlysta establish pharmaceutical dermatology augmentin avodart coreg eperzantanzeum imigranimitrex lamictal requip serevent seroxatpaxil valtrex zeffix pharmaceutical vaccine turnover total europe international revise growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingle shingrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine represent growth actual exchange rate cer represent growth constant exchange rate gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical turnover therapeutic area total europe international revise growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory anoro ellipta arnuity ellipta avamysveramyst flixotideflovent incruse ellipta nucala relvarbreo ellipta seretideadvair ventolin hiv epzicomkivexa selzentry tivicay triumeq immunoinflammation benlysta establish pharmaceutical dermatology augmentin avodart coreg eperzantanzeum imigranimitrex lamictal requip serevent seroxatpaxil valtrex zeffix pharmaceutical vaccine turnover total europe international revise growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine represent growth actual exchange rate cer represent growth constant exchange rate gsk annual report financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board comparative information report include effect divestment complete revise revise revise revise group turnover geographic region europe international divestment total turnover include divestment group turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover divestment complete pharmaceutical turnover respiratory hiv immunoinflammation establish pharmaceutical vaccine turnover meningitis influenza shingle establish vaccine consumer healthcare turnover wellness oral care nutrition skin health gsk annual report strategic report governance remuneration financial statement investor information year record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share million million million million million weight average number share issue basic dilute revise revise revise revise financial result adjust turnover operate profit profit taxation profit taxation pence pence pence pence pence adjust earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report financial record continue year record continue balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england buy rate average rate year calculate average buy rate day year average mar feb jan dec nov oct sep high low buying rate march gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition pharmaceutical vaccine product development pipeline key inlicence alliance relationship party maa marketing authorisation application europe iiv healthcare global specialist hiv company nda new drug application gsk pfizer inc shionogi limited shareholder phase valuation clinical pharmacology usually conduct responsible developing deliver hiv medicine volunteer optionbase alliance ionis pharmaceuticals inc phase etermination dose initial evaluation efficacy month submission conduct small number patient onth regulatory approval maa phase iii arge comparative study compound versus placebo approval letter andor establish treatment patient establish bla biological licence application clinical benefit safety maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla hiv infectious disease dolutegravir hiv integrase strand transfer inhibitor non hiv infection virologically suppress patientsapproved nov rilpivirine nucleoside reverse transcriptase inhibitor nnrti tafenoquine aminoquinoline plasmodium vivax malaria submit nov dectova zanamivir ivneuraminidase inhibitor influenza submit nov dolutegravir hiv integrase strand transfer inhibitor nucleoside hiv infection iii lamivudine reverse transcriptase inhibitor nrti fostemsavir hiv attachment inhibitor hiv infection iii cabotegravir hiv integrase strand transfer inhibitor longacte hiv preexposure prophylaxis iii cabotegravir hiv integrase strand transfer inhibitor non hiv infection iii rilpivirine nucleoside reverse transcriptase inhibitor nnrti longacte regiman gepotidacin type topoisomerase inhibitor bacterial infection hbv antisense oligonucleotide hepatitis hbv lica antisense oligonucleotide hepatitis cci viral replication inhibitor nucleoside viral exacerbation copd hiv maturation inhibitor hiv infection leucyl trna synthetase inhibitor tuberculosis respiratory mepolizumab interleukin monoclonal antibody eosinophilic granulomatosis polyangiitis approve adec trelegy fluticasone glucocorticoid agonist longacting beta chronic obstructive pulmonary disease copd approve anov asep furoate vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin monoclonal antibody copd submit snov fluticasone furoate glucocorticoid agonist longacte beta asthma iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin monoclonal antibody hypereosinophilic syndrome iii mepolizumab interleukin monoclonal antibody nasal polyposis iii nemiralisib phosphatidylinositol kinase delta pik inhibitor copd acute chronic danirixin chemokine cxc motif receptor cxcr copd antagonist oral recombinant human angiotensin convert acute lung injury enzyme rhace tumour necrosis factor receptor tnfr acute lung injury domain antibody tolllike receptor tlr agonist asthma nemiralisib phosphatidylinositol kinase delta pik inhibitor activate pik delta syndrome interleukin ilr monoclonal antibody severe asthma recombinant human angiotensin convert pulmonary arterial hypertension enzyme rhace gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continued achieve regulatory review milestone compound type indication phase maa ndabla respiratory continue alpha beta integrin antagonist idiopathic pulmonary fibrosis nemiralisib phosphatidylinositol kinase delta bronchiectasis pik inhibitor phosphatidylinositol kinase delta copd pik inhibitor interleukin longacte asthma monoclonal antibody oncology nyeso autologous engineer sarcoma multiple myeloma nonsmall cell lung cancer tcrt cell engineer tcr melanoma ovarian cancer bcell maturation antigen antibody multiple myeloma drug conjugate bet family bromodomain inhibitor solid tumour haematological malignancy agonist monoclonal antibody solid tumour haematological malignancy protein arginine methyltransferase cancer prmt inhibitor induce tcell costimulator icos cancer agonist antibody tolllike receptor tlr agonist cancer phosphatidylinositol kinase pik beta castration resistant prostate cancer inhibitor immunoinflammation benlysta lymphocyte stimulator monoclonal systemic lupus erythematosus approve nov jul antibody granulocyte macrophage colony osteoarthritis stimulate factor monoclonal antibody granulocyte macrophage colony rheumatoid arthritis stimulate factor monoclonal antibody benlysta rituxan lymphocyte stimulator monoclonal sjogren syndrome antibody cluster differentiation monoclonal antibody receptorinteracte protein rip psoriasis kinase inhibitor receptorinteracting protein rip rheumatoid arthritis kinase inhibitor oncostatin osm monoclonal antibodysystemic sclerosis receptorinteracting protein rip ulcerative colitis kinase inhibitor lymphocyte activation gene lag autoimmune disease protein monoclonal antibody receptorinteracte protein rip inflammatory bowel disease kinase inhibitor kynurenine monooxygenase inhibitor acute pancreatitis future pipeline optionality daprodustat prolyl hydroxylase inhibitor oral anaemia associated chronic renal disease iii dezamizumab serum amyloid component sap amyloidosis monoclonal antibody sap depleter cphpc oxytocin inhale oxytocin postpartum hemorrhage tapinarof nonsteroidal antiinflammatory topical atopic dermatitis tapinarof nonsteroidal antiinflammatory topical psoriasis selective androgen receptor modulator muscle waste follow strategic review asset rare disease unit long include pipeline table future ownership asset consideration gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound type indication phase maa ndabla vaccine shingrix recombinant herpe zoster prophylaxis approve nov oct zoster vaccine submit rotavirus live attenuate pcv rotavirus prophylaxis iii porcine circovirus free mmr live attenuate measle mump rubella prophylaxis iii ebola recombinant viral vector ebola haemorrhagic fever prophylaxis pneumoniae recombinant conjugate streptococcus pneumoniae disease prophylaxis generation copd recombinant reduction frequency moderate severe acute exacerbation copd patient target nontypeable haemophilus influenzae moraxella catarrhali hepatitis heterologous recombinant viral vector hepatitis virus prophylaxis prevention establishment chronic infection malaria generation recombinant malaria prophylaxis plasmodium falciparum man abcwy recombinant conjugate meningococcal abcw disease prophylaxis adolescent shigella conjugate outer membrane shigella diarrhea prophylaxis tuberculosis recombinant tuberculosis prophylaxis rsv replicationdefective recombinant respiratory syncytial virus prophylaxis paediatric viral vector population flu universal universal inactivated influenza vaccine flu infection prophylaxis broad protection iii multiple season hiv recombinant protein hiv infection prophylaxis brand name appear italic trade mark own license gsk group company exception rituxan own biogen inc gsk annual report pipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand respiratory anoro ellipta umeclidinium bromide copd respimat stiolto vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort asmanex alvesco nce device formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expire expire diskus device diskus device expire hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat eklira genuair nce nce seebri breezhaler device device formulation formulation nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair fasenra expire relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire expire fluticasone propionate flutiform dulera diskus device diskus device expire hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil striverdi expire expired respimat onbrez disku device diskus device breezhaler hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate nce nce umeclidinium bromide device device formulation formulation ventolin hfa albuterol sulphate asthmacopd generic company expire hfadevice hfadevice antiviral valtrex valaciclovir genital herpe coldsore shingle famvir expire expire central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire seroxatpaxil paroxetine depression anxiety effexor cymbalta expire expire disorder lexapro cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax expire expire finasteride coreg carvedilol phosphate mildtosevere heart failure toprol hypertension leave ventricular formulation dysfunction post antibacterials augmentin amoxicillinclavulanate common bacterial generic product expire potassium infection note financial statement legal proceeding generic competition commence include supplementary protection certificate grant multiple country patent term extension grant data exclusivity expire gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand rare disease volibris ambrisentan pulmonary hypertension tracleer revatio immunoinflammation benlysta benlysta belimumab systemic lupus erythematosus hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla expire descovy genvoya combination odefsey juluca dolutegravir rilpivitine hivaids genvoya odefsey descovy atripla nce nce lexivatelzir fosamprenavir hivaids prezista kaletra expire reyataz nce selzentrycelsentri maraviroc hivaids isentress intelence prezista nce nce tivicay dolutegravir hivaid isentress prezista reyataz kaletra nce nce biktarvy triumeq dolutegravir lamivudine hivaids atripla descovy abacavir odefsey genvoya nce nce biktarvy vaccine product competition intellectual property major patent expiry date product compound indication competitor brand bexsero meningococcal groupb meningitis group prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expire expire pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired polio hepatitis haemophilus tetanus pertussis polio pentaxim pentavac influenzae type hepatitis haemophilus hexaxim hexyon influenzae type vaxeli cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtype vaxigrip qiv subtype fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigen virus subtype fluzone influvac subtype aggripal fluad intenza flumist menveo meningococcal group meningitis group nimenrix menactra conjugate vaccine prophylaxis prepandrix derive split inactivated pandemic influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuate measle mump measle mump rubella mmr mmrvaxpro expire varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar polysaccharide disease pneumonia acute otitis medium shingrix zoster vaccine herpe zoster zostavax recombinant adjuvante shingle note financial statement legal proceeding refer priorix priorix tetra patent varilrix expire generic competition commence market relate compoundsindication measle mump rubella vaccineprophylaxis include supplementary protection certificate grant relate compound varicella vaccine multiple country patent term extension grant gsk annual report pipeline product competition continue consumer healthcare product competition brand product application market competition wellness respiratory otrivin nasal spray nasal decongestant germany poland afrin merck russia sweden ukraine nasivin merck theraflu tablet syrup cold flu relief russia poland ukraine tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flonase nasal spray allergy relief claritin bayer nasacort sanofi flixonase piriton nasal spray tablet allergy relief ireland benadryl johnson johnson nicorette lozenge gum transdermal treatment nicotine withdrawal global nicorette johnson johnson nicoderm patch aid smoking reduction niquitin perrigo nicotinell cessation australia pain relief panadol tablet caplet infant paracetamolbase treatment global advil pfizer panadol cold syrup drop headache joint pain fever aspirin bayer flu cold symptom tylenol johnson johnson voltaren topical gel nonsteroidal diclofenac base global advil pfizer antiinflammatory aspirin bayer tylenol johnson johnson eno effervescent immediate relief antacid global estomazil hypermarca gelusil pfizer tum chewable tablet immediate relief antacid alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi oral health sensodyne toothpaste toothbrushe relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protect colgatepalmolive acid erosion elmex colgatepalmolive oral procter gamble parodontax toothpaste medicate help prevent bleed gum germany ireland colgate total gum health corsodyl mouthwash gel spray treat prevent gingivitis italy united kingdom colgatepalmolive yunnan baiyao state enterprise china polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser denture clean denture procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavity global colgate colgatepalmolive mouthwash maintain healthy tooth gum crest procter gamble fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicate patch onset cold sore carmex carma labs blistex blistex incorporate retail label nutrition horlick malt drink food nutritional indian subcontinent bournvita mondelez beverages food united kingdom ireland complan heinz gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie principal risk discuss risk uncertainty similarly global business expose litigation government relevant business financial condition result operation investigation include limited product liability litigation affect performance ability achieve objective patent antitrust litigation sale marketing litigation risk believe cause actual litigation government investigation include related provision result differ materially expect historical result unfavourable outcome increase related cost insurance premium materially adversely adapt comply broad range law affect financial result regulation requirement apply research development manufacturing testing approval distribution sale marketing detail status uncertainty involve pharmaceutical vaccine consumer healthcare product significant unresolved dispute potential litigation set affect cost product development time note legal proceeding page require reach market likelihood regulation require discussion mitigating activity successfully company take address principal risk uncertainty rule regulation change governmental summary activity group take manage interpretation rule regulation evolve nature principal risk accompany description principal particular risk change change certain regulatory regime risk principal risk uncertainty list substantial change failure comply order significance applicable law regulation materially adversely affect financial result patient safety risk definition individual medical officer pharmaceutical vaccine failure appropriately collect review follow report adverse consumer healthcare business substantial safety event potential source act relevant finding pharmacovigilance organisation track adverse issue timely manner report product course clinical study group product approve marketing extensive risk impact postmarkete surveillance signal detection system information risk impact potential compromise ability possible effect product receive source conduct robust safety signal detection interpretation include unsolicited report healthcare professional hcp ensure appropriate decision take respect risk patient regulatory authority medical scientific literature benefit profile product include completeness traditional medium social medium policy employee accuracy product label pursuit additional study require report immediately issue relate safety analysis appropriate lead potential harm quality product country manager responsible patient reputational damage product liability claim monitor exception tracking training help assure litigation governmental investigation regulatory action fine collection safety information report information penalty loss product authorisation relevant central safety department accordance policy context legal requirement preclinical clinical trial conduct development information change riskbenefit profile investigational pharmaceutical vaccine consumer healthcare product result certain action characterise communicate product determine safety efficacy product use minimise risk propose action discuss human notwithstanding effort determine regulatory authority include modify prescribing safety product appropriate preclinical clinical information communication physicians healthcare trial unanticipate effect evident provider restriction product prescribingavailability help product widely introduce marketplace question assure safe use carry clinical trial safety product raise certain case appropriate stop clinical trial ongoing safety surveillance postmarkete study withdraw medicine market governmental agency party analyse publicly available clinical trial result global safety board gsb comprise senior physician representative support function integral component group currently defendant number product liability system gsb include subsidiary board dedicate lawsuit include class action involve significant claim consumer healthcare product vaccine review safety damage relate product litigation particularly investigational market product authority inherently unpredictable class action seek sweep stop clinical trial continue conduct trial ethically person product increase potential liability scientifically justify light information emerge claim pain suffer punitive damage frequently start trial assert product liability action allow represent potentially openende exposure materially addition medical governance framework describe adversely affect group financial result use mechanism foster early evaluation mitigation resolution dispute arise potential mitigating activity claim occur goal programme chief medical officer cmo medical officer create culture early identification evaluation risk pharmaceutical responsible medical governance claim actual potential order minimise liability litigation global policy policy safeguard human subject clinical trial patient product paramount importance cmo authoritative role evaluate addressing matter human safety gsk annual report principal risk uncertaintie continue product quality risk definition industry standard incorporate quality concept failure comply current good manufacturing practice product lifecycle gsk pqs augment cgmp inadequate control governance quality consolidation numerous regulatory requirement define supply chain cover supplier standard manufacturing market world assure meet external distribution product expectation product quality market supply pqs routinely update ensure keep pace evolve risk impact external regulatory environment new scientific failure ensure product quality far reach understanding product process drive implication term patient consumer safety result continually improve operational deployment pqs product launch delay supply interruption product recall make policy procedure simple understand potential damage reputation implement adopt innovative tool result regulatory legal financial consequence userfriendly experience context extensive global network quality compliance professional patient consumer hcps trust quality product align business unit provide oversight assist product quality influence factor include delivery quality performance operational compliance product process understand consistency manufacturing site level senior management level management oversight component compliance gmp accuracy labelling reliability activity accomplish hierarchy quality external supply chain embodiment overarching council independent chief product quality officer quality culture internal external environment continue global product quality office provide corporate evolve new product new legislation introduce executive team risk oversight compliance council critically address impact brexit supply integrate assessment regulate quality gxp performance chain management quality oversight define key performance indicator cover manufacture practice develop deploy appropriate contingency clinical practice pharmacovigilance practice regulatory practice plan avoid interruption supply patient drug safety assessment animal welfare mitigating activity implement riskbase approach assess develop implement single pharmaceutical manage party supplier provide material quality system pqs define quality standard system finish product contract manufacturer make product business associate pharmaceutical vaccine expect comply gsk standard regularly consumer healthcare product clinical trial material audit provide assurance standard meet system broad scope applicable product lifecycle mature commercial supply staff member regularly train ensure cgmp standard behaviour base value follow single external quality standard system govern additionally advocacy communication programme routinely detail global regulatory expectation quality medicinal deploy ensure consistent message convey product requirement complex fragmented organisation originate change regulation national regional boundary consequently adopt learning inspection regulatory submission internationally recognise principle ich continue emphasis value quality performance metric pharmaceutical quality system framework basis facilitate improvement foster culture right time gsk pqs financial control report risk definition change substance application govern tax failure comply current tax law incur significant law failure comply tax law significant loss loss treasury activity failure report accurate financial treasury activity materially adversely affect information compliance accounting standard applicable financial result legislation context risk impact group require law jurisdiction disclose noncompliance exist new financial report publicly financial result event materially affect disclosure requirement change recognition income financial result group regulator routinely review expense expose litigation regulatory action financial statement list company compliance new materially adversely affect financial result change revise exist accounting regulatory requirement tax law application respect matter group believe complie appropriate regulatory transfer pricing foreign dividend control company tax requirement concern financial statement disclosure credit taxation intellectual property restriction tax relief material information include transaction relate business allow interest debt funding impact effective restructure acquisition divestiture tax rate significant loss arise inconsistent application subject investigation potential noncompliance treasury policy transactional settlement error counterparty accounting disclosure requirement lead default restatement previously report result significant penalty gsk annual report strategic report governance remuneration financial statement investor information financial control report continue treasury group deal high value transaction foreign share accountability financial result exchange cash management transaction daily basis business financial result review approve regional transaction involve market volatility counterparty risk management review financial controller group effective tax rate reflect rate tax jurisdiction chief financial officer cfo allow financial controller group operate high low cfo assess evolution business time rate take account regime encourage innovation evaluate performance plan significant judgment review investment science provide tax incentive confirm senior management business reorganisation change affect group tax rate addition worldwide newly acquire activity integrate risk assessment nature operation mean intellectual property appropriate control review apply manufacturing operation centre number key disclosure committee reporting board review location consequence crossborder supply group quarterly result annual report determine route necessary ensure supply medicine numerous year consultation legal advisor end market complex result conflict claim tax necessary disclose publicly information group authority profit tax individual country tax stock exchange announcement treasury management legislation complex differ country group meet regular basis seek ensure liquidity operate tax risk arise difference interest rate counterparty foreign currency transaction foreign interpretation legislation tax charge include currency translation risk manage line conservative financial statement good estimate tax liability pende audits approach detail associate risk strategy policy tax authority adopt board expect continue focus tax reform counterparty exposure subject define limit approve future year drive organisation economic cooperation board credit rating individual counterpartie oversight development base erosion profit shift project treasury role manage counterparty risk line agree european commission initiative include use fiscal state aid policy perform corporate compliance officer investigation domestic initiative world operate independently treasury detail mitigation result significant change establish tax principle treasury risk find page note increase tax authority dispute regardless financial instrument relate disclosure tax risk manage merit outcome costly divert management attention robust internal policy process training compliance adversely impact reputation relationship key programme ensure alignment business stakeholder meet tax obligation seek maintain open positive mitigating activity relationship government tax authority worldwide maintain control environment design identify material welcome constructive debate taxation policy monitor error financial reporting disclosure design operate government debate tax policy key jurisdiction deal effectiveness key financial reporting control regularly test proactively potential future change tax law engage management independent business monitoring advisor legal counsel confirm implication provide assurance control key financial business tax legislation recently enact tax cut report disclosure process operate effectively job act appropriate active provide relevant minimum standard control set implement business input tax policy maker significant decision finance personnel irrespective size geographical location submit consideration tax governance board require apply ensure monitored global finance meet quarterly comprise senior personnel risk management control centre excellence provide extra gsk finance division support large group organisation undergo transformation tax affair manage global basis coordinate system deployment significant business transformation team tax professional lead global head tax work add operational resource ensure process closely business suitably qualified role control maintain business transformation upgrade perform support training need order financial system process additional risk mitigation continue able provide date technical advice submit introduce amend programme timeline tax return accord statutory time limit engage tax system upgrade authority seek ensure tax affair current enter uptodate late development financial arrangement continuous audit programme advance reporting requirement work external auditor price agreement appropriate agreement provide legal advisor longterm certainty tax authority tax treatment business exceptional case matter settle agreement tax authority resolve dispute formal appeal proceeding gsk annual report principal risk uncertainty continue antibribery corruption risk definition mitigate activity failure gsk employee consultant party comply code conduct value behaviour commitment antibribery corruption abac principle standard zero tolerance integral mitigate risk light applicable legislation complexity geographic breadth risk constantly evolve oversight activity datum reinforce workforce clear risk impact expectation acceptable behaviour maintain regular failure mitigate risk expose group associate communications centre local market person governmental investigation regulatory action civil criminal liability compromise group ability supply enterprisewide abac programme design ensure product certain government contract addition legal compliance abac policy mitigate risk bribery penalty failure prevent bribery comply abac corruption build value business standard legislation regulation substantial implication form comprehensive practical approach compliance reputation company credibility senior leader flexible evolve nature business erosion investor confidence governance risk abac programme build good class principle management subject ongoing review development provide context basis seek manage risk expose bribery corruption risk global example programme comprise toplevel business operation market government structure commitment board director leadership global rule law develop bear risk assessment enable target intervention compliance bribery corruption risk exposure addition global nature monitoring activity programme underpin global business healthcare sector nature maintain abac policy write standard address commercial relationship government body highly competitive practice rise abac risk ongoing training subject regulation increase instance communication addition programme mandate enhance expose activity interaction bribery corruption risk control interaction government official business development transaction provide mandatory periodic group subject number abac inquiry abac training staff relevant party accordance reach resolution authority role responsibility risk face abac inquiry follow subject selfmonitoring arrangement september government investigation programme governance provide abac governance china business operation ongoing board include representation key functional area investigation discuss note legal business unit dedicate abac team responsible proceeding implementation evolution programme response development internal external environment complement independent oversight assurance undertake audit assurance independent business monitoring team continually benchmark abac programme large multinational company use external expertise drive improvement programme gsk annual report strategic report governance remuneration financial statement investor information commercial practice risk definition mitigate activity failure engage commercial activity consistent strategic objective design ensure achieve letter spirit legal industry group requirement relate mission help people feel well live long marketing communication medicine continue strive new product launch competitive associate therapeutic area appropriate interaction hcp resource effectively strive healthy proportion patient legitimate transparent transfer value group sale ratio attributable new product innovation sale risk impact failure manage risk relate commercial practice innovation help defray effect example downward materially adversely affect ability grow diversified global price pressure major market decline emerge market growth business deliver product value patient negative foreign exchange impact establish new product consumer failure comply applicable law rule price balance expectation patient consumer regulation result governmental investigation regulatory action hcp payer shareholder community enable legal proceeding bring group governmental maintain strong global business remain relevant need private plaintiff result government sanction patient consumer value behaviour provide guide criminal andor financial penalty failure provide accurate lead decision constantly strive complete information relate product result incomplete right thing deliver quality product ensure supply awareness riskbenefit profile product possibly sustain meet customer need demand requirement suboptimal treatment patient consumer seek ensure action reflect value behaviour mission company practice find misaligned value result reputational harm dilute trust establish take action enhance improve standard external stakeholder procedure promotional interaction include increase focus digital marketing base value transparency respect context integrity patient focus policy standard operate global basis industry highly govern promotional activity undertake behalf competitive highly regulate competitor activity conduct worldwide conform high significant product innovation technical advance ethical regulatory industry standard local standard intensify price competition light competitive environment differ global standard stringent apply continued development commercially viable new product harmonise policy procedure guide development additional use exist product reflect country commercial practice process clarify insight help ensure product address need applicable standard operation market patientsconsumer hcp payer critical achieve operate business unit adopt internal control strategic objective framework support assessment management risk pharmaceutical vaccine consumer company commercial practice activity appropriate monitoring face downward price pressure major market decline emerge programme oversight business unit risk market growth negative foreign exchange impact management compliance board country executive develop new pharmaceutical vaccine consumer healthcare board manage risk incountry business activity product costly lengthy uncertain process product past fall candidate fail stage include significant economic regulatory industry standard sought improve human resource invest competitor framework culture compliance process product pricing strategy failure develop promotional material activity review commercially successful product develop additional use approve accord policy standard conduct exist product materially adversely affect ability accordance local law regulation seek ensure achieve strategic objective material activity fairly represent product service commit ethical responsible commercialisation group necessary discipline product support mission improve quality include termination employee engage misconduct human life enable people feel well live long broaden ability claw remuneration accomplish mission engage healthcare community senior management event misconduct way provide important information medicine evolve commercial operating model embed promotion approve product seeks ensure hcp globally industry lead change compensation model sale access information need patient consumer professional manager interact hcp access information product need change eliminate reward base individual sale market product prescribe recommend manner share prescription product individual territory favour provide maximum healthcare benefit patient consumer reward base quality individual interaction commit communicate information relate hcp allow fair market value payment approve product responsible legal ethical manner gsk expert researcher practitioner speak science product disease clinical practice limited number gsk sponsor medicalled meeting gsk annual report principal risk uncertainty continue research practice risk definition scientific engagement define interaction failure adequately conduct ethical sound preclinical exchange information gsk external community clinical research addition failure engage scientific activity advance scientific medical understanding include consistent letter spirit law industry appropriate development use product essential group requirement failure secure adequate patent scientific discourse nonpromotional engagement protection gsk product external stakeholder group vital gsk mission necessary scientific medical advance activitie essential risk impact present legal regulatory reputational risk share data impact risk include harm human subject reputational invite medium coverage payment hcp perceive damage failure obtain necessary regulatory approval promotional intent product governmental investigation legal proceeding bring group governmental private plaintiff product wide variety biological material gsk discovery liability suit claim damage loss revenue research development phase convention inadequate patent protection inability supply gsk product biological diversity cbd nagoya protocol regulatory action fine penalty loss product international community establish global framework authorisation consequence materially regulate access use genetic resource nonhuman adversely affect financial result cause loss trust origin support principle access benefit customer patient share genetic resource outline cbd nagoya protocol recognise importance appropriate effective context proportionate implementation measure national regional research relate animal raise ethical concern level attempt address proactively animal study remain vital research case method addition loss patent protection market gsk investigate effect potential new medicine living product develop include reduce body test human generally mandate availability scope patent right compulsory licensing regulator ethically imperative animal research provide government force manufacturer license patent critical information cause disease specific product competitor materially adversely develop nonetheless continually seek way affect financial result market absence adequate minimise use animal research whilst comply patent datum exclusivity protection lead regulatory requirement example competition manufacturer generic pharmaceutical product limit opportunity rely market clinical trial healthy volunteer patient assess future sale growth product materially demonstrate investigational product efficacy safety adversely impact financial result follow expiration certain evaluate product approve intellectual property right generic manufacturer lawfully market work human biological sample produce generic version product generic drug sample fundamental discovery development safety manufacturer exhibit readiness market generic monitoring product version important product prior integrity datum essential success stage expiration patent introduction generic product typically research datum lifecycle design generation recording lead rapid dramatic loss sale reduce management analysis report storage retrieval revenue margin proprietary product research datum govern legislation regulatory common patent infringement action requirement research datum support document core prompt claim antitrust law violate component stage pipeline progression decision prosecution patent litigation involve defence make form content regulatory submission poor datum patent integrity compromise research effort negatively impact company reputation innate complexity interdependency require regulatory filing particularly give global research development footprint continually change increasingly stringent submission requirement continue increase complexity worldwide product registration gsk annual report strategic report governance remuneration financial statement investor information research practice continue mitigate activity establish access benefit sharing centre establish office animal welfare ethic excellence oversee applicable requirement enforcement strategy oawes lead chief animal welfare ethic measure acquisition use genetic material non strategy ensure humane responsible care animal human origin scope nagoya protocol increase knowledge application nonanimal maintain control prepublication procedure guard alternative oawes provide framework animal welfare public disclosure advance filing patent application governance promote application replacement refinement addition loss patent protection occur lack reduction animal research conduct quality assessment datum integrity prepare patent application datum information develop deploy strategy animal model reproducibility legal expert collaborate support review process translatability new patent application chief medical officer oversee follow enterprise medical research practice risk align new enterprise governance board framework seeks ensure strengthen governance human subject research board place provide business pharmaceutical vaccine consumer oversight management clinical trial sponsor healthcare leadership chief research practice support ensure conform ethical medical officer management risk take pragmatic approach scientific standard information sharing streamline risk identification escalation ensure ownership stay business unit level allow datum disclosure board provide oversight disclosure proportional risk treatment sponsor support clinical trial information available clinical study include summary result positive negative company publish clinical study report form basis submission regulatory agency publicly post clinical study report addition study result summary detail appropriately protect patientlevel datum approximately clinical study request access clinicalstudydatarequestcom specific accountability authorisation oversee scientific engagement promotional practice board board responsible oversight applicable policy seek ensure high level integrity continuous development global human biological sample management hbsm governance framework place oversee ethical lawful acquisition management human biological sample global hbsm network champion hbsm activity provide experienced group support internal sample custodian good practice remain important priority enhance datum integrity control datum integrity committee place provide oversight datum integrity quality assurance team conduct assessment provide independent business monitor internal control activity chief regulatory officer chair regulatory governance board serve global regulatory risk management compliance board promote compliance regulatory requirement procedure oversee groupwide write standard cross business regulatory process gsk annual report principal risk uncertainty continue party oversight risk risk definition mitigate activity failure maintain adequate governance oversight business unit leadership team retain ultimate accountability party relationship failure party meet manage party interaction risk work contractual regulatory confidentiality obligation party employee expect manage external interaction commitment responsibly expectation embed risk impact value code conduct responsibility activity failure adequately manage party relationship result carry behalf perform safely compliance business disruption exposure risk range suboptimal applicable law value standard code conduct contractual term condition severe business legal sanction andor significant reputational damage guide enforce global principle interaction consequence materially adversely affect business party place policy framework applicable buying operation financial result good service manage external spend pay work party policy framework apply context employee complementary worker worldwide framework party critical business delivery integral complement technical local standard design ensure solution meeting business objective rely alignment nature party interaction good party include supplier advisor distributor individual manufacturing practice adherence local law regulation contractor license pharmaceutical biotechnology independent business monitor key financial operational collaboration partner discovery manufacture marketing control place supplement periodic check product support important business process company independent audit assurance function business relationship present material risk example continuous monitoring performance party enhance share critical sensitive information marketing plan clinical party oversight programme manage datum employee datum specific party conduct global ethic compliance organisation programme take relevant outsourced business activity inadequate protection enterprisewide view party relate risk strengthen misuse information party significant risk assessment contractual term diligence effort business impact similarly use distributor agent range party improve overall management party risk activity promotion tender inherent risk lifecycle party engagement inappropriate promotion corruption insufficient internal compliance control distributor affect reputation risk increase complexity work large number party diverse geographical spread environment health safety sustainability risk definition mitigate activity failure manage environment health safety sustainability corporate executive team cet responsible ehss ehss risks line objective policy governance global policy policy cet seek relevant law regulation ensure control framework place manage risk impact legal compliance issue relate ehss risk impact assign responsibility senior manager provide failure manage ehss risk lead significant harm maintain control individual manager seek ensure people environment community operate fine ehss control framework effective implement failure meet stakeholder expectation regulatory requirement respective business area fully compliant litigation regulatory action damage group reputation applicable law regulation adequately resource maintain materially adversely affect financial result communicate monitor additionally employee context personally responsible ensure applicable local standard subject health safety environmental law operating procedure follow expect jurisdiction law impose duty protect people responsibility ehss matter environment community operate riskbase proactive approach articulate refresh potential obligation remediate contaminate site global ehss standard support ehss policy identify potentially responsible party objective discover develop manufacture supply sell comprehensive environmental response compensation product harm people environment addition liability act number site remediation cost relate design provision safe facility plant equipment use ownership site failure manage operate rigorous procedure help eliminate hazard environmental risk properly result litigation regulatory practicable protect employee health wellbee action additional remedial cost materially continue effort improve environmental sustainability adversely affect financial result note financial reduce value chain carbon intensity pack water statement legal proceeding discussion consumption waste generation actively manage environmental relate proceeding involve environmental remediation obligation seek ensure practice routinely accrue amount relate liability matter environmentally sustainable compliant ehss performance result share externally year responsible business supplement gsk annual report strategic report governance remuneration financial statement investor information information protection risk definition aim apply industry good practice information risk gsk business activity information disclose security policy process technology invest strategy authorise information system fail commensurate change nature security threat available corrupt typically cybersecurity threat landscape include suitable level cyberrisk insurance accident malicious insider action contributory cover future cause cyber threat grow evolving include risk failure collect secure use increasingly involve highlyresource threat actor nation personal information accordance datum privacy law state organise criminal combine size complexity system supply chain partner risk impact include outsourced operation mean system failure adequately protect critical sensitive system information expect continue information result loss commercial strategic advantage subject cyberattack type materially affect ongoing business operation scientific research clinical trial manufacturing supply enhance approach datum privacy compliance chain activity failure comply datum privacy law lead comply new general data protection regulation adverse impact individual example financial loss distress gdpr deploying enterprisewide privacy programme prejudice case damage reputation litigation launch schedule deployment business disruption include regulatory sanction occur involve great standardisation additional expert materially adversely affect financial result resource support business new standard control context enable well address datum privacy outset rely critical sensitive system datum corporate business process change prepare strategic plan intellectual property manufacturing system introduction gdpr trade secret potential computer system employee require complete training privacy information expose misuse unauthorised disclosure appropriate handling maintain personal information believe cyber security incident programme governance provide privacy governance experience date result significant disruption board include representation key functional area operation significant adverse effect dedicated privacy team responsible result operation party threat implementation evolution programme response evolve provide assurance significant effort development internal external environment protect monitor system information successful prevent compromise disruption future part business process personal information use information critical operation innovation include development sale product management employee new evolve law regulation european union general data protection regulation gdpr likely bring increase scrutiny datum management mitigating activity global information protection policy accompany information technology standard process support dedicated team programme activity information protection function provide strategy direction oversight include active monitoring cyber security enhance global information security capability ongoing programme investment fifth year assess change information protection risk environment briefing government agency subscription commercial threat intelligence service knowledge share pharmaceutical business crossindustry body change regularly review executive team board suitable adjustment agree gsk annual report principal risk uncertainty continue supply continuity crisis management risk definition mitigate activity failure deliver continuous supply compliant finished product supply chain model design ensure supply quality inability respond effectively crisis incident timely manner security product globally far possible closely recover sustain critical operation include key supply chain monitor supply chain governance committee inventory status delivery product aim ensure risk impact customer pharmaceutical vaccine consumer recognise failure supply product adversely healthcare product need improved link commercial impact consumer patient rely material forecasting manufacturing possible core interruption supply exclusion healthcare programme commercial cycle time reduce risk associate expose litigation regulatory action financial demand fluctuation impact ability supply penalty adversely affect group financial result cost writeoff product exceed expiry date group international operation partner node supply chain periodically review ensure adequate expose workforce facility operation information safety stock balance work capital endtoend technology potential disruption natural event storm supply chain particular attention place mitigate supply risk earthquake manmade event civil unrest terrorism global associate medically critical highrevenue product emergencies ebola outbreak flu pandemic important robust crisis management recovery plan place routinely monitor compliance manufacture external manage event supplier identify manage risk supply base practical minimise dependence single source supply context critical item alternative source arrangement supply chain operation subject review approval possible inventory strategy aim protect supply chain regulatory agency effectively provide licence unanticipated disruption operate failure manufacture distribution facility supplier key service material lead litigation continue implement anticounterfeit system product regulatory action product recall seizure interruption serialisation accordance emerge supply chain requirement supply delay approval new product suspension world manufacturing operation pende resolution manufacture corporate policy require business unit functional area logistic issue head ensure effective crisis management business continuity rely material service provide party supplier plan place include authorise response recovery product include active pharmaceutical ingredient strategy key area responsibility clear communication api antigen intermediate commodity component route business disruption occur manufacture packaging pharmaceutical vaccine corporate security support business coordinating crisis consumer healthcare product party service management business continuity training facilitate simulation procure service provide contract manufacturing exercise assess preparedness recovery capability clinical research organisation support development key provide assurance oversight central repository plan product important ensure continuous operation support critical business process business unit business governance board perform risk oversight monitor undertake risk mitigation recognise certain include identify new emerge threat event result delay service interruption coordinate approach evaluate manage implication use effective crisis management business continuity business arise brexit approach brexit set planning provide health safety people minimise impact maintain functional operation follow activity help ensure appropriate level readiness natural manmade disaster public health emergency response capability maintained develop maintain partnership external body like business continuity institute international strategy disaster risk reduction help improve business continuity initiative disasterprone area support development community resilience disaster gsk annual report strategic report governance remuneration financial statement investor information shareholder information share capital control detail issue share capital number share hold share buyback programme treasury december find note board authorise issue allot ordinary share financial statement share capital share premium account article company article association power article authority company purchase ordinary share list london stock exchange share subject shareholder authority quote new york stock exchange nyse seek annual basis annual general meeting agm form american depositary share ad ad share purchase company cancel hold represent ordinary share detail list debt treasury share satisfy share option grant list refer note financial statement group employee share plan net debt programme cover purchase share cancellation holder ordinary share ad entitle receive hold treasury share accordance authority dividend declare company annual report attend renew shareholder agm speak general meeting company appoint proxy company authorise purchase maximum exercise vote right million share detail share purchase cancel restriction transfer limitation hold hold treasury share subsequently transfer ordinary share ad requirement obtain approval treasury satisfy awards group employee share prior transfer ordinary share ad carry special plan disclose note financial statement share right regard control company capital share premium account restriction vote right major shareholder determine specific share repurchase level company voting right share shareholder consider development free cash flow year give known arrangement financial right hold impact sustain strength sterle free cash flow person holder share know company suspend share repurchase programme agreement restriction share transfer voting right share purchase financial year end share acquire group employee share plan rank equally share issue special right company confirm currently intend trustee employee share ownership plan trust market purchase company review waive right dividend share hold trust potential future share buyback line exchange control limitation affect security holder usual annual cycle subject return rating criterion certain economic sanction force market capitalisation time time currently applicable law decree market capitalisation base share issue exclude regulation force restrict import export treasury share gsk december billion capital affect remittance dividend payment date gsk sixth large company market holder company share nonresident capitalisation ftse index similarly certain economic sanction force time time limitation relate share price nonresident english law company article association right holder vote january respect company share december interest voting right decreaseincrease state far aware high year person significant direct indirect holding company low year information provide company pursuant financial conduct authoritys fca disclosure guidance transparency table set middle market closing price rule dtrs publish regulatory information service company share price decrease compare company website wwwgskcom increase ftse index year company receive notification accordance share price march fcas dtrs follow notifiable interest voting right company issue share capital december march percentage percentage issue issue share capital shares capital blackrock inc percentage ordinary share issue exclude treasury share acquire disposed interest share period review exception transfer treasury satisfy awards group employee share plan share price ad price gsk annual report shareholder information continue share capital control continue nature trading market follow table set period indicate high low middle market closing quotation pence share london stock exchange high low closing price dollar ad nyse ordinary share ad pence share dollar share high low high low march february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december year end december year end december march analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bny mellon depositary company ad list nyse ordinary share represent company ad programme manage depositary register bny nominees limited march bny nominees limit hold ordinary share represent issue share capital exclude treasury share date march number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holder gsk annual report strategic report governance remuneration financial statement investor information dividend company pay dividend quarterly continue return cash shareholder dividend policy dividend remain essential component total shareholder return gsk recognise importance dividend shareholder company aim distribute regular dividend payment determine primarily reference free cash flow generate business funding investment necessary support group future growth board intend maintain dividend current level share subject material change external environment performance expectation time free cash flow strengthen intends build free cash flow cover annual dividend target range return dividend growth detail dividend declare amount payment date give note financial statement dividend dividend share dividend calendar table set dividend share ad exdividend year dividend ad translate dollar quarter date record date payment date applicable exchange rate february february april july year dividend pence august august october november november january special interim ordinary dividend receivable ad holder calculate base exchange rate april annual fee ad ad quarter charge depository cumulative dividend receivable ad holder special dividend relate return net cash proceed novartis transaction complete march pay fourth quarter ordinary dividend financial calendar result announcement event date result announcement issue london stock exchange quarter result announcement april available news service send annual general meeting securities exchange commission nyse issue quarter result announcement july media available website quarter result announcement october financial report preliminaryquarter result announcement february company publish annual report available annual report publication februarymarch website date publication shareholder annual report distribution march elect receive annual report contact registrar alternatively shareholder elect receive notification information company include share price available email publication financial report register website wwwgskcom information available wwwshareviewcouk website constitute annual report copy previous financial report available website print copy obtain registrar contact detail gsk annual report shareholder information continue annual general meeting time ad holder wish attend meet contact bny queen elizabeth centre broad sanctuary westminster mellon depositary request proxy appointment london swp enable attend vote business transact ad holder instruct bny mellon way agm company principal forum communication share represent ad vote complete private shareholder addition formal business return voting card provide depositary presentation ceo performance group future development opportunity document display question ask board chairman board articles association company director service committee question relate committee contract applicable letter appointment director company subsidiary investor hold share nominee service arrange letter relate severance term pension arrangement nominee service appoint proxy respect available inspection company register office shareholding order attend vote meeting available inspection agm tax information shareholder summary certain tax federal income tax taxation capital gain consequence holder share ad citizen resident shareholder liable tax gain set complete analysis disposal share ad possible tax consequence purchase ownership sale disposal individual tax year onwards security intend general guide holder taxable capital gain accrue disposal share ad advise consult adviser respect tax tax basic rate taxpayer allowable consequence purchase ownership sale share deduction individual taxable income year exceed ad consequence state local tax law basic rate income tax limit note follow use implication current ukus tax convention exception available individual taxpayer annual holder ad generally treat owner exempt underlie share purpose current usuk double corporation taxpayer entitle indexation allowance taxation convention relate income gain income tax apply reduce capital gain extent gain convention estate gift taxis estate gift tax convention arise inflation indexation allowance reduce chargeable purpose internal revenue code amend gain create allowable loss asset acquire code january legislation finance bill shareholders freeze level indexation allowance give calculate summary apply resident shareholder hold company chargeable gain value apply share capital asset disposal asset december asset acquire january onwards legislation finance bill taxation dividend remove indexation allowance disposal tax year resident individual entitle dividend tax allowance inheritance tax dividend receive tax year free tax allowance individual ukdomicile shareholder liable reduce tax year onwards dividend inheritance tax transfer share ad tax excess allowance tax basic rate charge value shareholder taxpayer high rate taxpayer additional estate reduce result transfer way lifetime gift rate taxpayer disposal market value case bequ death tax charge value share resident shareholder corporation taxpayer note date shareholder death gift disposal dividend payable ordinary share generally entitle subject inheritance tax estate gift tax exemption corporation tax estate gift tax convention generally provide tax pay credit tax payable gsk annual report strategic report governance remuneration financial statement investor information tax information shareholder continue stamp duty stamp duty reserve tax dividend qualify subject taxation stamp duty andor stamp duty reserve tax sdrt subject federal graduate tax rate maximum rate certain exemption payable transfer share rate type dividend automatically exclude qualified rounded near case stamp duty dividend meet requirement include consideration transfer notwithstanding provide limit instrument execute pursuance agreement give rise capital gain distribution charge sdrt instrument stamp year agreement include stamp exempt dividend bank deposit sdrt charge cancel sdrt ividend held corporation employee stock pay repaid ownership plan esop shareholder dividend pay taxexempt corporation summary apply shareholder citizen resident domestic corporation person state local tax rate qualify nonqualified dividend subject federal income tax net income basis vary assess addition federal tax rate respect share ad hold share ad capital communicate asset resident tax purpose taxation capital gain hold share purpose trade profession vocation generally holder subject capital gain tax carry branch agency subject tax capital gain realise sale summary address tax treatment holder disposal share ad gain longterm capital subject special tax rule bank taxexempt gain subject reduce rate taxation individual holder entity insurance company dealer security currency share ad hold year date person hold share ad integrate investment share vestedrelease shortterm capital gain include straddle comprise share ad subject taxation rate longterm capital position person directly indirectly gain subject rate state local tax voting stock company address tax rate capital gain apply treatment applicable result international income information report backup withholding tax treaty dividend payment proceed sale share taxation dividend ad pay certain usrelated financial gross dividend receive treat foreign source intermediary subject information reporting dividend income tax purpose eligible dividend subject backup withholding holder corporation receive deduction allow corporation dividend ad exempt recipient provide taxpayer identification number payable dollar dividend share payable certifie loss exemption occur nonus sterling dividend pay sterling include income holder generally subject information report backup dollar calculate reference exchange rate withholding require provide certification day dividend receive holder subject certain nonus status connection payment receive amount exception shortterm hedge position individual eligible withhold allow refund credit holder holder subject taxation maximum rate federal income tax liability provide require information respect qualified dividend qualified dividend define furnish internal revenue service internal revenue service irs dividend meet estate gift taxis follow criterion estate gift tax convention shareholder issue corporation corporation incorporate generally subject inheritance tax possession corporation eligible stamp duty benefit comprehensive income tax treaty deem stamp duty andor sdrt subject certain exemption satisfactory publish irs payable transfer share ad custodian dividend list irs dividend depository rate consideration qualify provide transfer sale value transfer consideration require dividend hold period meet share own day stamp duty sdrt payable transfer hold period define day period agreement transfer ad begin day exdividend date day stock trade dividend price example stock exdividend date october share hold day period august november year order count qualified dividend gsk annual report shareholder information continue shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance wwwshareviewcouk tel tel outside equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend choose drip election form download drip reinvest dividend buy gsk share wwwshareviewcouk request contact equiniti dividend payment direct bank currently receive dividend cheque dividend bank mandate form account bank mandate post instead pay directly bank download wwwshareviewcouk building society account quick secure request contact equiniti avoid risk cheque go astray dividend payment direct bank instead wait sterling cheque arrive post detail service cost account overseas shareholder equiniti convert dividend local currency involve contact equiniti send direct local bank account service available country worldwide electronic communication shareholder elect receive electronic notification register wwwshareviewcouk company communication include annual report dividend payment pay way bank mandate access electronic tax voucher availability online vote general meeting time gsk mail hard copy shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view register wwwshareviewcouk share balance movement update address dividend payment instruction register vote agm duplicate publication mailing receive duplicate copy report mailing contact equiniti contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificated form internet transaction log hold corporate sponsor nominee internet wwwshareviewcoukdealing note market trading hour time telephone postal dealing service provide equiniti telephone transaction monday friday exclude public financial service limit holiday england wale outside postal transaction request deal form corporate sponsor nominee account convenient way manage share require application form request share certificate service provide facility hold wwwshareviewcouk share nominee account sponsor company contact equiniti continue receive dividend payment annual report attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas company arrange equiniti financial service detail available wwwshareviewcouk limited provide gsk corporate isa hold gsk request telephone equiniti ordinary share line open deal enquiry monday friday exclude public holiday england wale line open monday friday exclude public holiday england wale provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statement investor information shareholder service contact continue ad depositary contact investor relation ad programme administer bank new york mellon investor relation contact follow bny mellon shareowner services great west road box brentford middlesex louisville tel overnight correspondence send bny mellon shareowner services crescent drive south street suite philadelphia louisville tel toll free wwwmybnymdrcom tel outside tel toll free gsk response center tel outside tel toll free email shrrelationscpushareownerservicescom share scam alert depositary provide global buydirect direct ad receive unsolicited telephone offering sell buy purchasesale dividend reinvestment plan ad holder share extra care caller detail enrol visit wwwmybnymdrcom highly organise financial scam helpline number obtain enrolment pack shareholder contact financial conduct glaxo wellcome smithkline beecham authority information similar activity corporate pep wwwfcaorgukconsumer consumer helpline share centre limited oxford house oxford road aylesbury buck tel tel tel outside wwwsharecom line open time monday friday public donating share save child holiday saturdays gsk embark ambitious global partnership responsible business supplement save child share expertise resource publish responsible business supplement aim help save live million child online outline gsk approach performance shareholder small number share value key responsible business area health behaviour make uneconomical sell wish consider donate people planet save child donate share aggregate sell save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report statutory disclosure law regulation number provision law regulation apply responsible establish maintain internal company share quote new york stock control financial reporting provide reasonable assurance exchange nyse form ad reliability financial reporting preparation financial statement external purpose accordance nyse rule generally accept accounting principle general nyse rules permit company follow corporate governance practice instead apply disclose annual report form provide explain significant variation explanation change internal control financial reporting contain form access period cover annual report form security exchange commission sec edgar database materially affect reasonably likely affect materially website nyse rule come effect require company internal control financial reporting file annual interim write affirmation concern audit disclose base recent evaluation internal control risk committee statement significant difference financial report external auditor arc corporate governance significant deficiency material weakness design operation internal control financial reporting sarbanesoxley act reasonably likely affect adversely company ability record follow number corporate accounting scandal process summarise report financial information fraud congress pass sarbanesoxley act sarbanesoxley regardless materiality involve person significant wideranging piece legislation concern largely financial role company internal control financial reporting report corporate governance group carry evaluation supervision recommend sec company establish participation management include ceo disclosure committee committee report ceo cfo effectiveness design operation group cfo audit risk committee arc chair disclosure control procedure december company secretary member consist senior manager finance legal corporate communication investor relation inherent limitation effectiveness system disclosure control procedure include possibility external legal counsel external auditor internal expert human error circumvention override control invite attend meeting periodically responsibility procedure accordingly effective disclosure control consider materiality information timely basis procedure provide reasonable assurance achieve determine disclosure information responsibility control objective timely filing report sec formal review annual report form committee meet ceo cfo expect complete certification time report conclusion effectiveness disclosure control procedure march follow certificate sarbanesoxley require annual report form file sec group form contain statement member arc audit committee financial expert define sarbanesoxley section management annual report internal control statement relevant member arc judy lewent financial reporting include audit risk committee report accordance requirement section sarbane biography additional disclosure requirement arise oxley follow report provide management respect section section sarbanesoxley respect company internal control financial reporting define disclosure control procedure internal control rule securities exchange financial reporting act amend exchange act section corporate responsibility financial report management responsible establish maintaining sarbanesoxley introduce requirement ceo adequate internal control financial reporting group cfo complete formal certification confirm internal control financial reporting design provide reasonable assurance reliability financial reporting review annual report form preparation financial statement external purpose base knowledge annual report form accordance ifrs contain material misstatement omission management conduct evaluation effectiveness base knowledge financial statement internal control financial reporting base framework financial information fairly present material respect internal control integrate framework issue financial condition result operation cash flow committee sponsor organisation treadway date period present annual report commission coso form change group internal control responsible establish maintain disclosure financial reporting materially affected control procedure ensure material information reasonably likely affect materially group internal known evaluated effectiveness control financial reporting control procedure yearend result management assess effectiveness internal control evaluation contain annual report financial reporting december form conclusion file group form gsk annual report strategic report governance remuneration financial statement investor information law regulation continue pricewaterhousecooper llp audit group regularly receive information consolidated financial statement group year identity distributor downstream customer end december assess effectiveness establish proportion gross revenue sale potentially group internal control financial reporting attributable entity affiliate iranian government party audit standard public company accounting sanction disclosable activity result group oversight board united states audit report file report entire gross revenue million net profit group form million group sale iran section exchange act group aware hospital medical section exchange act section require issuer facility lebanon affiliate control hezbollah specific disclosure annual report certain type designate united states terrorist organisation dealing iran include transaction dealing group deal directly facility sell governmentowne entity dealing entity distributor group unable identify sanction activity relate terrorism proliferation certainty degree nature affiliation end customer weapon mass destruction activitie hezbollah group unable establish proportion prohibit law involve person group gross revenue sale potentially attributable reportable export certain pharmaceutical vaccine consumer product entity result group report entire gross revenue iran sale nonus entity privately hold iranian million net profit million group sale distributor lebanon believe group direct dealing addition section law generally restrict dealing iran require specific disclosure requirement person person subject jurisdiction certain country territory subject comprehensive group regularly receive information sanction group business nonus entity identity distributor downstream customer iran jurisdiction target sanction law include syria cuba possible customer include entity north korea crimea believe group complie governmentowne hospital pharmacy own applicable sanction law law complex control directly indirectly iranian government continue evolve rapidly person entity sanction connection terrorism proliferation activity donation political organisation political expenditure effect january ensure consistent approach notwithstanding policy company act require political contribution group introduce global company continue obtain shareholder approval policy stop voluntarily corporate political contribution donation political organisation incur political expenditure intend period january december group donation political party organisation political donation noneu organisations incur political expenditure definition political notwithstanding introduction policy accordance donation political expenditure political organisation federal election campaign act continue legislation wide annually seek shareholder support employeeoperate political action committee pac authorisation inadvertent expenditure particular facilitate voluntary political donation eligible gsk definition political organisation extend body employee concerned policy review law reform representation pac control gsk decision amount business community special interest group recipient contribution participate employee concerned environment company exercise legal right pool resource political subsidiary wish support result definition contribution subject strict limitation total cover legitimate business activity ordinary sense donate political consider political donation political expenditure organisation gsk employee pac activity design support political party independent election candidate authority board seek annually precautionary measure ensure company subsidiary inadvertently breach legislation authorisation process expenditure year date agm hold follow introduction political party election referendum act authority renew annually gsk annual report statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement address register office effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold glaxosmithkline plc percentage hold class share state state subsidiary company register office country incorporation subsidiary company resident tax purpose country incorporation state security register address wholly own subsidiary alberta ulc common street calgary canada action potential venture capital limit ordinary great west road brentford middlesex england adechsa gmbh ordinary prv provide treuhandgesellschaft dorfstrasse baar switzerland affymax research institute common corporation service company gateway oak drive suite sacramento california united states alenfarma especialidades farmaceuticas limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal allen hanbury limit ordinary great west road brentford middlesex england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria barrier therapeutics inc common corporation service company little fall drive wilmington delaware united states beecham group plc shares share great west road brentford middlesex england beecham pharmaceutical pte limited ordinary quality road jurong industrial estate jurong singapore beecham pharmaceuticals nominative agosto naciones unidas edificio electroectuatoriana piso quito ecuador beecham portuguesaprodutos farmaceuticos quimicos lda ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal beecham ordinary parc noire epine rue fleming wavre belgium biddle sawyer limited equity annie besant road mumbai india biovesta ilalari ltd sti nominative bykdere caddesi levent plaza blok levent istanbul turkey burrough wellcome australia pty limited liquidation ordinary mountain highway boronia vic australia burrough wellcome bangladesh limited ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh burrough wellcome international limited ordinary great west road brentford middlesex england cascan gmbh partnership capital industriestrasse bad oldesloe germany castleton investment ltd ordinary dtos cybercity floor standard charter tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited ordinary great west road brentford middlesex england cellzome therapeutics inc ordinary corporation service company little fall drive wilmington delaware united states cellzome inc ordinary corporation service company little fall drive wilmington series preferred delaware united states series prefer series convertible prefer series convertible prefer charles midgley limit ordinary cumulative preference great west road brentford middlesex england chiron behring vaccine private limited ordinary wing floorfloral deck plaza opp rolta bhavan central midc road mumbai andheri india clarge pharmaceutical limit ordinary preference great west road brentford middlesex england colleen corporation common par value corporation service company little fall drive wilmington delaware united states corixa corporation common corporation service company little fall drive wilmington delaware united states coulter pharmaceutical inc common corporation service company little fall drive wilmington delaware united states dealcyber limited ordinary great west road brentford middlesex england desarrollo energia solar alternativa ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain gsk annual report strategic report governance remuneration financial statement investor information group company continue security register address wholly own subsidiary continue domantis limit ordinary great west road brentford middlesex england duncan flockhart australia pty limited ordinary mountain highway boronia vic australia edinburgh pharmaceutical industry limit ordinary preference shewalton road irvine ayrshire scotland eskaylab limited ordinary great west road brentford middlesex england etex farmacutica limitada social capital avenida andre bello piso las conde santiago chile fipar thailand ltd liquidation ordinary floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oak drive suite sacramento california united states glaxo ordinary klaus torgrd vei oslo norway glaxo group limit ordinary great west road brentford middlesex england glaxo kabushiki kaisha ordinary asasaka minatoku tokyo japan glaxo laboratories nigeria limit ordinary marine road apapa lagos nigeria glaxo laboratory limit ordinary great west road brentford middlesex england glaxo new zealand pension plan trustee limited ordinary level zurich house queen street auckland new zealand glaxo operation limit ordinary great west road brentford middlesex england glaxo property ordinary huis ter heideweg zeist netherlands glaxo verwaltung gmbh ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal glaxo wellcome international ordinary huis ter heideweg zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary rue franois jacob rueilmalmaison france glaxo wellcome pst pty ltd liquidation ordinary mountain highway boronia vic australia glaxo wellcome limit ordinary great west road brentford middlesex england glaxo wellcome vidhyasom limit ordinary floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome ordinary poligono industrial allendeduero avenida extremadura aranda duero burgo spain glaxo ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain glaxoallenburys nigeria limit ordinary creek road apapa lago pmb nigeria glaxochem unlimite ordinary great west road brentford middlesex england ordinary ordinary glaxochem pte ltd ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal glaxosmithkline cambodia ltd ordinary floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment ltd ordinary room building ocean international center mid east ring road bejing chaoyang district china glaxosmithkline china company limited equity building halei road zhang jiang tech park pudong new area shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center floor nicosia cyprus glaxosmithkline gsk srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street box petachtikva israel glaxosmithkline malta limit ordinary floor cruz avenue qormi qrm malta glaxosmithkline private limited ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline aebe ordinary kifissias avenue halandri athens greece glaxosmithkline ordinary hemvarnsg solna sweden glaxosmithkline ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quotas bollore africa logistics angola estrada cacuaco bairro petrangol luanda angola gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline argentina ordinary tucumn piso buenos aire caaa argentina glaxosmithkline ordinary klaus torgrd vei oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline ordinary huis ter heideweg zeist netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz mnchen germany glaxosmithkline biological shanghai ltd ordinary niudun road zhangjiang hiteck park shanghai china glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological ordinary preference rue rixensart belgium glaxosmithkline brasil limitada quotas estrada do banderiantes rio janeiro brazil glaxosmithkline capital inc ordinary wilmington trust services inc north market street suite wilmington delaware united states glaxosmithkline capital plc ordinary great west road brentford middlesex england glaxosmithkline caribbean limited ordinary great west road brentford middlesex england glaxosmithkline chile farmaceutica limitada social capital avenida andre bello piso las conde santiago chile glaxosmithkline colombia ordinary avenida dorado bpiso bogota colombia glaxosmithkline consumer healthcare investment ireland ordinary cork airport business park kinsale road cork county cork limited ireland glaxosmithkline consumer healthcare ireland limited ordinary currabinny carrigaline county cork ireland glaxosmithkline consumer holding ordinary huis ter heideweg zeist netherlands glaxosmithkline doo quota zmja bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador ordinary agosto naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ordinary ltsa tallinn estonia glaxosmithkline ehf dissolve january ordinary thverholt reykjavik iceland glaxosmithkline salvador ordinary avenida boqueron calle izalco parque industrial boqueron santa elen antiguo custatlan libertad salvador glaxosmithkline eood ordinary tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limit ordinary great west road brentford middlesex england glaxosmithkline export panama ordinary panama city republic panama panama glaxosmithkline far east ordinary huis ter heideweg zeist netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex england glaxosmithkline gmbh partnership capital prinzregentenplatz mnchen germany glaxosmithkline guatemala ordinary novena avenida zona guatemala city guatemala glaxosmithkline hold ordinary klaus torgrd vei oslo norway glaxosmithkline holdings americas inc common par value wilmington trust services inc north market street suite wilmington delaware united states glaxosmithkline holdings ireland limited ordinary defer great west road brentford middlesex england glaxosmithkline holding limited ordinary great west road brentford middlesex england glaxosmithkline holding limit ordinary great west road brentford middlesex england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras ordinary tegucigalpa mdc honduras glaxosmithkline ihc limit ordinary great west road brentford middlesex england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza blok levent istanbul turkey glaxosmithkline inc class common class preference mississauga road north mississauga canada glaxosmithkline insurance ltd ordinary parlaville road hamilton bermuda glaxosmithkline intellectual property limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property development limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property holding limit ordinary ordinary great west road brentford middlesex england glaxosmithkline intellectual property limit ordinary defer great west road brentford middlesex england glaxosmithkline intellectual property management limit ordinary great west road brentford middlesex england glaxosmithkline international limited ordinary great west road brentford middlesex england glaxosmithkline investigacin desarrollo ordinary severo ochoa parque tecnolgico madrid tres cantos madrid spain gsk annual report strategic report governance remuneration financial statement investor information group company continue security register address wholly own subsidiary continue glaxosmithkline investment holding limit ordinary great west road brentford middlesex england glaxosmithkline investment service limit ordinary great west road brentford middlesex england glaxosmithkline investments ireland limited ordinary currabinny carrigaline county cork ireland glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline ordinary asasaka minatoku tokyo japan glaxosmithkline korea limited ordinary yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary dunte iela riga latvia glaxosmithkline lietuva uab ordinary ukmerge vilnius lithuania glaxosmithkline limit ordinary unit tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline manufacture spa ordinary alessandro fleming verona italy glaxosmithkline maroc ordinary angle rachidi abou ham glaza casablanca morocco glaxosmithkline medical healthcare product limit ordinary csorsz utca budapest hungary glaxosmithkline mercury limit ordinary great west road brentford middlesex england glaxosmithkline mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico glaxosmithkline limit ordinary level zurich house queen street auckland new zealand glaxosmithkline ordinary piispansilta box espoo fin finland glaxosmithkline peru ordinary javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limit ordinary floor icea lion centre riverside park west wing chiromo road westland box nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan semangat petale jaya selangor darul ehsan malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals suzhou limited ordinary hong road suzhou industrial park suzhou china glaxosmithkline pharmaceuticals costa rica ordinary metros este rotonda betania mercede montes oca sabanilla montes oca san jose costa rica glaxosmithkline pharmaceuticals ordinary grunwaldzka poznan poland ordinary ordinary ordinary glaxosmithkline pharmaceutical ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceutical ukraine llc charter capital pavla tychyny avenue kiev ukraine glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common centro internacional mercadeo road tower suite guaynabo puerto rico glaxosmithkline republica dominicana ordinary ave lope vega torre novocentro local santo domingo dominican republic glaxosmithkline research development limit ordinary great west road brentford middlesex england glaxosmithkline ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain glaxosmithkline spa ordinary alessandro fleming verona italy glaxosmithkline sro ordinary hvezdova prague czech republic glaxosmithkline services gmbh partnership capital prinzregentenplatz mnchen germany glaxosmithkline services inc common corporation service company little fall drive wilmington delaware united states glaxosmithkline service unlimite ordinary great west road brentford middlesex england glaxosmithkline holdings llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline partnership great west road brentford middlesex england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline superannuation company pty ltd ordinary mountain highway boronia vic australia liquidation glaxosmithkline trading services limited ordinary currabinny carrigaline county cork ireland glaxosmithkline trading zao ordinary yakimanskaya nab moscow russian federation glaxosmithkline tunisia sarl ordinary immeuble les quatre rue lac lochness berge lac tunis tunisia glaxosmithkline limit ordinary great west road brentford middlesex england glaxosmithkline uruguay register share provisory stock salto montevideo uruguay glaxosmithkline venezuela ordinary urbanizacion trinidad calle luis camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company equity capital metropolitan dong khoi street district floor unit chi minh city viet nam glycovaxyn common preferred grabenstrasse schlieren switzerland preferred preferred group laboratories south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa groupe glaxosmithkline sas ordinary rue franois jacob rueilmalmaison france gsk business service centre sdn bhd ordinary level quill jalan semangat petale jaya selangor darul ehsan malaysia gsk capital ordinary asasaka minatoku tokyo japan gsk argentina nominative non endorseable ordinary share tucumn piso buenos aire caaa argentina gsk commercial ordinary rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk kazakhstan llp charter capital furmanov street almaty medeu district kazakhstan gsk pharmaceutical trading ordinary poienelor street brasov romania gsk service ordinary grunwaldzka poznan poland gsk vaccine ordinary hullenbergweg amsterdam netherlands gsk vaccine gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota fiorentina siena italy gsk vaccines srl quota fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany hgs france sarl ordinary rue belle feuille boulognebillancourt france horlick limited ordinary great west road brentford middlesex england human genome sciences pacific pty ltd liquidation ordinary mountain highway boronia vic australia human genome sciences inc common corporation service company little fall drive wilmington delaware united states biomedical corporation quebec common parc technologique qubec canada biomedical corporation washington common corporation service company little fall drive wilmington delaware united states instituto luso farmaco limitada quota rua antonio loureiro borge arquiparque miraflore alge portugal interpharma dienstleistungen gmbh quotas wagenseilgasse euro plaza gebude stock vienna austria technologies llc interest corporation service company shockoe slip floor richmond united states laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerde algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerde algeria laboratoires paucourt ordianry rue franois jacob rueilmalmaison france laboratoires saintgermain ordianry rue franois jacob rueilmalmaison france laboratorios dermatologico darier ordianry calzada mexico xochimilco san lorenzo huipulco district federal mexico mexico laboratorios farmaceuticos stiefel portugal ltda ordinary rua antonio loureiro borge arquiparque miraflore alge portugal laboratorios stiefel chile compaa limitada social capital avenida andre bello piso las conde santiago chile laboratorios stiefel venezuela ordinary urbanizacion trinidad calle luis camoems edif apatado posta caracas venezuela laboratorios stiefel ltda ordinary rua professor joao salem guarulhos sao paulo brazil gsk annual report strategic report governance remuneration financial statement investor information group company continue security register address wholly own subsidiary continue laboratorios wellcome portugal limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal maxinutrition limited liquidation ordinary baker street london england mixis genetics limit ordinary ordinary euro great west road brentford middlesex england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire scotland montrose pharma company limit ordinary quota csorsz utca budap hungary novartis vaccine diagnostic liquidation ordinary obc suisse aeschenvorstadt basel switzerland novartis vaccine diagnostic pty ltd ordinary mountain highway boronia vic australia okairos liquidation common obc suisse aeschenvorstadt basel switzerland prefer preferred penn labs inc common corporation service company little fall drive wilmington delaware united states international ordinary huis ter heideweg zeist netherlands limit unit common corporation service company interstate drive suite harrisburg pennsylvania united states setfirst limit ordinary great west road brentford middlesex england smith kline french laboratory limit ordinary great west road brentford middlesex england smith kline french portuguesaproduto ordinary rua antonio loureiro borge arquiparque miraflore alge farmaceuticos lda portugal smithkline beecham australia pty ltd liquidation ordinary mountain highway boronia vic australia smithkline beecham bangladesh private limited ordinary topkhana road segunbagicha dhaka bangladesh smithkline beecham cork limited ordinary currabinny carrigaline county cork ireland smithkline beecham export limit ordinary great west road brentford middlesex england smithkline beecham limit noncumulative nonredeemable ordinary great west road brentford middlesex england smithkline beecham investment limit ordinary great west road brentford middlesex england smithkline beecham manufacturing limited ordinary currabinny carrigaline county cork ireland smithkline beecham swg limit ordinary great west road brentford middlesex england smithkline beecham biological partnership partnership interest corporation service company little fall drive wilmington delaware united states smithkline beecham egypt llc quotas amoun street salam city cairo egypt smithkline beecham farma ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain smithkline beecham holdings australia pty limited ordinary mountain highway boronia vic australia liquidation smithkline beecham interamerican corporation common corporation service company little fall drive wilmington delaware united states smithkline beecham limit ordinary great west road brentford middlesex england smithkline beecham marketing technical service limit ordinary great west road brentford middlesex england smithkline beecham nominee limit ordinary great west road brentford middlesex england smithkline beecham overseas limit ordinary great west road brentford middlesex england smithkline beecham pension plan trustee limit ordinary great west road brentford middlesex england smithkline beecham pension trustee limit ordinary great west road brentford middlesex england smithkline beecham pharma gmbh partnership capital prinzregentenplatz mnchen germany smithkline beecham pharma verwaltung gmbh ordinary prinzregentenplatz mnchen germany smithkline beecham pharmaceuticals pty limited ordinary flush meadow build campus sloane street bryanston south africa smithkline beecham pharmaceutical common corporation service company little fall drive wilmington delaware united states smithkline beecham port louis limited ordinary cim corporate services ltd les cascade build edith cavell street port louis mauritius smithkline beecham retirement plan nominee pty limited ordinary mountain highway boronia vic australia liquidation smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex england limited stiefel distributor ireland limited ordinary finisklin business park sligo ireland stiefel dominicana srl ordinary ave lope vega torre novocentro local santo domingo dominican republic stiefel farma ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain stiefel gmbh partnership capital industriestrasse bad oldesloe germany gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue stiefel india private limited equity wing floor floral deck plaza opp rolta bhavan central midc road mumbai andheri india stiefel laboratory maidenhead ltd ordinary eurasia headquarters concorde road maidenhead berkshire england stiefel laboratory ltd ordinary eurasia headquarters concorde road maidenhead berkshire england stiefel laboratory legacy ireland limited ordinary finisklin business park sligo ireland stiefel laboratory limit ordinary eurasia headquarters concorde road maidenhead berkshire england stiefel laboratory pte limited ordinary gul circle singapore stiefel laboratories pty ltd liquidation ordinary mountain highway boronia vic australia stiefel laboratories inc common corporation service company little fall drive wilmington delaware united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia vic australia stiefel research australia pty ltd ordinary mountain highway boronia vic australia stiefel west coast llc llc interest corporation service company little fall drive wilmington delaware united states strebor inc common corporation service company little fall drive wilmington delaware united states tempero pharmaceuticals inc series preference corporation service company little fall drive wilmington series preference common delaware united states sydney ross ordinary corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states wellcome foundation limit ordinary great west road brentford middlesex england ucb pharma asia pacific sdn bhd ordinary level symphony house pusat dagangan dana jalan pju petale jaya selangor darul ehsan malaysia wellcome consumer healthcare limit ordinary great west road brentford middlesex england wellcome consumer product limit ordinary great west road brentford middlesex england wellcome developments pty ltd ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex england wellcome operation pty ltd ordinary mountain highway boronia vic australia effective security ownership register address subsidiary effective interest amoun pharmaceutical industry sae new monetary share salam city box cairo egypt beecham enterprises inc common corporation service company little fall drive wilmington delaware united states block drug company inc common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states block drug corporation common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states british pharma group limited captial great west road brentford middlesex england micln ordinary priemyselny park gena sachsa levice slovakia duncan consumer healthcare philippines inc common chino roce avenue makati city philippines duncan pharmaceuticals philippines inc common chino roce avenue makati city philippines exlax inc common prentice hall corporation system puerto rico inc fast solution llc citi tower ponce leon avenue floor san juan puerto rico galvani bioelectronics inc common corporation service company little fall drive wilmington delaware united states galvani bioelectronic limit ordinary great west road brentford middlesex england ordinary glaxo saudi arabia limit ordinary box area warehouse city stage khomrah jeddah saudi arabia gsk annual report strategic report governance remuneration financial statement investor information group company continue effective security ownership register address subsidiary effective interest continued glaxo wellcome ceylon limit ordinary galle road kaldemulla moratuwa sri lanka ordinary glaxosmithkline tianjin ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya boumerdes algeria glaxosmithkline bangladesh limit ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh glaxosmithkline brasil produtos para consumo saude ltda quota vitor civita street barra tijuca rio janeiro brazil glaxosmithkline consumer healthcare china ltd ordinary room headquarters building tibet road shanghai china glaxosmithkline consumer healthcare hong kong limit ordinary unit tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline consumer healthcare ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare thailand limited ordinary floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare limited ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare trading limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare ordinary nykaer brondby denmark glaxosmithkline consumer healthcare vii ordinary nykaer brondby denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare ordinary huis ter heideweg zeist netherlands glaxosmithkline consumer healthcare colombia sa ordinary avenida dorado bpiso bogota colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova prague czech republic glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare finland ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare greece societe ordinary kifissias avenue halandri athens greece anonyme glaxosmithkline consumer healthcare holding llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare holding limit ordinary great west road brentford middlesex england ordinary glaxosmithkline consumer healthcare inc common mississauga road north mississagua canada glaxosmithkline consumer healthcare investment ireland ordinary knockbrack dungarvan waterford ireland limited glaxosmithkline consumer healthcare investment ireland ordinary knockbrack dungarvan waterford ireland unlimited company glaxosmithkline consumer healthcare japan ordinary asasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea ltd ordinary yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline consumer healthcare llc llc interest corporation service company interstate drive suite harrisburg pennsylvania united states glaxosmithkline consumer healthcare limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico mexico glaxosmithkline consumer healthcare new zealand limited ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary klaus torgrd vei oslo norway glaxosmithkline consumer healthcare pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common chino roce avenue makati city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline consumer healthcare spa ordinary zambeletti snc baranzate milan italy glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu kelang industrial estate selangor malaysia glaxosmithkline consumer healthcare slovakia ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa pty ltd ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline consumer healthcare spzoo common rzymowskiego warsaw poland glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex england holdings limited glaxosmithkline consumer healthcare srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline consumer healthcare vietnam charter capital floor metropolitan dong khoi ben nghe ward district company limit chi minh city viet nam glaxosmithkline consumer healthcare partnership interest corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare produto para ordinary quota rua antonio loureiro borge arquiparque miraflore alge saude higiene lda portugal glaxosmithkline consumer nigeria plc iii ordinary industrial avenue ilupeju ikeja lagos nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading service limit ordinary great west road brentford middlesex england glaxosmithkline costa rica ordinary san jose este rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limited ordinary knockbrack dungarvan waterford ireland glaxosmithkline healthcare ordinary presnenskaya nab moscow glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue kiev ukraine glaxosmithkline limit ordinary likoni road box nairobi kenya glaxosmithkline otc pvt limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline panama ordinary panama city republic panama panama glaxosmithkline paraguay ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay glaxosmithkline pharmaceuticals limited equity annie besant road mumbai india glaxosmithkline philippines inc common chino roce avenue makati city philippines glaxosmithkline sae ordinary boomerang office building land zone district town center tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary rue franois jacob rueilmalmaison france glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability company membership csorsz utca budapest hungary gsk kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little fall drive wilmington delaware united states gsk consumer healthcare israel ltd ordinary basel street petech tikva israel gsk consumer healthcare schweiz ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little fall drive wilmington delaware united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street box salam city cairo egypt nch nutrition consumer health ltd ordinary hamephalsim petach tikva israel novartis consumer health australasia pty ltd ordinary hughe avenue ermington nsw australia redeemable preference novartis consumer health gmbh ordinary barthstr mnchen germany gsk annual report strategic report governance remuneration financial statement investor information group company continue effective security ownership register address subsidiary effective interest continued novartis consumer health ordinary route prangin switzerland novartis consumer health limit ordinary park view riverside way watchmoor park camberley surrey england smithkline beecham pharmaceuticals share pulobuaran raya kav iii kawasan industri pulogadung share jakarta indonesia sterling product indonesia share graha paramita build jalan denpasar raya blok jakarta share indonesia panadol gmbh ordinary barthstr mnchen germany phivco jersey limit ordinary castle street helier jersey phivco jersey limit ordinary castle street helier jersey phivco limited ordinary great west road brentford middlesex england phivco limit ordinary great west road brentford middlesex england phivco llc llc interest corporation service company little fall drive wilmington delaware united states phivco llc llc interest corporation service company little fall drive wilmington delaware united states glaxo wellcome indonesia share pulobuaran raya kav iii kawasan industri pulogadung timur share jakarta indonesia gsk consumer healthcare indonesia ordinary graha paramita floor denpasar raya blok kuningan jakarta indonesia bina dentalindo liquidation ordinary gedung graha ganesha lantai raya bekasi jakarta timur indonesia shionogiviiv healthcare llc common interest corporation service company little fall drive wilmington delaware united states sinoamerican tianjin smith kline french laboratories ltd ordinary cheng lin zhuang industrial zone dong district tianjin china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limit ordinary great west road brentford middlesex england smithkline beecham ordinary ctra ajalvir alcala henares madrid spain smithkline beechambiome ooo participation interest krylatskaya str moscow russian federation staffordmiller ireland limited ordinary clocherane youghal road dungarvan waterford ireland staffordmiller limit ordinary great west road brentford middlesex england noncumulative non redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggang ampangulu kelang industrial estate selangor malaysia sterling product international incorporate common corporation service company little fall drive wilmington delaware united states stiefel consumer healthcare limit ordinary great west road brentford middlesex england stiefel egypt llc quota amoun street salam city cairo egypt stiefel laboratories ireland limited ordinary finisklin business park county sligo ireland viiv healthcare south africa proprietary limited ordinary flush meadow build campus sloane street bryanston south africa viiv healthcare ordinary huis ter heideweg zeist netherlands viiv healthcare company common corporation service company little fall drive wilmington delaware united states viiv healthcare finance limit ordinary great west road brentford middlesex england viiv healthcare finance limit ordinary great west road brentford middlesex england viiv healthcare finance limit ordinary great west road brentford middlesex england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz mnchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limit ordinary tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kabushiki kaisha ordinary asasaka minatoku tokyo japan viiv healthcare limited class share defer great west road brentford middlesex england class share class share class class class cumulative preference gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued viiv healthcare overseas limited ordinary great west road brentford middlesex england viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interest centro international mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota alessandro fleming verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc participation interest krylatskaya str moscow russian federation viiv healthcare trading service limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary castle street helier jersey viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare ulc common street calgary canada viiv healthcare venture llc llc interest corporation service company little fall drive wilmington delaware united states viivhiv healthcare unipessoal lda quota rua antonio loureiro borge arquiparque miraflore alge portugal winster pharmaceutical limit ordinary association avenue ilupeju industrial estate lago box nigeria zhejiang tianyuan biopharmaceutical ltd ordinary tian road yuhang economic development zone hangzhou zhejiang province china associates apollo therapeutics llp partnership interest calci medica inc series junior prefer glaxosmithkline landholde company inc common index venture life jersey partnership interest innoviva inc common japan vaccine distribution ltd ordinary kurma biofund fcpr partnership interest longwood founder fund partnership interest medicxi ventures partnership interest joint ventures chiron panacea vaccines private limited liquidation floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india japan vaccine ltd yonbancho chiyodaku tokyo japan qualivax pte limited robinson road singapore qura therapeutics llc corporation service company little fall drive wilmington delaware united states key directly own glaxosmithkline plc dormant company xempt provision section company act tax resident ireland accordance exemptions note section act entity expect dispose remove iii onsolidated subsidiary accordance section vii incorporate sweden company act ground dominant influence gsk annual report strategic report governance remuneration financial statement investor information glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidence title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party novartis transaction threepart interconditional transaction novartis involve consumer healthcare vaccine oncology business complete march ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue corporate governance code require list authority company disclose annual report apply good practice corporate governance provision financial reporting council corporate governance code gsk annual report index access highquality product investment associate joint venture accountability investor relation accounting principle policy key accounting judgement estimate acquisition disposal key performance indicator adjustment reconcile profit tax operating leadership effectiveness cash flow legal proceeding annual general meeting major restructuring cost approach brexit modern employer approach tax movement equity asset hold sale net debt associate joint venture new accounting requirement audit risk committee report nomination committee report cash cash equivalent noncontrolle interest ceos statement noncontrolle interest viiv healthcare chairmans statement nonexecutive director fee chairmans governance statement note financial statement chairman remuneration annual statement operate profit commitment intangible asset consolidate balance sheet investment consolidate cash flow statement noncurrent asset consolidate income statement noncurrent liability consolidated statement change equity operating income consolidate statement comprehensive income provision consumer healthcare board consumer healthcare product competition longterm prioritie contingent consideration liability pay performance contingent liability pension postemployment benefit corporate executive team pharmaceutical corporate governance pharmaceutical product competition corporate responsibility committee report intellectual property critical accounting policy pipeline director senior management presentation financial statement director interest share principal group company director statement responsibilitie principal risk uncertaintie dividend property plant equipment donation political organisation quarterly trend political expenditure reconciliation net cash flow movement net debt earning share registrar employee cost related party transaction employee share scheme relation stakeholder ethical conduct environmental sustainability remuneration governance exchange rate remuneration policy summary executive director remuneration remuneration report finance expense reporting framework finance income science committee report financial calendar segment information financial instrument relate disclosure share capital control financial position resource share capital share premium account financial statement glaxosmithkline plc prepare share price gaap shareholder information year record shareholder service contact global health science taxation glossary term tax information shareholder goodwill trade payable group company trade receivable group financial review treasury policy create longterm value trust manage risk law regulation independent auditor report vaccine industry trend vaccine product competition intellectual property inventory viability statement gsk annual report gsk glaxosmithkline plc incorporate english brand name brand name appear italic report public limited company december trade mark own andor license gsk associate company exception edurant form merger glaxo wellcome plc own janssen cialis own eli lilly company rituxan own biogen inc zofran own smithkline beecham plc gsk acquire novartis trumenba own pfizer inc english company december acknowledgement design merger arrangement friend wwwfriendstudiocom printing pureprint group iso share list london stock exchange fsc certify carbon neutral new york stock exchange paper annual report print revive silk recycle paper fsc certification pulp deinked paper waste elemental chlorine free manufacturing mill hold iso ecolabel certificate environmental management read wwwgskcom download pdfs annual report form responsible business supplement cautionary statement number adjust measure report give potential development option group forwardlooke statement performance business measure define pipeline outlook affect additional group report file furnish reconciliation adjust result total datadriven investment decision expectation securities exchange commission sec include result set give constant currency basis outlook sdh txf rea lao ytg otu hio sop rrda cfen rtt maow rer cmt set ute etfi ttgo fir aev tae stt elo tee hgf eae ytn tur sas dict neo mro dor sno stb elf pfh nvcfe ein pla iti iro ttan htn uri rdio oeom frb soe ato dho acr ncao pon agt tec ohn fin noln obt rot chee aii tdk line aen agd iuo geo eoe noe mst beu aabb tse soc ooat nnd tja tmu hhxea dit sei ail eteh hfi dxa iif csdoi trd haahru ext aec bst anticipate estimate expect intend project assumption relate outlook tax cut job act available assumption plan believe word term similar underlying estimate change consequent meaning connection discussion future outline expectation fiveyear adjustment charge take material operate financial performance particular period group certain impact result group assumption healthcare sector different include statement relate future action prospective market group operate delivery notice limitation product product approval future performance revenue financial benefit current portfolio director liability english law result current anticipate product sale effort expense outcome contingency legal pipeline restructuring programme company act safe harbour limit proceeding financial result group specifically period gsk liability director respect statement accordance legal regulatory obligation expect decline sale seretideadvair omission director report include list rule disclosure introduction generic alternative advair strategic report remuneration report transparency rule financial conduct factored group assessment future english law director liable authority group undertake obligation update performance group assume premature loss company party forwardlooke statement result exclusivity key product period group report contain error result recklessness new information future event reader expect billion revenue annum cer know misstatement dishonest concealment consult additional disclosure basis product launch include material fact liable page group document publish contribution shingrix inclusive comprise andor file sec reader locate director report page inclusive comprise note disclosure accordingly assumption group revenue earning strategic report page inclusive comprise assurance give particular expectation expectation assume material interruption supply remuneration report draw meet shareholder caution place group product material merger acquisition present accordance reliance undue reliance forwardlooke statement disposal litigation cost share repurchase english company law liability director company change group shareholding connection report shall subject forwardlooke statement subject assumption viiv healthcare consumer healthcare assume limitation restriction provide law inherent risk uncertaintie relate material change macroeconomic healthcare factor group control precise environment guidance outlook website estimate group caution investor number factor divestment product exit gsk website wwwgskcom give additional information important factor include document include divestment exit group notwithstanding reference cause actual result differ materially express noncore tail brand billion annual sale annual report gsk website imply forwardlooke statement announce july information available website constitute annual report shall deem incorporated factor include limit discuss group expectation assume successful delivery reference principal risk uncertaintie page group integration restructuring plan period annual report forwardlooke statement include extension enhancement behalf group speak date combine programme announce july material base knowledge cost investment new product launch information available director date factor expectation give annual reporthead office register office glaxosmithkline plc great west road brentford middlesex united kingdom tel search register number wwwgskcom